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“No estalla como las bombas,  
ni suena como los tiros.  
Como el hambre, mata callando.  
Como el hambre, mata a los callados;  
a los que viven condenados al silencio  
y mueren condenados al olvido.  
Tragedia que no suena,  
enfermos que no pagan,  
enfermedad que no vende.” 
 
Eduardo Galeano 
 
 
 
 
 
 
 
 
“It does not explode like a bomb, 
or echo like gunfire. 
Like hunger, it kills in silence. 
Like hunger, it kills the silent:  
those who live condemned to silence,  
those who die condemned to oblivion. 
Tragedy that makes no sound,  
patients that can not pay,  
illness that will not sell.”  
 
 
 
 
 
“Sie explodiert nicht wie eine Bombe,  
und klingt nicht wie Kanonenfeuer. 
Wie Hunger, tötet sie still.  
Wie Hunger tötet sie die, die schweigen: 
Jene, die zum Schweigen verdammt sind,  
jene, die verdammt sind, in Vergessenheit zu sterben. 
Eine Tragödie, die keinen Lärm macht,  
Patienten, die nicht bezahlen können, 
eine Krankheit, die sich nicht verkauft.“  
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SUMMARY 
Chagas disease, caused by the flagellate Trypanosoma cruzi, is endemic in Latin 
America where it imposes a high burden on disability and death combined with enormous 
economic losses for up to 18 million people. Useful tests for the diagnosis of the disease are 
available, but they are too expensive to be used in in large scale in most of the affected 
countries. Furthermore, many diagnostic kits cannot clearly discriminate between Chagas 
disease and visceral leishmaniasis, which can be tolerated for immunological screening of 
samples in blood banks, but not for patients, since both diseases can occur in the same areas, 
however, need to be treated with different drugs. In addition, it is essential to recognise infection 
with T. cruzi in time, i.e. before the onset of severe clinical symptoms, since the available drugs 
are effective in the early stages of the disease only. This demands developing more specific 
and less expensive diagnostic tools.  
By means a bioinformatic approach, several recombinant antigens were produced, 
predominantly consisting of tandemly repeated amino acid sequences which occur in large 
numbers in different proteins of the parasite. Since the corresponding repeated DNA structures 
could not be maintained stably in E. coli, the whole range of possible base variations in codons 
was used to create varying coding sequences for up to nine tandem repeats of identical amino 
acid sequences. Some but not all of the expressed proteins were found to react strongly with 
sera from infected patients. To simplify purification as well as production, the most suitable 
antigens were fused. At the end a product composed of four different tandem repeat motives 
was obtained revealing an unexpected high diagnostic sensitivity, which was several orders of 
magnitude higher than with the antigens known so far. When used in ELISA, one milligram of 
the recombinant antigen is sufficient for one million single tests.  
Immunoassays  can frequently not discriminate between acute infection and overcome 
disease. Therefore, two different PCR assays were developed in addition to determine the 
number of  parasites circulating in blood after therapy with drugs. Targets of the one PCR assay 
are the more than 200 fold amplified genes for 18S rRNA and, for the other assay, the 
kinetoplast minicircle DNA which occurs in approximately 10.000 copies per parasite. Both of 
these test can detect as few as 10 trypanosomes per millilitre of blood and can clearly 
discriminate T. cruzi infections from infections with other Trypanosomatides.  
In conclusion, several highly sensitive and specific diagnostic procedures have been 
created, which are relatively simple to be performed and which can be produced  for a low price. 
It is the goal to instruct scientist in Latin America to produce and to use these tests in the long 
term by their own means, independent of support from abroad.   
                                                                                                                                                                                                             II  
_________________________________________________________________________________________________________ 
ZUSAMMENFASSUNG 
 
 Die Chagas-Krankheit wird durch den Flagellaten Trypanosoma cruzi ausgelöst und ist 
in Lateinamerika endemisch. Sie betrifft dort bis zu 18 Millionen Menschen und führt in vielen 
Fällen zu schweren gesundheitlichen Schäden, nicht selten mit tödlichem Verlauf. Es gibt 
empfindliche diagnostische Nachweisverfahren für die Krankheit, aber sie sind entschieden zu 
teuer um in den betroffenen Ländern zum Einsatz zu kommen. Außerdem können viele dieser 
Verfahren nicht izwischen Chagas-Krankheit und viszeraler Leishmaniose unterscheiden.  Das 
kann bei der Untersuchung von Proben in Blutbanken zwar toleriert werden, ist aber für die 
Diagnose von Patienten inakzeptabel, da beide Krankheiten in derselben Region auftreten 
können, jedoch mit unterschiedlichen Medikamente behandelt werden müssen.  Darüber hinaus 
ist es wichtig, Infektionen mit T. cruzi rechtzeitig zu erkennen, lange bevor schwere Symptome 
auftreten, denn die verfügbaren Medikamente sind nur in der früheren Phase der Krankheit 
wirsam.  Dies erfordert die Entwicklung neuer diagnostischer Methoden mit höherer Spezifität 
und niedrigeren Kosten. 
 Im Rahmen der Arbeit wurden mittels bioinformatischer Methoden mehrere 
rekombinante Antigene hergestellt, die hauptsächlich aus Wiederholungen von Aminosäure-
sequenzen bestehen und in großen Zahl in verschiedenen Proteinen der Parasiten vorkommen.  
Weil die entsprechenden repetitiven DNA Segmente nicht stabil in E. coli  etabliert werden 
konnten, wurden Gene mit möglichst vielen Austauschen in variablen Codons hergestellt.  Auf 
diese Weise gelang es, codierende Bereiche für bis zu neun identische Aminosäurensequenz-
Wiederholungen stabil in E. coli zu etablieren.. Manche der gereinigten Proteine reagierten 
stark mit Seren von infizierten Patienten.  Um Produktion und Reinigung zu vereinfachen, 
wurden die am stärksten reaktiven Antigene fusioniert. Am Ende enstand ein Antigen mit vier 
unterschiedlichen repetitiven Motiven, das in verschiedenen immunologischen Tests zu einer 
extrem starken Reaktivität mit Patientenseren führte. Ein Milligram dieses rekombinanten 
Proteins ist ausreichend um  eine Million Einzelversuche im ELISA durchzuführen. 
 Immundiagnose kann im Allgemeinen oft nicht zwischen akuter und überstandener 
Infektion unterscheiden. Dies ist aber wichtig um den Erfolg einer medikamentösen Behandlung 
verfolgen zu können. Daher wurden zusätzlich zwei verschiedene PCR-Nachweisverfahren für 
die Krankheit entwickelt. Mit der einen PCR werden die Gene der 18S rRNA amplifiziert, die in 
mehr als 200 Kopien im Genom von T. cruzi vorliegen, die andere PCR ist spezifisch für die 
mitochondriale Minicicle-DNA, die etwa 10.000fach im Parsiten vorliegt. Beide Tests haben eine 
Nachweisempfindlichkeit von ca. 10 Parasiten pro Milliliter Blut und können klar zwischen 
Infektionen mit den verschiedenen anderen auftretenden Trypanosomatiden unterscheiden. 
 Insgesamt wurden in Rahmen dieser Arbeit mehrere äußerst empfindliche und 
spezifische Diagnoseverfahren für die Chagas-Krankheit entwickelt. Sie können alle mit relativ 
geringem Aufwand durchgeführt und mit niedrigen Kosten hergestellt werden. Das weitere Ziel 
wird sein, Wissenschaftler in Lateinamerika anzuleiten, diese Diagnoseverfahren nicht nur zur 
Anzuwendung zu bringen, sondern sie auch in Eigenregie, d.h. ohne Hilfe von außen 
herzustellen. 
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1.  INTRODUCTION 
1.1   What is Chagas disease? Background 
Chagas disease (also known as American trypanosomiasis) is a parasitic disease 
endemic in Latin America, where it affects at present at least 10-14 million of people, probably 
more.  Its pathogenic agent is a flagellate protozoan, Trypanosoma cruzi, which is transmitted to 
humans and other mammals mostly by blood-sucking bugs of the subfamily Triatominae (Family 
Reduviidae). Those insects are known by numerous common names varying by country, 
including benchuca, vinchuca, chipo, chupança and barbeiro.   
DNA obtained from mummified human tissues from the northern coast of Chile indicates 
that Chagas disease was also prevalent 4.000 years ago in Latin America (Aufderheide et al., 
2004). However, it was not until 1909 when a Brazilian physician and infectologist, Carlos 
Chagas, described the disease for the first time, which was later named after him (Chagas, 
1909).  
 
1.2   Trypanosoma cruzi 
Trypanosoma cruzi is a parasitic protozoan that belongs to the order Kinetoplastida and 
the family Trypanosomatidae, characterised by the presence of one flagellum and a single 
mitochondrion in which the Kinetoplast is situated, a specialized DNA-containing organelle. 
T. cruzi is included in the section Stercoraria because it is the only human trypanosome to be 
transmitted by the feces of its invertebrate vector, as opposed to other trypanosomes 
transmitted by saliva (Salivaria section) such as Trypanosoma rangeli, a non-pathogenic 
species from South America transmitted by Triatominae and also able to infect humans; and 
Trypanosoma brucei, causing agent of the “sleeping sickness” in Africa (African 
trypanosomiasis).  An important difference between this latter and T. cruzi is that T. cruzi is an 
intracellular parasite, whereas T. brucei lives and reproduces in the bloodstream.  To the same 
family belongs another important human parasite, Leishmania spp., which is responsible for the 
leishmaniasis (cutaneous, mucocutaneous and visceral), also called kala-azar in some regions, 
and very closely related to Trypanosoma cruzi. 
The Trypanosoma cruzi population is not homogeneous and is composed of various 
strains. It has been demonstrated that this parasite undergoes some mechanisms of genetic 
exchange (Gaunt et al., 2003); however, its genetic diversity mainly results from the long-term 
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Figure 1.2-1 Trypanosoma cruzi morphology.  T. cruzi has a single tubular 
mitochondrion where the kinetoplast is located.  The kinetoplast is  a fibrous network of 
DNA which constitutes 20-25% of the total parasite DNA.  The flagellum is connected to 
the basal body and emerges from a specialized invagination, the flagellar pocket, which 
is apparently involved in the ingestion and uptake of nutrients from  the external medium . 
Subpeculliar tubules are organized as cytoskeleton of the organism (Brener, 1992). 
(Image: http://www.scielo.br/img/fbpe/mioc/v94s1/html/8308.html). 
evolution of independent clones (Tibayrenc, 2003).  After both isoenzyme and DNA analyses, a 
consensus has been reached to group most of the several existing clones into two principal 
subspecies, T. cruzi I and T. cruzi II (Fernandes et al., 1998) with marked heterogeneity, and 
five subdivisions within the T. cruzi II (II a-e).  The T. cruzi strain selected for the genome 
sequencing project is a hybrid IIe strain.  While both subspecies cause the human disease, 
T. cruzi II is more frequently associated with the domestic cycle, and T. cruzi I with the sylvatic 
cycle (see section 1.4).  Furthermore, isolation and study of T. cruzi populations from different 
origins demonstrated the presence of a large range of strains with distinct characteristics.  This 
intraspecific variation includes morphology of blood forms, curves of parasitemia, virulence, 
pathogenicity and sensitivity to drugs.  
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Figure 1.3-1 Trypanosoma cruzi life cycle.  When introduced into the mammal host (a), 
the metacyclic trypomastigotes must invade a cell to achieve its life cycle.  After a latency time 
of 20-35 hours, amastigotes initiate a process of binary division that is repeated every 12-14 
hours  (b).  When the cell is saturated with parasites , amastigotes begin their differentiation into 
trypomastigotes. The intense movements of trypomastigotes disrupt the cell (c), releasing free 
parasites that can invade other cells or can be sucked from blood by a vector, likewise 
completing the parasite life cycle (d).   (Image: adapted from Peters and Pasvol, 2006). 
 
1.3   Life cycle of T. cruzi and disease transmission 
Infective metacyclic trypomastigotes contained in the feces of the Triatoma bug enter the 
human body through the skin at the site of bite or through mucosal surfaces such as the eyes, 
producing in some cases a local swelling. While some parasites stay at the bite site, other 
trypomastigotes reach the circulatory system, from where they penetrate different organs 
(especially heart, walls of the gastrointestinal tract, or skeletal muscle).  Trypomastigotes can 
infect most vertebrate cells, especially leukocytes and macrophages. In the host cell, they 
convert to amastigotes, which reproduce by binary fission to form pseudocysts.  Some 
amastigotes later transform into trypomastigotes that re-enter the blood circulation, where they 
can be taken up when another triatomine feeds, entering the bug’s midgut.  In the gut, the 
flagellates change to short epimastigote and rounded spheromastigote forms, in which they 
multiply profusely by binary fission.  After one or two weeks, longer epimastigotes enter the 
rectum, where they form metacyclic trypomastigotes that are passed again to another human or 
animal host when the bug defecates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
(c) 
(d) 
Introduction                                                                                                                                                                                       4                                                                                                                                       
_____________________________________________________________________________ 
 As described above, people can become infected with Chagas disease by contact with 
the insect vectors.  This way of transmission accounts for about 80% of the cases, and it is only 
possible in endemic areas where the insects live. It occurs when the bugs directly deposit their 
infected feces on the skin of a person, and the parasite penetrates the skin through scratch 
wounds (bugs bites cause itching).  It is also possible that the person gets infected, unknowingly 
touching their eyes, mouth, or open cuts after having come into contact with infective Triatomine 
bug feces.  It takes place generally at night, when people sleep and the bugs are more active, 
getting out of the wall crevices where they live looking for food.   
Blood transfusion and organ transplantation is the second most important way of 
infection, being responsible for 5 to 20% of the cases, depending on the region. It occurs while 
receiving an infected blood transfusion or organ transplantation.   
In congenital infection, Trypanosoma cruzi crosses the placenta, and the foetus receives 
the infection from the mother during pregnancy.  About 4% of the total Chagas disease cases 
have the origin on vertical transmission.  This way of transmission does not have to be confused 
by the possibility of infection during birth through the contact of contaminated blood of the 
mother and open wounds or mucosas of the newborn.   
Other minor transmission ways which account for less than 1% of the cases include 
laboratory accidents, while manipulating living parasites or infected blood; and ingestion of 
contaminated food, such as the outbreak in 2005 in Brazil, where many people got infected by 
eating contaminated sugar cane (Steindel et al., 2008).  Other transmission modes have been 
reported including breast feeding and sexual transmission, but they where most probably due to 
open wounds, and therefore to contact with infected blood (Bittencourt et al., 1988; Nathan-
Larrier, 1921).  
 
1.4   Vectors 
Vectors of Chagas disease are insects of the order Hemiptera, family Reduviidae, 
subfamily Triatominae. Members of this subfamily are blood-feeding insects and are called 
many different names including Triatomine bugs, reduvid bugs, kissing bugs, cone nosed bugs 
and assassin bugs.  There are about 118 species of Triatominae, however, only a small number 
are significant T. cruzi vectors. The three most important vector species of the human Chagas 
disease are Triatoma infestans, Rhodnius prolixus, and Triatoma dimidiata. From Mexico to 
Venezuela and Colombia, R. prolixus and T. dimidiata are the principal vectors, while 
T. infestans is undoubtedly the main source of human Chagas disease below the Equator line.   
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Depending on the intermediate hosts and vectors, two different T. cruzi life cycles are to 
be distinguished, the “sylvatic cycle”, which involves the interaction between vectors and animal 
hosts; and the “domestic cycle”, that results from human-vector contact, which is responsible for 
Chagas disease.  Generally, in the sylvatic cycle a balance between the vector, parasite and 
host (various mammals such as opossums and armadillos) is maintained. Human 
encroachment into the forest and destruction of the natural habitat forced the Triatomine and 
mammals to colonize human domiciles (poor quality rural housing) thereby initiating the 
domestic cycle.  In this cycle, humans are the main domestic reservoirs, followed by dogs, cats 
and domestic rodents.  It has to be noted that only mammals are susceptible to T. cruzi 
infection.  Birds, amphibians and reptiles are naturally resistant, while pigs, goats, cattle and 
horses exhibit only transitory parasitemia and do not play an important role in transmission 
(Dias JCP,1992). 
 
 
 
 
 
 
 
 
1.5   Pathogenesis of Chagas disease 
1.5.1   Invasion and survival strategy of T. cruzi.  Immune response 
Trypanosoma cruzi is an intracellular parasite, and invades phagocytic cells, especially 
macrophages.  The parasite recognizes lectin and integrin receptors at the cellular membrane.  
After binding of ß-integrin on the surface of the host cell, there is an increase of Ca2+ 
concentration in the cytoplasm of the cell (Tan and Andrews, 2000).  The Ca2+ signal attracts 
the lysosomes to the places where the parasite is located.  They fuse with the cellular 
membrane and form a surrounding that allows T. cruzi to enter the cell.  Once inside the 
vacuole, the parasite secrets a trans-sialidase enzyme, that cleaves the sialic acid (that T  cruzi 
    
 
Figure 1.4-1 Rhodnius prolixus (left) and Triatoma infestans (right).  Triatoma 
bugs are haematophagous insects of 3 to 5 cm size, varying between species. Their head 
is elongated and exhibits a tubular form , adapted to the blood-sucking function. Compound 
eyes are positioned laterally, and the projection of the head hairs allows to distinguish one 
species to the other. Vectorial transmission of T.cruzi to humans and other mammals is 
due to the contact of these vertebrates with the feces of the infected vector. 
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is not able to synthesize) from the lysosomal proteins and transfers them to its own surface 
molecules.  On that way, T. cruzi is covered with sugars from the host cell, being then able to 
invade the cell.  Finally, the parasite secrets a porus bilding-toxin, that lyses the vacuole, and 
the parasite is free in the cytoplasma where it reproduces.  Once in the cytoplasma, the 
trypomastigotes, by means of the protease cruzipain, transform into amastigotes and divide.  
The amastigotes transform to trypomastigotes, start an intense movement and the cell bursts 
out, releasing hundreds of parasites to the bloodstream, where they can distribute through the 
entire organism and invade new cells again. 
 In the parasited cells, such as macrophages, T. cruzi uses different survival strategies.  
For example, it neutralises toxic oxygen derivatives, inhibits the nitric oxide synthesis (Clark et 
al., 1996), and modulates the programmed cell death (apoptosis) (Heussler et al., 2001), 
helping the trypomastigote forms to be released. The parasites are also able to alter the 
cytokine production of the host, in such way that they induce the secretion of cytokines that can 
inhibit the parasitic death, for example, IL-10 and TGFß.  When the parasite is inside the cells, a 
TH1 immune response predominates.  But the host produces also an immune response against 
the extracellular forms of the parasite, playing the antigenic variability of the parasite, in this 
case, an important role in the evasion mechanisms. 
Contradictory results have been reported on the participation of autoimmunity in 
experimental infection, and its role in the pathogenesis of Chagas disease remains 
controversial.  However, the existence of molecular homologies between the parasite and host 
molecules, so called “molecular mimicry”, is indisputable, such as between the epitope B13 of 
T. cruzi and the heavy chain of cardiac myosin (Cunha-Neto et al. 1996), or between the 
ribosomal proteins of T. cruzi and some human P proteins and an extracellular functional loop of 
the human ß1-adrenergic receptor.  The antibodies from patients with T. cruzi chronic infection, 
by recognising such human antigens, might contribute to worsening the cardiac dysfunction 
induced by the parasites (Tibbetts et al., 1994; Cunha-Neto et al., 2006).   
The parasite plays a fundamental role in the genesis and development of organ lesions 
by sequentially inducing an inflammatory response, cellular lesions and fibrosis.  Such 
pathological processes may occur in many organs but appear more frequently and more 
intensively in the heart, esophagus, and colon. The inflammatory response results from the 
rupture of infected cells releasing trypomastigotes and is intense in the acute phase.  Cellular 
lesions affect the myocytes and the nervous cells (leading to an autonomic denervation), and 
fibrosis, which appear slowly and gradually, and is associated with chronic chagasic 
myocardiopathy (Carlier, 2003).    
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1.5.2   Clinical manifestations.  Phases of Chagas disease 
Three phases can be distinguished on the Chagas disease course: acute phase, 
indeterminate (or latent) phase and chronic phase.  During the acute phase (1 to 4 months), the 
disease is characterised by active infection with circulating trypomastigotes in the blood.  This 
phase frequently passes unnoticed, although there may be an inflamed swelling at the 
trypanosome entry site such as Romaña’s sign (see Figure 1.5-1), which is characterised by 
periorbital edema and conjunctivitis (Romaña, 1935).  An inflammatory lesion in the skin at the 
parasite entry site, known as chagoma, develops less frequently.  Other symptoms, if they 
become apparent, will occur within seven to nine days post-bite and may include fever, 
tiredness and swelling of lymph nodes.  These symptoms spontaneously resolve within three or 
four months.  A small number of individuals develop severe complications associated with an 
acute myocarditis or meningoencephalitis, and die. During this stage, a large number of 
parasites are found in blood, although parasitemia levels vary between individuals. 
 
 
 
 
 
 
 
 
 
During the indeterminate (or latent) phase, patients are clinically asymptomatic, and as 
good as no parasites are detectable in blood, however, they are seropositive.  Some 50-70% of 
persons in this phase never develop recognizable chronic lesions and remain asymptomatic, 
but they are vulnerable to sudden death due to cardiac conduction abnormalities, sometimes 
without being diagnosed with Chagas disease. 
The chronic phase develops 10-30 years after infection in approximately 30% of infected 
patients.  During this phase, organs including heart, oesophagus, colon, and peripheral nervous 
 
 
Figure 1.5-1 Romaña’s sign.  Conjunctival 
contamination with the vector's feces results in 
unilateral painless palpebral and periocular swelling. 
One of the few characteristic symptoms which occur in 
the acute phase of Chagas disease (Image: 
WHO/TDR). 
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Figure 1.5-2 Apical aneurysm  (left), and megacolon (right). The "apical aneurysm" 
is a very special heart lesion whose identification helps in the macroscopic diagnosis of the 
cardiopathy. Its location is the left heart apex, less frequently the right side.  On acquired 
Chagas  disease megacolon, degenerative changes  occurs, including a quantitative reduction 
in the intramural ganglia of the entire intestinal tract. The denervated muscle layer becomes 
hypertrophic and lacking in propulsive efficiency owing to its in-coordinate contractions 
(aperistalsis). The result is fecal stasis, dilatation and finally hypoxic atony. (Images: Peters 
and Pasvol, 2006). 
system can be affected.  Chronic Chagas disease most often manifests itself as 
cardiomyopathy or autonomic neuronal dysfunction resulting in megasyndromes.   
The heart is frequently affected in the chronic stage of disease, with significant 
destruction of the conduction system, myocytes, and parasympathetic cardiac nerves.  This and 
the appearance of arrhythmogenic electric foci in the inflammatory areas are at the origin of 
arrhythmic syndrome (EKG abnormalities).  The hypertrophy of remaining myocytes and the 
intense fibrosis replacing the destroyed myocytes predispose to cardiac dilatation and failure, 
and as a consequence, enlarged hearts are observed in patients.  The left ventricular wall can 
become thinner, allowing the formation of an apical aneurysm, which is a feature of Chagas 
disease (Figure 1.5-2).  Most of the “sudden death” cases by this disease are due to cardiac 
complications.  
At digestive level, lesions (parasympathetic intramural denervation) are dispersed 
irregularly and mainly affect the esophagus and the colon.  The affected segment may have a 
normal macroscopic appearance with only peristaltic alteration, leading frequently to 
constipation, which in many cases remains unnoticed by the patients.  However, it may be 
dilated (megaesophagus or megacolon, Figure 1.5-2), or it may be dilated and elongated 
(dolichomegaesophagus).  An increase of rigidity and tension of the cardia is present at the 
onset of esophageal dysfunction. The digestive pathology can be easily underdiagnosed, 
especially when the symptoms are mild, and therefore might be more frequent as previously 
described (Guevara et al., 1997).   
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Chagas disease can be an opportunistic infection on HIV/AIDS individuals (Vaidian et 
al., 2004), occurring in endemic areas as well as in non-endemic areas, but frequently linked to 
social exclusion and poverty.  The reactivation of the chronic Chagas disease, which can 
manifest in form of meningoencephalitis or myocarditis, has been observed in many of these 
cases.  This happens because the immune response against Trypanosoma cruzi is mediated by 
T cells and, in HIV positive patients, this cell population is altered.  In addition, coinfection of 
Chagas disease and HIV/AIDS shows difficulties on the immunodiagnosis, due to the 
diminished anti-T. cruzi antibody production.  On the other hand, the elevated parasitemia level 
in these patients represents an advantage while using microscopy and xenodiagnosis to detect 
T. cruzi (Braz et al., 2001).   
 
Acute and subacute 
form 
Death Subacute form 
Chronic stage 
Indefinite early stage 
Chronic cardiac form Digestive form Permanent indefinite 
form 
Slight cardiopathy Severe cardiopathy 
5 to 10% 
60% 
90% 
2 to 3% 
15% 
30% 10% 
15% 
Fig 1.5-3 Diagram showing different Chagas disease stages.  Almost all patients pass 
from the acute or subacute stage to a latent chronic stage, which can take 10 to 20 years.  
Most patients remain in an indefinite stage for the rest of their lives, but others develop cardiac  
or digestive complications. Cardiopathy severity varies between individuals. In some cases the 
complication level increases, leading to death. Taken together, patients which do not show 
any apparent symptoms, basically latent and mild foms, represent the majority of the cases 
(adapted from Albajar-Viñas et al., 2007). 
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Figure 1.6-1 Geographical distribution of Chagas disease. The disease is 
distributed in the Americas, ranging from Mexico to Argentina, mostly in poor, rural 
areas of Central and South America.  It predominates in warm areas were the insect 
vector lives.  However, the new distribution tendency includes urban centres where 
other ways of transmission, different to vectorial, exist.  
(Image:http://upload.wikimedia.org/wikipedia/commons/c/c3/Carte_maladie_Chagas.png) 
1.6  Epidemiology of Chagas disease: geographical distribution, 
prevalence, incidence and mortality 
Chagas disease is endemic in 18 countries in Central America (Belize, Costa Rica, El 
Salvador, Guatemala, Honduras, Mexico, Nicaragua and Panama) and in South America 
(Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Paraguay, Peru, Uruguay and Venezuela).  
In addition, it is prevalent but less well documented in Guyana, French Guiana and Suriname 
(Figure 1.6-1). Originally, the disease was almost exclusively found in rural areas, characterized 
by poor sheltering, huts constructed with mud and covered by grass or palm leaves, where very 
poor population lives in contact with Triatomines (Figure 1.6-2). In such situation of poverty, 
people tend to emigrate to urban centres, spreading by this way the disease to cities. 
 Current estimates of the prevalence of Chagas disease range from 9.9 to 14 million 
infected individuals.  This amounts to approximately 2-3% of the population of Latin America, 
with 100 million (25% of the Latin American population) at risk of acquiring the disease, which is 
killing around 50.000 people annually.  Estimates of incidence range from 185.000 to 317.000 
new cases per year, with a WHO-cited figure of 200.000 new cases per year.  Due to the lack of 
an adequate reporting system, Chagas disease prevalence and mortality rates are chronically 
underestimated and dark numbers are higher as some published official statistics. 
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Figure 1.6-2 Palm house in El Beni, Bolivia (left) and ”adobe“ house  in Guatemala. These kinds of 
dwellings are characteristic of low-income settlements. Triatomine bugs live in the palm roofs and in crevices of adobe 
houses, getting out, mainly at night, to feed blood from sleeping people.  (Image left: courtesy of Beck E; right: Médecines 
Sans Frontières, MSF). 
1.7   Control of Chagas disease: vectors and blood banks 
With no vaccine or specific treatment available for large scale public health interventions, 
the main control strategy still relies on prevention of transmission.  Over the course of several 
decades, all available resources and planned activities targeted predominantly vector control.  
But with the arrival of the HIV/AIDS pandemic, this focus was extended to the monitoring of 
blood transfusions, and then large-scale screening of blood donors in Latin America began 
(Dias et al., 2002).  
Through the Southern Cone initiative, which started in 1991, governments of the six 
Southern Cone countries (Argentina, Bolivia, Brazil, Chile, Paraguay and Uruguay) launched an 
ambitious initiative to control Chagas disease through both elimination of the main vector, 
Triatoma infestans, and large-scale screening of blood donors (Schofield et al., 1999).  
Stimulated by the Southern Cone success, two further regional strategies were launched in 
1997 in Central America and the Andean Pact region.  In both cases, the main targets are 
R. prolixus and T. dimidiata.  More recently started in 2004 the Amazonic Initiative, that targets 
Rhodnius and Panstrongylus, vector species present in the Amazonic area.  These initiatives 
have knocked down transmission rates dramatically primarily through insecticidal spraying of 
houses (Talerton et al., 2007).  Unfortunately, the required repeated spraying to prevent re-
infestation of houses by the insect vector, also promotes the development of insecticidal 
resistance, which has been already documented (Picollo et al., 2005).  For this reason, 
improvement of housing would potentially reduce vectorial transmission permanently, but the 
economic costs of this strategy are too high for some regions, even though there are successful 
examples in Venezuela (Tonn, 1988).  
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Figure 1.8-1 Infectious and parasitic disease burden in Latin America. 
The economic impact of Chagas  disease during the chronic stage is very high, 
representing the first cause of cardiac lesions in young, economically productive 
adults in the endemic countries in Latin America. Data in DALYs (Disability-Adjusted 
Life Years). (Image: OneWorldHealth Institute, 2007) 
1.8   Economic burden of Chagas disease 
Chagas disease remains the most important vector-borne neglected disease in the 
Americas today (Inter-American Development Bank, 2005). As in all neglected diseases, 
Chagas disease creates financial and social burdens to the affected individuals and countries.  
The early mortality and substantial disability caused by this disease, which often occurs in the 
most productive population, young adults, results in devastating economic loss.  Recent data 
demonstrate that globally, Chagas disease is associated with 0.7 million DALYs (Disability-
Adjusted Life Years) constituting the sixth most important neglected tropical disease worldwide 
(Hotez et al. 2006).    
In Latin America, Chagas disease holds the fourth place among the ailments with the 
largest burden of disease. The comparative burden of Chagas disease among infections and 
parasitic diseases in the region is less than diarrhoeal disease, HIV, and tuberculosis, but 
higher than meningitis, sexually transmitted diseases, hepatitis B and C, and malaria (Figure 
1.8-1).   
 
 
 
 
 
 
 
Poor housing, lack of access to safe blood-bank supplies, and inadequate prenatal care 
are linked to social and health inequalities in many areas of Latin America.  People living under 
these conditions are the ones at risk of acquiring Chagas disease. At the same time, this 
disease contributes to maintain the poverty cycle, keeping people in many areas unable to 
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work, stigmatised, and therefore poor and in underdevelopment. Additionally, T. cruzi infection 
impose an overwhelming load to the healthcare system due to hospitalizations and medical and 
surgical treatments especially as consequence of chronic manifestations such as chagasic 
cardiomyopathy, gastrointestinal dysfunction, and meningoencephalitis.    
The annual economic loss in Latin America due to early morbidity and mortality from 
Chagas disease has been estimated to be as high as $18 billion.  Countries with larger rural 
populations generally have higher prevalence rates, less vector control and less available 
resources for healthcare, and hence are more negatively impacted economically than countries 
with larger urban populations (Franco-Paredes, 2007). 
 
1.9 International impact 
In our days, travel of persons from one point of the planet to the another has become 
much easier than it was one century ago.  People are constantly moving in their own countries, 
from the land to the cities, but are also traversing borders; and with them, their infections.  
Globalisation includes not only humans, but also pathogenic agents. Thus, diseases are not any 
longer only limited to their original endemic area, but are becoming cosmopolite.  The so called 
tropical diseases exist not only in tropical regions, but can appear in almost every place on the 
planet linked to moving people. Therefore, according to this new tendency, the term “emergent 
infectious disease” has been defined. This means an infectious disease that has newly 
appeared in a population, where it originally did not exist, or a disease which has been already 
eradicated and it arises again, rapidly increasing in incidence or geographic range. 
Chagas disease has been classified as emergent disease, not only due to the 
urbanization tendency, but also because migration is causing thousand of persons every year to 
abandon their homes, and leave for other places where they hope to have better opportunities.  
Many people from Chagas disease endemic countries in Latin America migrate to other rich 
countries, especially in North America (United States and Canada) and Europe. A minor group 
of migrants moves to Asia and Australia.   
The fact that Chagas disease can be transmitted by blood transfusion and organ 
transplantation, together with the lack of specific test screening in blood banks and hospitals, 
has facilitated the spreading of the disease enormously.  There are already several registered 
cases of infection by this ways in the United States and Europe (CDC, 2006; Young et al., 2007; 
Flores-Chavez et al., 2008).   
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Figure 1.9-1 Global aviation network.  A geographical representation of the civil 
aviation traffic among the 500 largest international airports in 100 different countries is 
shown. Each line represents a direct connection between airports. The colour encodes the 
number of passengers per day (see colour code at the bottom) travelling between two 
airports  (Hufnagel et al., 2004). The expansion of international air travel has enhanced 
exponentially the hazard of spreading pathogens through human-to-human contact from a 
limited locality across the continents. 
 
Vertical transmission of the disease is an additional uncontrolled spreading factor, 
because children born with Trypanosoma cruzi infection remain undiagnosed in most of the 
cases, transmitting later the disease to other persons via blood and organ donation or, in the 
case of women, giving birth to infected children perpetuating congenital transmission (Muñoz et 
al., 2007).  
Travel from tourists to Chagas disease endemic areas and infection there, is extremely 
rare, because people do not usually sleep in poor conditions or receive blood transfusions in 
these countries.  However, it can occur, and people travelling to these areas are potentially 
exposed to infection and should be previously informed.  Because physicians outside Latin 
American countries do often not recognize the disease, the probability of underdiagnosing the 
infection is extremely high.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25.000 10 
Introduction                                                                                                                                                                                       15                                                                                                                                       
_____________________________________________________________________________ 
 
 
 
Figure 1.10-1 Nifurtimox (a) and Benznidazole (b) chemical 
structure.  Both are nitroheterocyclic compounds , Nifurtimox is a 
nitrofuran, and Benznidazole a nitroimidazole derivative.   
1.10   Current therapy and potential new therapies. Vaccines 
At present, two drugs are available for the treatment of Chagas disease: Benznidazol 
(Rochagan® or Radanil®, Roche) and Nifurtimox (Lampit®, Bayer), both nitroheterocyclic 
compounds (Figure 1.10-1).  They resulted from veterinary investigations in the 1970es, and 
have never been improved. These drugs show significant activity only in the acute and short-
term chronic phase, with up to 80% parasitological cures in treated patients, and their 
effectiveness varies according to the geographical area.  It has been observed that children 
tolerate these drugs better than adults.  For this reason the early diagnosis and treatment leads 
to high chances to be cured. 
Trypanosoma cruzi has been shown to be deficient in detoxification mechanisms for 
oxygen metabolites, particularly hydrogen peroxide, and is thus more sensitive to oxidative 
stress than are vertebrate cells (Docampo, 1990).  Benznidazol acts via reductive stress, which 
implies the covalent modification of macromolecules by nitroreduction intermediates.  Nifurtimox 
acts via the reduction of the nitro group to unstable nitroanion radicals, which react to produce 
highly toxic, reduced oxygen metabolites (superoxide anion, hydrogen peroxide).  Side-effects 
of both compounds are probably resulting of their oxidative and reductive damage to the host’s 
cells.  Unfortunately, the antiparasitic activity of these compounds is obligatory bound to their 
toxicity to the vertebrate host.   
Differences in drug susceptibility between different T. cruzi strains have been observed 
(Andrade et al., 1992).  These differences are product of the natural susceptibility, but also 
drug-resistant Trypanosoma cruzi strains have been described (Buckner et al., 1998). 
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It is important to note that, due to the fact that the acute phase is frequently 
asymptomatic, many people do not realise to be infected until they are in a chronic phase, being 
then the effectiveness of the drugs very low.  For this reason, there is an urgent need for a new 
drug (safer and more effective), with minimal side-effects and with activity also in the chronic 
phase.    
It is easier to use drugs which are already in the market and are being used for other 
diseases, than to develop new ones.  Efforts are being done in this direction.  Some of the most 
promising new approaches for the development of drugs against Chagas disease, which have 
already completed pre-clinical studies, include sterol biosynthesis inhibitors.  These are based 
on the fact that T. cruzi requires specific sterols for viability and proliferation in all stages of its 
life cycle, and the parasite has been shown to be very susceptible to inhibitors of ergosterol 
biosynthesis (Urbina et al., 2003). Cysteine protease inhibitors have been also tested.  These 
are selective inhibitors for a protease (named cruzipain, cruzain or gp51/57), responsible for 
essential functions of the parasite.  When it is blocked, proliferation of epimastigotes and 
amastigotes is arrested.  Pyrophosphate metabolism inhibitors are other possible anti-
trypanosomatid and anti-apicomplexan drugs, based on the specialized organelles that 
trypanosomatid and apicomplexan parasites contain, acidocalcisomes, which are involved in 
polyphosphate and cation storage, and in the adaptation of these microorganisms to 
environmental stress.  Bisphosphonates are selectively accumulated in the parasite and inhibit 
enzymes involved in inorganic and organic pyrophosphate reactions.   
Another promising possibility, still in pre-clinical studies, includes inhibitors of purine 
salvage.  Trypanosomatids are absolutely deficient in the de novo synthesis of purines.  
Instead, they scavenge the essential compounds from their growth medium.  Allopurinol, used 
since long time for the treatment of gout, acts as a purine analogue, and is incorporated into the 
parasite’s DNA, disrupting the synthesis of RNA and proteins. 
Other possible drugs against Trypanosoma cruzi include inhibitors of trypanothionine 
metabolism, based on the unique biochemical pathway to kinetoplastid protozoa, which 
replaces glutathione and glutathione reductase in the cell; inhibitors of phosphatidylcholine 
biosynthesis, such as miltefosine, already used for the treatment of leishmaniasis; transialidase 
inhibitors, Na+H+ Exchange inhibitors, and dihydrofolate reductase inhibitors.  
At the moment, there is no existing vaccine for Chagas disease and its development has 
had a low priority, due to the high effective impact of other measures such as vector control and 
blood bank screening.  However, question of cost-effectiveness increases the interest for the 
creation of a vaccine, but even though efforts are being made, progress is still slow. Current 
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strategies focus basically on recombinant subunit vaccines, live attenuated vaccines and DNA 
vaccines. 
Recombinant subunit vaccines, such the immunization of mice with recombinant 
paraflagellar rod proteins (PAR) (Luhrs et al., 2003) and cruzipain (Schnapp et al., 2002), 
showed protective immunity in acute infection but did not block completely parasitemia. The 
different attempts to use a whole killed cell or attenuated vaccines produced only partial 
immunity.  In this aspect, reduction of mortality and parasitemia in mice after immunization with 
Trypanosoma rangeli (Basso et al. 2004), and mucosal protective responses after oral feeding 
of mice with infected Triatomatide excreta (Hoft et al.,1996) have been observed.   
DNA vaccines have shown to elicit both humoral and cellular immunity. Attempts using 
trypomastigote surface antigen I (TSA-I) (Wizel et al., 1998), Tc52 protein (virulence factor of 
T. cruzi), and trans-sialidases have been made.  However, this kind of vaccines are still in a 
very early stage and it will take many years until they can be used in humans. 
 
1.11   Diagnosis 
Chagas disease is asymptomatic in most of its course in both, intermediate and chronic 
phases.  This fact represents a major problem and is the reason why so many people are 
unconscious to be infected.  In the acute phase some diffused and unspecific symptoms can 
appear, but not necessarily. Therefore, the diagnosis by symptoms is problematic and it is of 
great importance to apply other accurate diagnostic methods.  
 
1.11.1   Direct microscopic methods 
The classical direct microscopic observation of fresh anticoagulated blood or blood 
smears is highly specific, but its sensitivity varies, because the titre of circulating parasites can 
be very low and, in addition, a trained microscopist is required.  Observation of fresh blood 
allows seeing T. cruzi living parasites in movement.  Blood smears facilitate the differentiation of 
T. cruzi and T. rangeli, because it permits the easy visualization of the nucleus, kinetoplast and 
flagella, and can be used if the sample has to be transported.   
In order to concentrate the parasites and facilitate their detection, other alternative 
methods can be used. The microhematocrit technique consists on the detection of 
Trypanosoma cruzi parasites in the “buffy coat” prepared from whole blood in heparinized 
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capillary tubes by centrifugation.  Its use is specially extended in congenital Chagas disease, 
because only a little amount of blood is needed.  However, this manipulation represents a risk of 
infection, and requires a special protection for the laboratory workers.  The Strout method 
consists on the incubation of blood for 1 hour at 37ºC, collection of the serum by centrifugation 
to eliminate the erythrocytes, a second centrifugation of the obtained supernatant, and the 
examination of the precipitate from the last centrifugation under the microscope.   
 
 
 
 
 
 
 
 
1.11.2   Indirect methods 
Indirect methods consist on the multiplication of the parasites from the collected samples 
either in the Triatomine bug (xenodiagnosis) or in a culture medium (hemoculture).  
Xenodiagnosis is characteristic for Chagas disease. Excretes of sterile Triatomine insects breed 
in the laboratory are examined for Trypanosoma cruzi, after an incubation period (4 to 6 weeks) 
posterior to the bite of patients to be tested for Chagas disease. Alternatively, the insects can be 
put in contact with blood of the patients through a latex membrane.  It is 100 % specific, but it 
takes long time to obtain the results and retards therefore the beginning of the treatment. It is, 
however, a widespread method in endemic countries, because it is quite inexpensive and does 
not require sophisticated laboratory equipment.   
For the hemoculture, blood samples from patients are grown in liver infusion tryptose 
medium for a period of four to six months, and this is examined regularly for parasites.  As 
xenodiagnosis, it is a highly specific method, but it takes long time to obtain the results. In 
addition, the sensitivity of these indirect methods is very low in the chronic stage of the disease, 
when the parasite level in blood decreases.   
 
 
Figure 1.11-1 Trypanosoma cruzi microscopic observation in blood 
smears.  Blood smears have been stained with Giemsa, which highlights DNA, 
allowing to distinguish kinetoplast in extracellular Trypomastigote forms, but 
also in Amastigotes that are inside the cells. Trypomastigotes can be observed 
especially in blood samples from patients in acute phase.  
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1.11.3   Immunological methods 
Commercial serologic tests used routinely in the laboratory include indirect 
hemaglutination (IHA), indirect immunofluorescence (IIF) and enzyme linked immunosorbent 
assay (ELISA).  Indirect hemaglutination is based on the agglutination of crude antigens (from 
T. cruzi epimastigotes) with antibodies contained in the blood of patients.  It has a high 
sensitivity but low specificity.  Indirect immunofluorescence uses antigens from epimastigotes 
and fluorescein isothiocyanate-conjugated sheep anti-human immunoglobulin as secondary 
antibody.  It is less expensive than IHA, but it requires a UV microscope and a well trained 
person.  In addition, readings are subjective, and cross-reactions especially with visceral 
leishmaniasis can occur.  The ELISA technique can be performed using either crude extracts or 
recombinant antigens. The specificity increases while using recombinant antigens, because 
cross-reactions, obtained frequently with crude extracts, do not occur.  It requires a microplate 
reader and washer, but it allows large amounts of samples to be tested, and results are 
objective.       
A special test, the complement-mediated lysis (CoML), detects anti-T. cruzi lytic 
antibodies which are recognized by epitopes present on the surface of living trypomastigotes, in 
contrast to conventional serology, which detects antibodies that recognize epitopes present on 
the surface of fixed parasites, or parasite extracts.  This is a time-consuming technique that 
requires manipulation of living parasites, which represents a high risk for the laboratory 
personnel, and therefore it is not used as routine method.   
Western blot immunodiagnosis uses epimastigote antigens from T. cruzi.  This technique 
has been used to compare the antigenic pattern recognized by different sera and distinguish the 
antibodies transmitted by the mother and the ones produced by the baby, allowing on that way 
the detection of congenital Chagas disease. Other western blot immunoassays have been 
developed with excreted/secreted antigens to distinguish the acute from the chronic phase of 
the disease.  The specificity of this technique is not very high, because it uses crude antigens of 
the parasite.   
Lateral flow devices are the most appropriate method for the detection of Chagas 
disease in the field.  They have a user-friendly format, requiring only little amount of whole blood 
or serum, and results are obtained within few minutes.  In addition, they can be stored for long 
time at room temperature in a relatively wide range of climates.  However, specificity has proven 
to be not very high, and for this reason it is the method of choice for blood screening in the field, 
but the confirmation by a second method is recommended for diagnosis of patients (Figure 
1.11-2).   
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1.11.4   Molecular methods 
Molecular methods for the diagnosis of Chagas disease are based on the detection of 
DNA of the parasite.  The most important technique is the Polymerase Chain Reaction (PCR), 
which amplifies the parasite DNA in blood or tissue samples of patients. Many approaches 
including “nested” PCR or “real time” PCR (Piron et al., 2007) have been done, reaching highly 
specific and sensitive assays.  However, this technique requires a laboratory equipped with a 
thermocycler, and the enzyme Taq DNA polymerase, which is usually quite expensive.  PCR is 
also an appropriate method for the detection of congenital T. cruzi infection (Virreira et al., 
2003), due to its sensitivity and the small amount of blood obtained in these cases.   
To summarize, it can be concluded that direct microscopic examination, 
microhematrocrit, hemoculture and xenodiagnosis are generally specific techniques.  Their 
major disadvantages rely on the fact that they are not very efficient in low parasitemia cases; 
there is a delay in obtaining results and, in the specific case of xenodiagnosis, that it causes 
stress to the patients.  However, these are methods still widespread in the affected countries 
because they are inexpensive and do not require a high technology equipped laboratory. 
 Indirect hemagglutination and immunofluerescence as well as the complement mediated 
lysis and Western blot are quite sensitive but, in most of the cases, lack specificity, which can 
easily result in wrong diagnosis.    
Serologic methods based on the detection of antibodies in blood of patients have the 
general limitation that antibodies persist for long time even after cure, and therefore it is not 
possible to distinguish an active infection from an already cured patient.  With regard to the fact 
 
 
Figure 1.11-2 Lateral flow devices for diagnosis in the 
field. The only commercialised rapid tests for Chagas disease are 
used for large screening campaigns in the field (Image: MSF).   
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that drugs used for Chagas disease are very toxic, the treatment time has to be reduced as 
much as possible.  For these cases, PCR is highly recommended, even though this technique is 
not very popular in endemic countries, basically due to its equipment requirements and costs.  
According to WHO recommendations, the general lack of specificity of many diagnostic 
assays for the detection of T. cruzi infection can at present be solved by the use of at least two 
different techniques for confirmatory diagnosis of Chagas disease. Low specific methods can be 
used for blood screening without major danger, because blood conserves are going to be 
discarded, but if the purpose is the diagnosis of the patient, then the technique must be 
accurate enough to distinguish infections with different pathogens. 
 
Table 1.11-1 Chagas disease diagnostic methods summary table. 
 
Method Advantages Disadvantages 
Microscopic examination 
of blood 
Highly specific 
Trained microscopist needed  
Low sensitivity in chronic stage 
Microhematocrit 
A small amount of blood needed 
Specific  
Extraction of “buffy coat” needed 
Limited sensitivity 
Xenodiagnosis 
Specific   
Inexpensive 
Stressing for patient 
Takes long time to have a result 
Hemoculture Specific Takes long time to have a result 
Indirect Hemagglutination 
(IHA) 
Highly sensitive Low specificity 
Indirect 
Immunofluorescence (IIF) 
Sensitive 
Not specific enough 
Requires training and expensive 
UV microscope 
Complement-mediated 
lysis (CoML) 
Sensitive 
Handle of live parasites needed 
(high risk for laboratory staff) 
Western blot Sensitive Low specificity 
ELISA 
Automatable  
Quantifiable 
Requires a microplate reader 
  Not able to distinguish chronic 
and acute phase 
Lateral flow device 
Field applicable 
Small amount of sample required 
Results within few minutes 
Limited sensitivity and specificity  
PCR Highly specific and sensitive. High risk of contamination 
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Figure 1.12-1 Bolivia’s topography. Bolivia is a landlocked country in South 
America that borders with Peru, Brazil, Paraguay, Argentina and Chile. It has a 
territory of more than one million km2 and a population of more than nine million 
inhabitants spread over three distinct topographies: highland plateaus and Andean 
mountain slopes, valley area, and plains.  Almost the half of the population lives in 
the highlands. 
(Image: http://commons.wikimedia.org/wiki/Image:Bolivia_Topography.png). 
1.12   Bolivia, the most affected country 
1.12.1   Health situation 
In spite of its natural wealth, Bolivia is the poorest country in South America and 64% of 
the population lives below poverty line.  The government heavily depends on foreign assistance 
to finance development projects.  
Health conditions are notably poor, owing to inadequate hygiene conditions and 
insufficient number of medical doctors and hospitals, especially in rural areas, where 36% of the 
total population lives. The sustainable access to safe drinking water (only 85% of the 
population) and adequate sanitation (only 45% of the population) represents a main problem in 
these regions.  In Bolivia, life expectancy at birth was reported to be of 65 years in 2005, and 
the country’s population is young (38% of the population under 15), this latter due in part to high 
fertility rates (3.7 children per woman). However, maternal mortality accounts for 230 per 
100.000 live births (WHO, 2004) and children deaths due to perinatal complications are very 
frequent. 
 
 
 
 
 
 
 
 
 
 
 
 
Brazil 
Peru 
Chile 
Argentina 
Paraguay 
Bolivia 
La Paz 
Sucre 
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Leading death causes in Bolivia are cardiovascular problems (including those which are 
consequence of chagasic cardiopathy), communicable diseases and other causes such as 
diseases of the respiratory tract and affections originating in the perinatal period (PAHO, 2000).  
In 2003, 27% of children suffered from chronic malnutrition and of these, 8% from severe 
malnutrition. Children with chronic malnutrition are more likely to die from infectious diseases 
such as diarrhea and pneumonia, since their immune system is weak and they lack caloric 
reserves to fight off illnesses.  At present, diarrhea causes 36% of deaths in children under five 
years in Bolivia. 
Communicable diseases account for a high percentage of the deaths in the country, and 
the most common infectious disorders are acute respiratory diseases, tuberculosis, malaria, 
hepatitis, and Chagas disease.  The HIV prevalence is 0.1% and it is currently increasing. The 
high rates of morbidity and mortality due to these diseases reduce the productive potential of 
Bolivia’s human resources and reinforce the vicious cycle of poverty and hunger.  
 
1.12.2   Chagas disease in Bolivia 
Available information is not very accurate but, according to recent data, at present in 
Bolivia 1.6 to 2.1 million individuals are infected with Trypanosoma cruzi and 3.5 million are 
considered at risk to get infected.  Chagas disease accounts for 13% of all the deaths in the 
country (MSF, 2004).  The high disease prevalence, varying from 20 to 40% in some areas, is 
the largest infection rate in Latin America by far.  The endemic area in Bolivia covers 60% of the 
country, and the rural population is considered as the main population at risk of infection.  
However, it has been recently shown that vectorial transmission is occurring in suburbs of the 
main cities, too. In addition, due to the large chagasic population, congenital and blood 
transmission are very abundant. Infection rates greater than 50% were reported in blood donors 
in Santa Cruz (Carrasco et al., 1990) and a prevalence of almost 10% congenital Chagas 
disease has been reported in some rural areas in Bolivia (Azogue, 1993).   
Two major distinct monophyletic groups of clones (20 and 39) have been identified in the 
country in the domestic cycle, belonging to T. cruzi I and T.cruzi II respectively (Brenière et al., 
1998), and mixed infections have been already described (Bosseno et al., 1996).  
Some years ago, the Southern Cone Initiative, in which Bolivia was included, carried out 
spraying campaigns to eliminate the predominant insect vector, Triatoma infestans, and had a 
large impact in some areas, reducing enormously the infestation rates (Guillén et al. 1997).  In 
addition, Bolivia’s Ministry of Health, supported by the Pan-American Health Organization, 
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Figure 1.12-2. Chagas disease endemic area in Bolivia. The 
endemic area comprises around 55% of national territory (about 
600,000 km 2) where about 3.5 million people are considered at risk to 
the infection. In highly endemic communities, especially in the 
Departments of Cochabamba, Chuquisaca, Tarija, Santa Cruz and 
Potosi, seroprevalence rates may reach close to 100% in older age 
groups (Image: IDBAmérica). 
launched in the last years a campaign that aimed to control disease-bearing insects, treat 
Chagas disease in children under five years, safeguard national blood-bank supplies, and 
implement an epidemiological surveillance system.  However, there is still a lot to do, and 
Chagas disease  is still one of the most important public health problems in the country.   
 
 
 
 
 
 
 
 
 
 
1.13   Purpose of this work 
Infectious diseases continue to be the leading causes of disability and death in 
developing countries. In principle, these diseases would be preventable and treatable with our 
today's medical knowledge and are therefore listed as "preventable diseases" by the World 
Health Organisation. The causes for this unsatisfactory situation are manifold and complex, 
however, it is not always missing financial resources, but rather lack of rational strategies and 
appropriate tools. For the treatment of many of these diseases drugs are available, even at 
affordable prices. However, correct therapy presumes adequate diagnosis, and this is frequently 
more expensive than the drugs themselves, or the existing diagnostics are not applicable 
because they are not adapted to the needs of the specific conditions.  
Chagas disease which belonged for many years to the category of “most neglected 
diseases” is exemplary in this respect. It has been called a "silent" disease because it kills 
people after years of hidden infection without significant forewarning. Médecins Sans Frontières 
called also a "silenced" disease because it affects mainly the poorest amongst the poor, and 
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neither the world nor even the governments of the concerned countries were interested to 
interfere. Only after blood and organ donations became a lucrative market, the disease turned 
to the attention of the scientific society, and more specific diagnostics were developed to 
prevent accidental infections with contaminated material. Consistently, these new diagnostics 
are appropriate for use in blood banks, but not for patients because they cannot clearly 
discriminate between Chagas disease and other diseases, which would be essential for 
appropriate therapy. The same holds for the only available drugs, once developed for use in 
animals and leading to severe side effects. There are no efforts from the site of the rich 
countries, who could afford it, to develop more appropriate drugs because there is no much 
money to earn. 
However, when used on time, i.e. soon after infection, even these oldish drugs are 
useful and reveal a good cure rate combined with acceptable side effects. Under this aspect, a 
highly sensitive and specific diagnostic procedure would be highly beneficial when applied in 
regular periods of time for the whole population at risk. To be affordable for the impoverished 
countries even when used in large scale, it has to be inexpensive, too. Regarding the 
accumulated scientific data on Chagas disease, especially the almost complete genomic DNA 
sequence of T. cruzi and of several other Trypomastigotes, it looked very promising to develop 
new diagnostic procedures which would fulfil the conditions of being sensitive, specific and, at 
the same time, simple and inexpensive by combining molecular biological methods with 
contemporary bioinformatic tools.  
Thus, it was purpose of this work, to design appropriate diagnostic procedures and to 
test their usefulness for the diagnosis of Chagas disease. To avoid cross-reactions, the new 
procedures should differentiate between related species such as Leishmania species, or 
Trypanosoma rangeli.  In addition, the tests should be able to detect the disease in its acute as 
well as in its chronic phase, and they should also allow monitoring of the decrease of circulating 
parasites after treatment with drugs. 
Two general techniques appeared to be appropriate: the production of T. cruzi-specific 
recombinant antigens for use in immunoassays and the design of  primers for specific PCR 
diagnosis.  Similar methods had been developed already by others, and it was therefore not 
needed to start form scratch.  But the existing diagnostic tests appeared not good enough and 
were by far too expensive. Therefore, the new diagnostic procedures had to be as simple and 
inexpensive as possible and should not require very sophisticated laboratory equipment, 
otherwise their use in the affected countries would not be realistic.  
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2.   MATERIALS AND METHODS 
2.1   Instruments 
Gel electrophoresis systems 
Horizontal minigel system (8 x 8 cm) AGS, Heidelberg, Germany 
Vertical minigel chamber (8 x 10 cm) Keutz, Reiskirchen, Germany 
Power supply EPS 500/400   Pharmacia, Freiburg, Germany 
 
Shakers 
Horizontal shaker GFL 3020   Gesellschaft für Labortechnik, Burgweldel, 
      Germany 
Horizontal shaker GFL 3015   Gesellschaft für Labortechnik, Burgweldel 
      Germany 
Certomat R     Braun, Melsungen, Germany 
Vortex Genie 2    Scientific Industries, Bohemia, NY, USA 
 
Centrifuges 
Cooling centrifuge Beckman J2-21,   Beckman Instruments, Summerset, USA 
(with Rotors: JA 14 and JA 20) 
Microfuge: Biofuge Pico   Heraeus Instruments, Hanau, Germany 
Multifuge 3     Heraeus Instruments, Hanau, Germany 
 
Waterbath  
GFL Wasserbad 1013    Gesellschaft für Labortechnik, Burgwedel, 
Germany 
Thermocyclers 
T1 Thermocycler 96    Biometra GmbH, Göttingen, Germany 
Primus 96     MWG Biotech AG, Ebersberg, Germany 
 
Sonifier 
Sonoplus HD70     Bandelin, Berlin, Germany 
 
Photographic equipment 
UV Transilluminator     Herolab GmbH, Wiesloch, Germany 
UV transilluminator MW 312nm N36 Roth, Karlsruhe, Germany 
Polaroid MP-4 Land Camera   Polaroid Corporation, Cambridge, MA, USA 
Film: Polaroid 667 Professional   Polaroid Corporation, Cambridge, MA, USA 
Olympus Camedia C-370 Digital camera Olympus, Germany 
 
Microplate reader 
Bio Rad Model 3550-UV                       Bio Rad, Munich, Germany 
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2.2   Materials 
2.2.1   Chemicals 
 
Acrylamid      Serva, Heidelberg, Germany 
Agarose for gel electrophoresis   Sigma-Aldrich, Munich, Germany 
Ammoniumpersulfate (APS)    Serva, Heidelberg, Germany  
Ammoniumsulfate     Carl Roth GmbH, Karlsruhe, Germany 
Ampicillin      Sigma-Aldrich, Munich, Germany 
Adenil Triphosphate (ATP)    Carl Roth GmbH, Karlsruhe, Germany 
Biorex 70 resin     BIO-RAD Laboratories, Hercules, USA 
Bovine serum albumin fraction V (BSA)  Carl Roth GmbH, Karlsruhe, Germany 
5-Bromo-4-chloro-3-indolylphosphat (BCIP) Gerbu, Wiesloch, Germany 
Coomassie Brilliant Blue R250   Serva, Heidelberg, Germany 
Dithiothreitol (DTT)     Biomol, Heidelberg, Germany 
Ethidium bromide     Serva, Heidelberg, Germany 
Ethylenediaminetetraacetic acid (EDTA)  Serva, Heidelberg, Germany 
Guanidiniumhydrochlorid (GHC)   ICN Biomedicals, Germany 
Heparin sepharose     Pharmacia-LKB, Upsala, Sweden 
Hydrogen peroxide 30% (w/v) (H2O2)   Sigma-Aldrich, Munich, Germany 
Isopropyl-ß-D-thiogalactopyranose (IPTG)   Gerbu, Wiesloch, Germany 
Kanamycin      Sigma-Aldrich, Munich, Germany 
ß-Mercaptoethanol     Serva, Heidelberg, Germany 
Nitro blue tetrazolium (NBT)    Gerbu, Wiesloch, Germany 
N,N-dimethylacetamine (DMA)    Sigma-Aldrich, Munich, Germany 
N,N,N‘,N‘- Tetramethylethylendiamine (TEMED) Serva, Heidelberg, Germany 
Phenylmethylsulphonylfluoride (PMSF)  Carl Roth GmbH, Karlsruhe, Germany 
Polyethyleneimmine     Sigma-Aldrich, Munich, Germany 
Polyethylenglycol (Mr 3500-4500)   Carl Roth GmbH, Karlsruhe, Germany 
Sodiumdodecylsulfate (SDS)   Carl Roth GmbH, Karlsruhe, Germany 
Tetracycline      Sigma-Aldrich, Munich, Germany 
Tetrabutylammonium borohydride (TBABH)  Sigma-Aldrich, Munich, Germany 3,3’,5,5’-
Tetramethylbenzidine (TMB)    Gerbu, Wiesloch, Germany 
Tween-20 (polyoxyethylen sorbitan monolaureat) Serva, Heidelberg, Germany 
Triton X-100      Merck, Darmstadt, Germany 
Tris (hydroxymethyl) aminomethane   Carl Roth GmbH, Karlsruhe, Germany 
Urea       ICN Biomedicals, Germany 
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Silica suspension for purification of nucleic acids 
 50 g of silica (SiO2) powder (Sigma No. S 5631) were suspended in 250 ml of water, 
centrifuged for 3 min at 5000 x g, the milky supernatant was discarded, the sediment 
resuspended in another 250 ml of water and centrifuged again. The procedure was repeated 3-
5 times more until supernatant became clear. The sediment was suspended in one volume of 
water and kept in 2 ml aliquots at -20°C. 
 
Nitrocellulose membrane 
Protran BA 85    Schleicher & Schuell Bioscience, Dassel, Germany 
       
DNA size marker 
Plasmid pSP 64 was cleaved a) with Hind III, b) with Dra I and c) with Hinf I. The 
individual cleavage assays were mixed in the relation 1:2:4 with respect to the amount of 
plasmid DNA, resulting in the following fragment sizes (bp): 
 
                                                                 
                                                                   
 
 
 
 
 
 
 
 
2999 
2288 
 
1198 
 
692 
517 
 
354 
396 
 
 
218 
 
176 
 
 
 
 
 
75 
65 
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2.2.2   Bacterial strains 
 Escherichia coli XL1-Blue    recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1  
      lac [F´ proAB, lacIZ .M15 Tn10 (Tet)] 
 Escherichia coli XL1-Blue/pREP  recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1  
      lac [F´ proAB, lacIZ .M15 Tn10 (Tet)]/pREP(Kan) 
  
2.2.3   Trypanosoma cruzi DNA 
 A sample of Trypanosoma cruzi DNA (strain MIHOM/CH/00/Tulahuen C2) was obtained 
from the Bernhard-Nocht Institute in Hamburg, Germany.  80 µl of 3 M sodium acetate were 
added to the sample (700 µl in 70% ethanol) and the tube was incubated at -20ºC for 2 days.  
Afterwards, the sample was centrifuged 15 min at 13.000 rpm, and the small sediment washed 
once with 70% ethanol.  DNA was redissolved in 400 µl TE buffer.  The estimated final DNA 
concentration is 0.1 µg/µl. 
 
2.2.4   Antisera 
30 antisera from Chagas patients (Latin American immigrants living in Barcelona) were 
obtained from the parasitology department of the University of Barcelona.  They were diluted 
with glycerol (50% final concentration) and kept at -20ºC.    
400 additional Chagas disease patient sera were obtained from a diagnostic laboratory 
at the Servicio Departamental de Salud (SEDES), Cochabamba, Bolivia.  They were diluted 1:1 
with a saturated solution of ammonium sulphate, and kept as a suspension at 4ºC.   
The leishmaniasis antisera from patients of cutaneous and visceral leishmaniasis used 
to test the cross-reactions of the recombinant antigens were obtained from a diagnostic 
laboratory in the Republic of Yemen, and were diluted 1:1 with a saturated solution of 
ammonium sulphate. 
Control sera were derived from German blood donors in the Academic Hospital at the 
University of Giessen, Germany. 
Phosphatase and peroxidase-conjugated goat anti-human IgG antibodies were bought 
from Dianova GmbH, Hamburg, Germany. 
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2.2.5   Enzymes 
Restriction enzymes 
  
Enzyme U / µl Buffer Target sequence Company 
Bam HI 20 NEB 2 + BSA G?GATCC New England Biolabs® 
EcoRI 20 NEB 2 + BSA G?AATTC New England Biolabs® 
Hind III 20 NEB 2 + BSA A?AGTCC New England Biolabs® 
PvuI 20 NEB 3 + BSA CGAT?CG New England Biolabs® 
 
  Other enzymes 
 
Enzyme Activity Company 
T4 DNA ligase 1 Weiss-U / µl New England Biolabs® 
Taq polymerase 5 U / µl self-made (see below) 
Proteinase K 0,3 U / µl Sigma / Alldrich® 
RNase A 0,5 Kunitz-U / µl Sigma / Alldrich® 
Lysozyme 100 U / µg Sigma / Alldrich® 
Polynucleotide kinase 10 U / µl New England Biolabs® 
 
2.3   Buffers and solutions 
2.3.1   Buffers and solutions for protein gel electrophoresis 
 
Tris-glycin electrophoresis buffer (TG): 
25mM Tris; 192 mM glycin 
0,1% SDS 
 
Sample buffer (SB) 
50 mM Tris-HCl (pH 6.8) 
2% SDS 
10% glycerol 
1% ß-mercaptoethanol 
12.5 mM EDTA 
0.025% bromphenol blue 
 
6 x SB buffer (10 ml) 
2 ml 1M Tris-HCl pH 6,8 
0.8 g SDS 
0.4 ml glycerol 
0.4 ml ß-mercaptoethanol 
1 ml 0.5 M EDTA 
1 ml 0.1% bromphenol blue 
add H2O to 10 ml 
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Coomassie Blue staining solution  
50% ethanol 
10% acetic acid 
0.12% Coomassie Brilliant Blue  
 
 
 
Distaining solution 
7.2% acetic acid  
5% ethanol 
 
 
 
 
 
2.3.2   Buffers and solutions for DNA gel electrophoresis 
 
 
Agarose gel electrophoresis buffer (E-buffer)  
40 mM Tris/acetate (pH 8,0)  
40 mM Na acetate 
2.0 mM EDTA 
 
 
 
 
Acrylamide gel electrophoresis buffer (TBE-buffer) 
90 mM Tris/borate pH 8.3  
2.5 mM EDTA 
 
 
 
 
 
 
Loading buffer 
20 mM Tris/HCl pH 7.5  
50% glycerol  
0.02% bromphenol blue  
0.02% xylene cyanol blue  
20 mM EDTA 
 
Distaining solution 
375 ml acetic acid 96% 
250 ml ethanol 99. 6% 
add H2O to 5 litre 
Coomassie Blue staining solution 
2.4 g Coomassie Blue  
1 litre ethanol 99.6% 
200 ml acetic acid 96% 
add H2O to 2 litres 
20 x E-buffer 
193.8 g Tris-OH 
131.2 g Na acetate 
160 ml 0.5 M EDTA 
adjust pH 8.3 with acetic acid 
        (approx. 55 ml of 96% HAc) 
add H2O to 2 litre 
10 x TBE-buffer  
108 g Tris-OH 
55 g boric acid 
40 ml 0.5M EDTA  
adjust pH 8.0 with acetic acid 
       (approx. 6 ml of 96% HAc) 
add H2O to 1 litre 
Loading buffer 
0.2 ml 1 M Tris/HCl pH 7.5 
5 ml glycerol 
0.2 ml 10 mg/ml bromphenol blue 
0.2 ml 10 mg/ml xylene cyanol 
blue 
0.4 ml 0.5 M EDTA 
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Ethidium bromide staining solution 
1 µg ethidium bromide / 100 ml E-buffer 
 
 
 
 
 
2.3.3   Buffers and solutions for methods of Molecular Biology 
 
 
TE buffer 
10 mM Tris/HCl pH 7.5 
0.1 mM EDTA  
 
 
T4 Ligase buffer 
30 mM Tris-HCl (pH 7,5) 
10 mM MgCl2 
10 mM dithiothreitol (DTT) 
10% polyethileneglycol (PEG) 
1 mM ATP 
100 µg /ml bovine serum albumin (BSA) 
 
 
 
Restriction enzyme cleavage buffer NEB 2 
10 mM Tris-HCl 
10 mM MgCl2 
50 mM NaCl 
1 mM dithiothreitol (DTT) 
 
 
 
Restriction enzyme cleavage buffer NEB 3 
50 mM Tris-HCl 
10 mM MgCl2 
100 mM NaCl  
1 mM dithiothreitol (DTT) 
 
 
 
 
 
Staining solution 
400 ml 1 x E-buffer 
40 µl 10 mg/ml ethidium bromide 
solution 
2 x T4 ligase buffer (1 ml) 
30 µl 1 M Tris-HCl 
10 µl 1 M MgCl2 
10 µl 1 M dithiothreitol  
200 µl 50% polyethileneglycol  
10 µl 0.1 M ATP 
20 µl BSA (5 mg/ml) 
720 µl H2O  
10 x NEB 2 
0.1 ml 1 M Tris/HCl pH 8.0 
0.1 ml 1 M MgCl2 
0.1 ml 5 M NaCl 
0.1 ml 100 mM dithiothreitol 
10 x NEB 3 
0.5 ml 1 M Tris/HCl pH 8.0 
0.1 ml 1 M MgCl2 
0.2 ml 5 M NaCl 
0.1 ml 100 mM dithiothreitol 
 
TE buffer (100 ml) 
1 ml 1 M Tris/HCl pH 7.5 
20 µl 0.5 M EDTA 
add H2O to 100 ml 
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GuHCl lysis buffer 
24 g GuHCl  
2 ml 1 M Tris/HCl pH 7.0 
2 ml of 0.5 M EDTA  
0.5 ml Tween 20 
RBC lysis buffer 
4.1 g NH4Cl 
0.6 g NH4HCO3 
0.5 g KCl 
0.1 ml 0.5 M EDTA 
add H2O to 500 ml 
adjust pH 7.2 with 1 M HCl 
 
2.3.4   Buffers for total DNA extraction 
 
 
GuHCl lysis buffer (DNA extraction buffer) 
5 M Guanidinum hydrochloride (GuHCl) 
40 mM Tris/HCl pH 7.0 
20 mM EDTA  
1% Tween 20  
 
 
Ethanol washing buffer 
70% ethanol 
10 mM TrisHCl pH 7.0 
 
 
 
RBC lysis buffer: 
300 mM NH4Cl 
30 mM NH4HCO3 
30 mM KCl 
0.1 mM EDTA 
 
 
 
 
 
2.3.5   Buffers for alkaline lysis/silica method for plasmid preparation 
 
Solution 1 
100 mM Tris/HCl pH 7.5 
10 mM EDTA 
 
 
Solution 2 
200 mM NaOH  
1% SDS  
 
 
Solution 3 
3 M Na acetate 
2 M acetic acid 
 
Ethanol washing buffer 
70 ml ethanol 
1 ml 1 M Tris/HCl pH 7.0 
29 ml H2O 
Solution 2 
4 ml 5 N NaOH 
10 ml 10% SDS 
86 ml H2O 
Solution 3 
60 ml 5 M Na acetate 
11.5 ml glacial acetic acid 
28.5 ml H2O 
Solution 1 
10 ml 1 M Tris/HCl pH 7.5 
2 ml 0.5 M EDTA 
88 ml H2O 
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GuHCl lysis buffer, GuHCl washing buffer, and Ethanol washing buffer needed for the further 
purification steps are shown above. 
 
 
2.3.6   Buffers for purification of His-tagged proteins with TALON® 
 
 
Protein lysis buffer 
6 M guanidinium hydrochloride (GuHCl) 
40 mM Tris/HCl pH 8.0 
250 mM NaCl 
 
 
 
Washing / equilibration buffer 
8 M urea 
40 mM Tris/HCl pH 8.0 
250 mM NaCl 
 
 
 
Elution buffer 
8 M urea  
40 mM Tris/HCl pH 7.0 
250 mM NaCl 
250 mM imidazol 
 
 
 
 
2.3.7   Buffers for immunoassays 
 
 
TBS-buffer 
10 mM Tris-HCl pH 8.0 
150 mM NaCl 
 
 
 
TBST-buffer 
10 mM Tris-HCl pH 8.0 
150 mM NaCl 
0.05% Tween 20 
Washing/equilibration buffer 
48 g urea 
4 ml 1M Tris/HCl pH 8.0 
5 ml 5 M NaCl 
add H2O to 100 ml 
 
Elution buffer 
48 g urea 
4 ml 1M Tris/HCl pH 7.0 
5 ml 5 M NaCl 
1.7 g imidazol 
add H2O to 100 ml 
adjust pH to 7.0 
Lysis buffer  
57.3 g GuHCl 
4 ml 1M Tris/HCl pH 8.0 
5 ml 5 M NaCl 
add H2O to 100 ml 
20 × TBST buffer (2 litres) 
200 ml 1 M Tris/HCl pH 8.0 
175 g NaCl 
10 ml Tween 20 
add H2O to 2 litres 
20 × TBS buffer (2 litres) 
200 ml 1 M Tris/HCl pH 8.0 
175 g NaCl 
add H2O to 2 litres 
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Antigen dilution buffer 
1 x TBS 
0.2% Tween 20 
10% glycerol 
1 mM  DTT 
 
 
 
Ab dilution buffer 
1 × TBST 
1% BSA 
1 mM  DTT 
 
 
 
AP buffer 
100 mM Tris-HCl pH 9,5 
100 mM NaCl 
5 mM  MgCl2 
 
 
 
NBT solution 
50 mg/ml NBT (nitro blue tetrazolium)  
in 70% dimethylformamide  
keep at -20°C 
 
 
BCIP solution 
50 mg/ml BCIP (5-Bromo-4-Chloro-3-Indolylphosphate)  
in 100% dimethylformamide  
keep at -20°C 
 
AP colour developing solution 
60 µl BCIP solution and 60 µl NBT solution dissolved in 10 ml of AP buffer (stable for 1 hour) 
 
 
ELISA Washing buffer (1 x PBS): 
 
0.1 M phosphate buffer (pH 7.2) 
0.15 M NaCl 
2.5 mM KCl  
 
Antigen dilution buffer (100 ml) 
5 ml 20 x TBS 
2 ml 10% Tween 20 
10 ml glycerol 
1 ml 1M DTT 
82 ml H2O 
Ab dilution buffer (100 ml) 
5 ml 20 x TBST 
1 g BSA 
1 ml 1M DTT 
93 ml H2O 
AP buffer (200 ml) 
20 ml 1M Tris-HCl pH 9,5 
4 ml 5 M NaCl 
1 ml 1 M MgCl2 
175 ml H2O 
10 x PBS 
90 g of NaCl 
14.4 g of Na2HPO4 
2.4 g of KH2PO4 
add H2O to 1 litre  
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Blocking buffer 
1% milk powder 
1x PBS 
 
 
 
Buffer A for ELISA assay 
0.2 M potassium citrate pH 4.0  
3 mM H2O2 
  
 
 
 
 
 
 
Solution B for ELISA assay 
41 mM tetramethylbenzidine (TMB)  
8.2 mM TBABH in N,N-dimethylacetamide (DMA) 
(absolute, H2O content <0.01%) 
 
 
 
Substrate working solution for ELISA assay 
Immediately before use, 
add 200 µl Solution B to 8 ml Buffer A with freshly added H2O2 
 
 
 
Stop Solution for ELISA assay 
1 M H2SO4 
 
 
 
 
 
 
Buffer A 
2.2 g citric acid 
2.5 g  tri-Na-citrate (Mr = 294) 
add H2O to 100 ml 
pH to 4.0 ± 0.1 
before use, add 25 µl of 30% 
H2O2 to 8 ml of this pH 4.0 
stock solution 
Solution B: 
100 mg TMB  
20 mg TBABH 
10 ml DMA 
Stop Solution: 
5.4 ml 98% H2SO4 
add H2O to 100 ml  
Blocking buffer 
1 g milk powder  
100 ml 1 x PBS 
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2.4   Methods 
2.4.1   DNA purification 
Isolation of nucleic acids using guanidinium-hydrochloride/silica 
The following procedure is appropriate to isolate total DNA (1-5 µg) from a variety of 
bacteria, eukaryotic cells, or homogenised tissue (10 to 20 mg).  500 µl of guanidinum 
hydrochloride (GuHCl) lysis buffer (5 M GuHCl, 40 mM Tris/HCl pH 7.0, 20 mM EDTA, 1% 
Tween 20) were added to 10-20 µl sedimented cells, vortexed and incubated for 10 min at 
65°C.  After 2 min centrifugation at 13.000 rpm in a minifuge, the supernatant was transferred to 
a new tube and 5 µl of silica suspension were added, mixed with vortex and incubated for 5 min 
at room temperature.  The sample was centrifuged for 30 s at 13.000 rpm, the pellet 
resuspended in 300 µl 70% ethanol washing buffer, centrifuged for 30 s at 13.000 rpm and the 
supernatant removed. The pellet was washed in the same way three more times with ethanol 
washing buffer (70% ethanol, 10 mM TrisHCl pH 7.0).  The last pellet was centrifuged again and 
the rest of ethanol removed. 5 µl of TE buffer were added, incubated for 5 min at 55°C and 
centrifuged for 1 min at 13.000 rpm.  The supernatant was collected and the pellet eluted with 
another 5 µl TE buffer. The supernatants were combined. 
For the particular case of blood samples conserved in guanidinium hydrochloride, 400 µl 
of the Gu-blood were mixed with 600 µl of guanidinium lysis buffer. Then, the general procedure 
for DNA extraction with silica (described above) was followed.  
 
Alkaline lysis/silica method for plasmid preparation 
The plasmid DNA purification procedure is a combination of the alkaline lysis protocol 
originally published by Ish-Horowicz and Burk (1981) and the above described silica adsorption 
method.  It can be used for mini plasmid preparations (1.5 ml cultures) as well as for bigger 
preparations (50 ml cultures or more).  In the following, the volumes of the different solutions 
needed in each step are given for mini plasmid preparations and for 50 ml cultures in brackets. 
1.5 ml [50 ml] of over night culture were centrifuged for 3 min.  The supernatant was removed 
by aspiration and the pellet resuspended in 100 µl [2 ml] of  Solution 1. 10 µl [100 µl] of Rnase A 
(5 mg/ml; kept at -20°C in 50 % glycerol) were added, and the sample was incubated at room 
temperature for 2 min. 200 µl [4 ml] of Solution 2 were added, quickly mixed (it is important not 
to vortex) and incubated for 2 min at room temperature (RT). Then, 150 µl [3 ml] of Solution 3 
were added and again well mixed (without vortexing) and incubated for 1 min. The sample was 
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centrifuged at 13.000 x g for 10 min at RT and the supernatant transferred to a new tube. Then, 
400 µl [7 ml] of GuHCl lysis buffer and 7 µl [100 µl] of silica suspension were added. The 
sample was mixed by vortexing, incubated at RT for 5 min, centrifuged for 1 min and the 
supernatant removed. To the pellet, 400 µl [7 ml] of ethanol washing solution were added. The 
sample was mixed by vortexing, centrifuged for 1 min and the supernatant discarded. The 
washing steps were repeated twice. Finally, the wet silica was centrifuged again for 1 min and 
the residual washing solution removed completely. To elute the DNA, silica was resuspended in 
20 µl [200 µl] TE buffer, incubated 10 min at 55°C, centrifuged for 2 min and the supernatant 
collected in a new tube. Silica was eluted once more with 20 µl [200 µl] TE buffer (only vortexed, 
not incubated at 55°C), centrifuged and the supernatants combined. 
 
DNA purification from agarose gels 
To purify DNA fragments from agarose gels the following protocol (Vogelstein et al., 
1979) was used.  The corresponding part of the gel was cut out under UV, and incubated with 
2-3 volumes of 4 M NaI at 60°C until the agarose was molten.  5-10 µl of silica suspension were 
added and incubated at room temperature for 5 min.  After centrifugation for 30 s, the silica 
pellet was washed three times with ethanol washing solution and the DNA eluted in the minimal 
volume of TE buffer as described above. 
 
Buffy coat DNA extraction 
 2-3 ml of citrate or EDTA-blood were centrifuged for 15 minutes at 1000 x g. Then, 
supernatant plasma was collected and kept in the refrigerator.  The yellow thin “buffy coat” layer 
on top of the sedimented erythrocytes was collected with a pipette (200 to 300 µl) and 
transferred to an Eppendorf tube.  1.2 ml of RBC lysis buffer were added, mixed shortly by 
vortexing, incubated 10 minutes at room temperatures, inverting the tube several times.  
Afterwards, the tube was centrifuged 1 minute at 2000 x g, and the supernatant removed.  A 
pellet of 10-20 µl was obtained and mixed with guanidinium hydrochloride lysis buffer.  DNA 
was extracted as described above.   
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2.4.2   Purification of recombinant Taq DNA polymerase 
Taq DNA polymerase was purified from a recombinant strain of E. coli (E. coli XL-1 
Blue/pQE-Taq) expressing an exonuclease-free mutant of the enzyme. The strain was 
constructed previously in the laboratory of E. Beck (unpublished results). The thermostable 
enzyme can also be purified without the cooling steps described in the following protocol.  
1 litre of LB medium containing 25 µg/ml kanamycin and 50 µg/ml ampicillin was 
inoculated with 100 ml of an over night culture of XL-1 Blue pQE-Taq cells.  The cells were 
grown at 37°C with optimal aeration for 1-2 hours.  At an OD600 of 1.8, 1 ml of 1 M IPTG was 
added and then the culture vigorously shaked for another 4 hours.  Cells were harvested by 
centrifugation (yield ~5 g) and frozen at -20°C. Freezing of the cells can be omitted, but is 
recommended if the enzyme preparation is not performed immediately.  The cells were 
resuspended in 15 ml TMN buffer (50 mM Tris-HCl pH 8.5, 1 mM EDTA, 20 mM (NH4)2SO4) 
together with 8 mg of lysozyme (from 10 mg/ml stock solution) and incubated for 15 min at 20-
25°C.  After adding 200 µl of 10% Triton X-100 and 200 µl of 10% Tween 20, the culture was 
mixed and incubated at 80°C for 20 min in a 50 ml screw-cap Falcon tube.  After the heating 
step, 250 µl of 100 mM PMSF were added to prevent proteolytic degradation. 
DNA was sheared by 1 min sonification (it is also possible to do it by repeated pressing 
through a syringe first with a 1 mm diameter needle and then with smaller needles) and 
centrifuged 15 min at 20.000 x g at 4°C.  The supernatant (~15 ml) was collected and 0.6 ml of 
5 M NaCl (0.2 M final concentration) were added.  
The DNA was precipitated with polyethyleneimine (PEI) by adding dropwise 500 µl of 5% 
PEI solution, mixing and incubating in ice for 10 min.  The sample was centrifuged at 10.000 x g 
for 5 min.  4 aliquots of 500 µl of supernatant were transferred to Eppendorf tubes each and 
mixed with increasing amounts (2-8 µl) of 5% PEI solution.  They were incubated 5 min on ice, 
centrifuged and the amount of pellet compared. The minimal amount of PEI to precipitate DNA 
quantitatively was determinated and added to the bulk extract (usually 100-200 µl; use 1/100 
volume of 5% PEI solution in excess). The suspension was left 20 min on ice and centrifuged at 
20.000 x g for 20 min. The supernatant was collected and diluted 6 fold with KTA buffer (20 mM 
Tris/HCl pH 8.5, 10 mM beta-mercaptoethanol, 10 % (w/v) glycerol, 0.1 mM EDTA, 0.05 % 
Triton X 100, 0.05 % Tween 20). 
The excess of PEI was removed by passing the extract through a 2 ml BioRex 70 
column equilibrated in KTA buffer + 30 mM ammonium sulphate. A disposable 4 ml plastic 
column (International Sorbent Technology, Hengoed, Mid Glamorgan, UK) was used.  The 
column was rinsed with 2 ml KTA buffer and the flow-through loaded on another plastic column 
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containing 2 ml heparin sepharose equilibrated with KTA buffer, 30 mM ammonium sulphate.  
The column was washed first with 50 ml KTA buffer, 40 mM ammonium sulphate. Thereafter, 
the column was washed with 20 ml KTA buffer, 40 mM ammonium sulphate, 50% glycerol. Taq 
DNA polymerase was eluted with KTA buffer, 150 mM ammonium sulphate, 50% glycerol. 0.5 
ml fractions were collected and 3 µl aliquots analysed on a 12.5% SDS polyacrylamide gel.  The 
enzyme was found in fractions 4 to 7. The enzyme was stored at -20°C. For long term storage, 
Tween 20 to 1% final concentration was added. The yield was approximately 30.000 units of 
enzyme at a concentration of 80 units/µl in the peak fraction. 
 
2.4.3   Standard cleavage assay 
 Cleavage of DNA with BamHI and HindIII in the same assay was performed with NEB2 
buffer, and 500 mg / ml BSA (end concentration) for 1 to 2 hours at 37°C.  For PvuI, NEB3 
buffer was used under the same conditions. In general, 20 U of each restriction enzyme were 
used in a 50 µl assay. 
 
2.4.4   Standard ligation assay 
 Ligation of fragments to be cloned in expression vectors was performed by T4 ligase (1 
Weiss-U / µl) with ligation buffer containing 5% PEG.  To the assay were added the previously 
with BamHI and HindIII cleaved vector and fragment.  The ligation assay was incubated over 
night at 12ºC, and used the next day, after purification with silica, for the transformation of the 
electroporation competent cells.   
 
2.4.5   Transformation of E. coli cells by electroporation 
Transformation by electroporation was performed essentially as described by Sambrook 
et al. (1989).  5 ml of a fresh pre-culture (over night culture is not recommended) were taken to 
inoculate 200 ml pre-warmed LB medium.  The cells were grown at 37°C until OD600 of 0.6 was 
reached. The culture was chilled on ice as quickly as possible and the cells centrifuged for 5 
min at 10.000 x g.  The pellet was resuspended in 25 ml ice-cold water. Centrifugation and 
resuspension were repeated two times and finally the pellet was resuspended in 400 µl ice-cold 
water and 10% glycerol (final concentration) added.  The cells were aliquoted in 40 µl portions 
and kept frozen at -70°C. 
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For transformation, 40 µl competent frozen cells were thawn in ice. 10 µl of silica purified 
ligase assay were added and the tube left in ice for 1 min. The cells were transferred in a pre-
cooled 2 mm electroporation cuvette and electroporated at 2500 V.  Immediately after, 1 ml of 
LB medium was added, the cells transferred in an Eppendorf tube and incubated for 1 h at 
37°C. 100 µl of the content of the Eppendorf tube were spread in one half of an agar plate 
containing selective antibiotics.  The rest of the cells was centrifuged, resuspended in approx 
100 µl of medium and spread on the other half of the plate.  The agar plate was incubated over 
night at 37°C. 
 
2.4.6   Expression and purification of His-tagged prote ins 
Expression and purification of His-tagged proteins was performed essentially as 
described by Hochuli et al. (1988). The recombinant antigens were cloned in pQE-30 (Qiagen, 
Hilden, Germany).  This vector provides a histidine tag to the N-terminus of the recombinant 
proteins (see Figure 2.4-1). Expression from the strong phage T5 promotor of this vector is 
regulated by a lac repressor provided in excess by the plasmid pREP (maintained in the cells by 
kanamycin selection).  
 E. coli XL-1Blue/pREP cells transformed with a gene cloned in pQE-30 were grown in LB 
medium containing 50 µg/ml ampicillin and 25 µg/ml kanamycin up to 5 x 108 cells per ml (OD600 
= 0.8-1.0). At that point, IPTG was added to a final concentration of 1 mM, and the cells (250 ml 
culture in a 1 litre Erlenmeyer flask) were further incubated under vigorous agitation on a shaker 
for 3-4 hours at 37°C. The induced cells were harvested by centrifugation and frozen at -20°C. 
Next day, the cells were thawn, resuspended in 10 ml of Lysis buffer (6 M guanidinium 
hydrochloride, 40 mM Tris/HCl pH 8.0, 250 mM NaCl) and incubated for 30 min at RT, shaking 
from time to time. The lysed cells were centrifuged 20 min at 20.000 x g in a cooling centrifuge, 
the pellet was discarded and the supernatant transferred to a 50 ml Falcon tube containing 1 ml 
suspension (0,5 ml packed volume) of TALON® (equilibrated in Washing buffer). The solution 
was mixed gently in a rotating wheel for 1 hour and centrifuged for 1 min at 3.000 x g in a 
swinging bucket centrifuge. The supernatant was removed carefully and 50 ml of Washing 
buffer (8 M urea, 40 mM Tris/HCl pH 8.0, 250 mM NaCl) were added. The solution was shaked 
5 min, centrifuged again for 1 min at 3.000 x g and the supernatant removed carefully. The 
washing steps were repeated two times. The resin was then suspended in 4 ml of Washing 
buffer and loaded on a disposable plastic column.  
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--------------------T5 promotor/lac operator---------- 
CTCGAGAAATCATAAAAAATTTATTTGCTTTGTGAGCGGATAACAATTATAATAGATTCA    60 
 
-------------------------->          >---RBS---> 
       >--pQE-forw primer-> Eco RI                     Met 
ATTGTGAGCGGATAACAATTTCACACAGAATTCATTAAAGAGGAGAAATTAACTATGAGA   120 
 
           His-tag       BamH I                      Sal I 
GGATCGCATCACCATCACCATCACGGATCCGCATGCGAGCTCGGTACCCCGGGTCGACCT   180 
 
       HindIII 
GCAGCCAAGCTTAATTAGCTGAGCTTGGACTCCTGTTGATAGATCCAGTAATGACCTCAG   240 
 
                                                  <-- 
AACTCCATCTGGATTTGTTCAGAACGCTCGGTTGCCGCCGGGCGTTTTTTATTGGTGAGA   300 
 
 <-pQE-rev primer 
ATCCAAGCTAGCTTGGCGAGATTTTCAGGAGCTAAGGAAGCTAAAATGGAGAAAAAAATC   360 
 
 
Figure 2.4-1 Multiple cloning site of the pQE-30 expression vector. Recognition sites of  
some restriction enzymes (red), histidine-tag (green), ribosome binding site (RBS),  hybridation sites 
of pQE forward and reverse primers (blue), metionine codon (violet) and T5 promotor and lac operator 
(orange) at the beginning of the sequence are shown. 
 
The column was rinsed with 5 ml of Washing solution and the proteins eluted by adding 
stepwise 0.5 ml of Elution buffer (8 M urea, 40 mM Tris/HCl pH 7.0, 250 mM NaCl, 250 mM 
imidazol). There was a break of 2 min between the single steps leading to elution of more 
concentrated protein. Aliquots of 3 µl and 15 µl of each of the 0.5 ml fractions were analysed 
with SDS PAGE.  Protein concentration was determined by the Bradford assay (Bradford, 
1976). 
 
 
 
 
 
 
 
 
 
 
 
2.4.7   Line blot 
The line blot is a simple immunoassay similar to the well known Western blot and was 
performed essentially as described by Klinkert et al., 1991.  In contrast to the Western blot, 
antigens are not electrotransferred but applied manually to the nitrocellulose membrane.   
 
Preparation of antigen test stripes 
Antigen was applied to nitrocellulose sheets as a line with a 1.0 mm tip of an ink pen 
(Rotring Radiograph, Rotring GmbH, Hamburg, Germany), using a ruler as a guide. 
Alternatively, a 200 µl plastic pipette tip was used whose opening was squeezed with pliers to 
reduce the speed of flow. The antigen solution was prepared by mixing recombinant antigen (in 
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7 M urea as eluted from the TALON column) with different amounts of antigen dilution buffer 
(1xTBS, 0.2 % Tween 20, 10 % glycerol, 1 mM DTT). The concentration of protein is in the 
range of 0.1 - 0.01 mg/ml, however, the appropriate dilution has to be determined empirically for 
each batch of antigen by serial two-fold dilutions. The concentration just not yet reactive with 
negative control sera is correct. Lines of individual antigens were placed 0.5 cm apart. Non-
specific binding sites were blocked by placing the air-dried nitrocellulose sheet in TBS buffer, 
1% Tween 20 for 1 hour. Sheets were then washed in TBS, 0.1% Tween 20 (TBST), cut 
perpendicularly to the antigen lines in 4 mm stripes, dried and stored at ambient temperature.  
 
Immunodetection 
The nitrocellulose stripes were re-hydrated in TBST and incubated in disposable 
incubation trays (Schleicher & Schuell, item No. 10448017) with 0.5 ml of a primary antibody 
solution (patient or control serum) diluted 1:100 - 1:200 in Ab dilution buffer (1 × TBST, 1 % 
BSA, 1 mM DTT) for 0.5-1 hours at room temperature or over night at 4°C on a shaker.  The 
antibody was removed from the solution and saved at 4°C.  The nitrocellulose stripes were 
washed three times for 10 minutes each with TBST and 0.5 M NaCl.  Then, they were incubated 
with goat anti human IgG conjugated to alkaline phosphatase (Dianova, Hamburg, Germany; 
1:7000 diluted in Ab dilution buffer) for 1-2 hours at room temperature on a shaker. Finally, the 
stripes were washed three times for 10 minutes in TBST and once with AP buffer (100 mM Tris-
HCl pH 9.5, 100 mM NaCl, 5 mM MgCl2).  The "disposable" incubation trays can be re-used 
many times when washed carefully with detergent using a brush. 
 
AP staining protocol 
To visualise the bound AP-conjugated antibodies, the following method was used.  An 
AP colour developing solution was prepared just before use by adding 60 µl BCIP solution (50 
mg/ml BCIP in 100% dimethylformamide) and 60 µl NBT solution (50 mg/ml NBT in 70% 
dimethylformamide) to 10 ml of AP buffer.  The membrane stripes were added to the AP colour 
developing solution with the protein side up and it was waited for colour to develop on the 
membrane. When bands became clearly visible, the membranes were transferred to 10 mM 
Tris-HCl pH 8.0, 1 mM EDTA to stop the reaction.  After drying at room temperature, the test 
stripes were photographed, or scanned into a computer. 
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2.4.8   ELISA 
Flat-bottom 96 well microtiter plates (Greiner Bio-One, Frickenhausen, Germany) were 
incubated over night at 4°C with 0.1 ml of antigen TcBCDE diluted in PBS to a concentration of 
1 ng/ml. The wells were washed three times with 0.35 ml PBS each and then incubated with 0.2 
ml blocking solution (1% milk powder in PBS) for 1 hour at ambient temperature. The blocked 
plates were washed three times with PBS, dried and stored at room temperature. For long term 
storage (more than one month), the antigen-coated plates were sealed in plastic sheets. 100 µl 
of serum samples diluted 1:200 in blocking solution were added to each well and incubated for 
1 hour at room temperature. The plates were washed three times with PBS, the wells filled with 
a 1:5.000 dilution of goat anti human IgG-HRP (horse radish peroxidase) conjugate (Dianova, 
Hamburg, Germany) and incubated again for 1 hour at room temperature. The plates were 
washed three times with PBS as before, then 75 µl of HRP substrate working solution were 
added to each well, incubated at room temperature, and the staining reaction stopped after 30 
minutes with 100 µl of 1 M sulphuric acid and the results read at 450 nm. The HRP substrate 
working solution was prepared immediately before use as follows: 25 µl of a 30 % solution of 
H2O2 and 200 µl of 41 mM 3,3',5,5'-tetramethylbenzidine, 8.2 mM tetrabutylammonium 
borohydride in N,N-dimethylacetamide were added to 8 ml of 0.2 M potassium citrate buffer pH 
4.0 (Frey et al., 2000).  
 
2.4.9   PCR procedures 
Standard PCR conditions 
For all PCR assays, the same Taq DNA polymerase buffer was used. It is prepared as a 
10 x buffer and has the following composition: 
 
1 x Taq buffer  
40 mM Tricine-KOH (pH 8.7 at 25°C) 
15 mM K acetate 
3.5 mM acetate 
0.1 % gelatine 
0.05 % Tween 20 
 
 
 
10 x Taq buffer (10 ml) 
4 ml 1 M Tricine-KOH 
1.5 ml 1 M K acetate 
350 µl 1 M acetate 
2.5 ml 4% heated gelatine solution  
500 µl Tween 20 
1.15 ml H2O 
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Standard PCR reaction assay 
 Using efficient standard thermocyclers such as T1 thermocycler 96 from Biometra, or 
Primus 96 from MWG Biotech which are appropriate for 200 µl reaction tubes, have a heated lid 
and heating/cooling rates of at least 2-3°C/s, highly reproducible results were obtained with 
assays as small as 10 µl. A standard PCR reaction had the following composition: 
1 µl 10 x Taq buffer 
1 µl mixture of 4 dNTPs (2.5 mM each)  
0.5 µl 10 µM forward primer 
0.5 µl 10 µM reverse primer 
1 µl template DNA  
5.8 µl H2O 
0.2 µl Taq DNA polymerase (5 units/µl) 
 
The standard program of the thermocycler was set as follows: 
step 1:    2 min at 94°C (denaturing of DNA template) 
step 2:    35 cycles of [94°C 20 s, 60°C 1 min, 72°C 1 min] 
step 3:    5 min 72°C (optional, to fill-inn the DNA ends completely) 
The same conditions were applied for nested PCR. 1 µl of a 1:10 dilution (with H2O) of 
the result of first PCR assay was used as DNA template. 
 
2.4.10   Gel electrophoresis 
Agarose gels 
Agarose gel electrophoresis was performed according to standard procedures 
(Sambrook et al. 1989).  Plasmid DNA and PCR fragments were analysed on horizontal 1% or 
2% agarose gels using a Tris/acetate electrophoresis buffer (E-buffer).  To check migration of 
the DNA fragments, the samples were mixed with 20% loading buffer containing 50% glycerol 
and marker dyes. In 1% agarose gels, bromphenol blue migrates at the position of 200 bp, 
whereas xylenecyanol blue migrates at the position of 300 bp.  The gels were stained for 20 min 
with ethidium bromide staining solution.  Then they were rinsed with tape water, the DNA bands 
visualised on an UV transilluminator and photographed by a Polaroid camera.  Alternatively, a 
simple digital camera in combination with a yellow filter was used.  
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Polyacrylamide gels 
 For the analysis of proteins, discontinuous polyacrylamide gels (10 x 8 x 0.1 cm) 
containing SDS (Lämmli, 1970) were prepared in different concentrations according to the 
following recipe:  
       Stacking gel      Separating gel  
           10 ml     16 ml      16 ml 
 
Stacking gel buffer: 
125 mM Tris-HCl (pH 6.8) 
0.1% SDS 
 
 
Separating gel buffer: 
 
375 mM Tris-HCl (pH 8.8)  
0.1% SDS 
 
 
 
 
 
 
 6% 12,5% 15% 
40% Acrylamide /  
1.3% bisacrylamide solution  
1,5 ml 5,0 ml 6,0 ml 
4 x buffer 2,5 ml 4,0 ml 4,0 ml 
H2O 6,0 ml 7,0 ml 6,0 ml 
Ammonium persulphate 10 µg 10 µg 10 µg 
TEMED  15 µl 20 µl 20 µl 
4 x Stacking gel buffer 
12.14g Tris-OH 
8 ml 10% SDS  
adjust pH 6.8 with HCl (~8 ml HCl 37%) 
add H2O to 200 ml 
4 x Separating gel buffer  
45.43 g Tris-OH 
10 ml 10% SDS  
adjust pH 8.8 with HCl (~6 ml HCl 37%) 
add H2O to 250 ml 
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3.   RESULTS 
The lack of appropriate diagnostic tools and the regular screening of the population at 
risk are still one of the main obstacles for the control and eradication of the Chagas disease 
(Talerton et al., 2007).  In the last years, several diagnostic methods have been developed, 
mainly for the use in blood banks.  In this case, the specificity of the diagnostic tools is not much 
taken into account, because these methods are assigned to the screening of donated blood 
which can be discarded in case of infection.  On the contrary, for the direct diagnosis of persons 
and particularly in areas where Chagas disease coexists with other diseases, and especially 
visceral leishmaniasis (Bastrenta et al., 2003), the specificity of diagnosis plays an important 
role.  Discrimination between T. cruzi and Leishmania infections represents a problem, since 
the cross-reactions between them are very usual, due to their close relation.  For this reason, 
false positives are often obtained, and therefore wrong diagnoses are done.  In addition, it has 
also been thought that there is an underestimated number of visceral leishmaniasis patients in 
Latin America, being some of these cases confused with Chagas disease.  
As mentioned above, regular screening of all the population at risk (about 90 million of 
people) would be necessary for efficient control of Chagas disease.  This is not possible at 
present,  primarily due to the high price of the available commercial diagnostic kits.  For this 
reason, the goal of this work was to develop highly sensitive and specific and at the same time, 
inexpensive diagnostic methods, with the perspective,  to establish these techniques in near 
future in a highly affected country, Bolivia. 
The principal methods developed in the present work are immunodiagnostics using 
recombinant proteins as antigens.  Most part of the work consists in the selection, cloning and 
expression of these antigens, and, finally, the test of them with a large number of chagasic 
patient samples provided from a Bolivian laboratory.  
Immunodiagnosis is, on the other hand, not sufficient for monitoring the treatment of the 
disease.  While taking drugs against Chagas disease, patients must be followed up.  As 
immunodiagnosis is based on the detection of antibodies in blood which have been shown to 
persist many years after cure, this is only possible by means of PCR, which detects the 
presence of the living parasite (or rests of its DNA) in blood.  Due to the toxicity of the drugs, the 
treatment period has to be as short as possible.  For this reason, it is very important to have an 
effective method for the confirmation of cure, able to detect an “active” infection, and not only 
the persisting antibodies in blood.  Two different PCR assays were established during this work.  
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However, they may have still to be improved and tested with a large amount of samples, which 
is only feasible in a laboratory of an endemic country.  
 
3.1   Establishing immunodiagnostics 
Most of the commercial kits for diagnosis of Chagas disease employ the ”crude” 
antigens, obtained from the lysis of trypomastigote or epimastigote forms of Trypanosoma cruzi.  
They show a high sensitivity, but, unfortunately, are not specific enough, leading in many cases 
to false positive reactions.  Therefore tests using recombinant antigens were chosen for this 
work.  Such tests have shown to be much more specific, and they can be as as sensitive as the 
ones using crude extracts. 
 
3.1.1   Selection of appropriate diagnostic antigens 
 Establishing of new immunoassays began with the searching for the most appropriate 
antigens in the existing publications, mainly from groups in Latin America. The corresponding 
genomic sequences were obtained from different DNA data banks, preferentially the Sanger 
Gene Data Base (GeneDB) (Hertz-Fowler et al., 2004). This data bank contains most of the 
available data of Trypanosoma cruzi CL Brener strain genomic sequence that was published in 
2005 (El-Sayed et al., Science).  The genomic sequence is incomplete. The T. cruzi release 
v4.0 consists of 4,008 annotated contigs (continuous sequences of up to more than 50.000 
base pairs) totalling 60.4 Mb, plus a further 28737 unannotated contigs totalling 29.2 Mb.  The 
contigs have never been put together to chromosomes, and there are redundant sequences.   
 The similarity of the sequences with other organisms was checked by means of the 
BLAST program (http://www.genedb.org/genedb/tcruzi/blast.jsp).  This program finds similarity 
regions between biological sequences. It compares nucleotide or protein sequences to 
sequence data bases and calculates the statistical significance of matches.   
 The genetic information extracted from GeneBank (http://www.ncbi.nlm.nih.gov/ 
Genbank) was used to clone the antigen 1F8 (Gonzalez et al.,1985), by amplifying the 
corresponding DNA sequence with PCR by using the genomic DNA of the parasite as template.  
Previous preparation of cDNA is not needed in the case of T.cruzi, because no introns have 
been found in the genes of this organism so far (El-Sayed et al., 2005).  By the same strategy, 
several unsuccessful repeated attempts were done to clone another antigen, A13 (Paranhos et 
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al., 1990). The failure was most probably due to the fact that A13 does not exist in the genome 
of the T. cruzi strain (Tulahuen C2) used in our laboratory, and it was also not contained in the 
CL Brener strain sequenced by the Sanger consortium.   
 The next antigens to be cloned were CRA (Cytoplasmic Repetitive Antigen) and FRA 
(Flagellar Repetitive Antigen), reported to be highly immunogenic (Krieger et al., 1992; Pereira 
et al., 2003), even though the exact sequence of the recombinant antigens has never been 
disclosed.  The natural gene products are huge, having calculated molecular masses of 120 
kDa (CRA) and 500 kDa (FRA), and contain multiple tandemly repeated amino acid sequences 
of 14 residues (CRA) and 68 residues (FRA). It is generally presumed that the tandem repeats 
represent major immunogenic epitopes for the induction of strong humoral response.   
 Attempts to clone representative parts of the antigens in E. coli failed, in spite the fact 
that PCR fragments containing several copies of tandem repeats were obtained. It was only 
feasible to maintain single copies of the repetitive DNA sequences stably in plasmid vectors, 
even trying with recA minus strains of E. coli for transformation (Troester et al., 2000). It 
appears that E. coli prevents efficiently the amplification of tandemly repeated sequences, 
which may represent a defence strategy against the amplification of structures such as 
transposable elements.   
 Cloning of sequences for tandem repeated amino acids was only possible by using 
synthetic DNA, whereby different nucleotides in variable codons were included in such way that 
repeats of more than eight identical nucleotides were prevented. The open reading frames were 
constructed by overlapping complementary oligonucleotides which were coupled by DNA ligase.  
On this way, it was possible to stably maintain three copies of the 14mer CRA repeat and two 
copies of the 68mer of the FRA repeat in an E.coli-specific expression vector.  At the same 
time, the coding sequence of the B13 antigen (Gruber et al., 1993), consisting of a trimer of 13 
repetitive amino acids, was constructed and successfully expressed.   
 All three synthetic antigens showed an excellent sensitivity of immunoreaction with 
chagasic patient sera.  However, some drawbacks prevent their direct use to establish a good 
diagnostic system. One disadvantage of the synthetic B13 and CRA antigens was that 
production and purification of the resulting polypeptides was demanding.  In addition, they did 
not stick efficiently on the nitrocellulose membrane or plastic surface of mictrotiter plates due, 
most probably, to their small size.  Part of this problem was solved by fusing them into a bigger 
single antigen, which led, in addition, to an unexpected increase of sensitivity in immunoassays.   
 The FRA antigen, at the other hand, turned out to cross-react with sera from patients 
with Leishmania infections. The reason for this became transparent in comparing the 
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corresponding genes between T. cruzi and L. infantum as well as L. major: the 68mer tandem 
repeats were conserved to almost 80% identity between the different species.  Thus the FRA 
antigen was of no use to discriminate these two diseases, even though it was highly 
immunoreactive.   
 Therefore additional potential diagnostic antigens were searched in the literature as well 
as in the genomic sequence of T. cruzi as contained in the Sanger GeneDB.  The search was 
concentrated on antigens containing repeat motives in their genes.  This limitation on repetitive 
antigenic motives was not only due to the high antigenicity of the sequences successfully 
cloned so far, but was also supported by reports in the recent literature.  Several authors had 
shown that most of the highly immunoreactive antigens contain such tandemly repeated amino 
acid sequences (Ibañez et al., 1988; Hoft et al., 1989; Frasch et al., 1991).  By means of a 
bioinformatic approach, a large number of additional potential diagnostic antigens consisting of 
tandemly repeated amino acid sequences were identified in the T. cruzi Sanger GeneDB using 
a computer program predicting tandem repeats in DNA (Tandem Repeats Finder: 
http://tandem.bu.edu/trf/trf.html). Analysis of genomic sequences of T. cruzi is demanding, 
because there are not yet arrayed chromosomes. Screening several hundred contigs 
statistically with TR Finder software, a number of new tandem repeats was found.  However, 
many of them had low repeat numbers only, or were also present in related form in the 
genomes of L. infantum and L. major.  Several of the repeats found by this way corresponded to 
antigens already described in the literature.  At the end, six different tandem repeats in addition 
to B13, CRA and FRA appeared to be appropriate as candidates for diagnostic antigens.  These 
sequences are listed in Table 3.1-1.   
 DNA sequences with open reading frames were constructed for all of these repeats by 
means of synthetic oligonucleotides.  A great help in this approach was the software program 
DNA Works (http://mcl1.ncifcrf.gov/dnaworks/dnaworks2.html, Hoover and Lubkowski, 2002).  
The program designs automatically oligonucleotides for PCR-based gene synthesis just by 
inserting the desired protein sequence and the preferred host for gene expression.  By means 
of this program it was easy to calculate how many repeats of a given amino acid sequence 
could be designed without to include repetitive DNA sequences longer than 8-10 nucleotides.  
The genes were synthesised using the oligoncleotides predicted by DNAWorks program 
according to Stemmer et al., 1995.  This method relies on DNA polymerase to build increasingly 
longer DNA fragments from overlapping oligonucleotides during the assembly process.  By this 
way, the coding sequences for up to nine amino acid repeats (in case of TcD) could be 
constructed and stably maintained in the expression plasmid.   
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antigen sequence of synthetic antigen  genomic 
repeats  
homology  
with Leishmania  
MAP 
PRHVDPDHFRSTTQDAYRPVDPSAYKRALPLEEEEDVG 
PRHVDPDHFRSTTQDAYRPVDPSAYKRALPLEEEEDVG 
PRHVDPDHFRSTTQDAYRPVDPSAYKRALPQEEEEDVG 
135 40 % homology with L. infantum 
JL8 AAEATKVAEAEKQR AAEATKAVEAEKQR AAEATKVAEAEKQK 140 very weak  
homology  
CRA KVAEAEKQKAAEAT KVAEAEKQKAAEAT KVAEAEKQKAAEAT 130 no homology  
B13  PFGQAAAGDKPS PFGQAAAGDKPS PFGQAAAGDKPK 103 no homology 
FRA 
AFLDQKPEGVPLRELPLDDDSDFVAMEQERRQLLEKDPRRNAREIAAL 
EESMNARAQELAREKKLADR AFLDQKPEGVPLRELPLDDDSDFVAME 
QERRQLLEKDPRRNAKEIAALEESMNARAQELAREKKLADR AFLDQK 
14 
80% homology 
with L. infantum 
TcD 
PKPAE PKPAE PKPAE PKPAE PKPAE PKPAE PKPAE PKPAE 
PKPAE 430 no homology 
TcE PAKAAA PPAKAAA PPAKAAA PPAKAAA PPAKAAA PPAKAAAP 70 no homology  
SAPA 
PVDSSAHGTPST PVDSSAHGTPST PVDSSAHSTPST 
PVDSSAHSTPST PADSSAHSTPST >130 no homology 
TcMyo 
LAQREADNEKLAED LAQREADNEKLAEE LAQREADNEKLTED 
LAQREADNEKLAED >170 no homology 
 
Table 3.1-1.  Synthetic tandem repeat  antigens of T. cruzi. 
 
 
3.1.2   Example of cloning by PCR amplification: 1F8 antigen. 
Design of PCR primers 
 1F8 is the only not-repetitive antigen that was cloned.  The gene sequence, which 
codes for a 24 kDa Ca+-binding protein, was obtained from the Sanger GB and is shown in 
Figure 3.1-2. Only part of the gene coding for 1F8 was amplified by PCR using primers derived 
from the sequence in GenBank.   
 For the ease of the cloning of different recombinant antigens, it was decided to use 
always the same restriction sites at the beginning (BamHI) and at the end (HindIII) of the open 
reading frames.  Furthermore, the sequences should not contain stop codons at the end to 
allow the fusion of different antigens as polyproteins in a later stage of the project. As BamHI 
and HindIII restriction sites should not occure inside of the open reading frames,  a search for  
these sequences within the genomic sequence was performed. This was possible by using “The 
Sequence Manipulation Suite” software (http://www.bioinformatics.org/sms2/, Stothard, 2000), 
that allows many different analysis of the selected sequence. By using the “Restriction 
Summary” option and introducing the 1F8 DNA sequence, the program returned the number 
and positions of commonly used restriction endonuclease cut sites. As a result, one BamHI and 
one HindIII restriction sites were found within the sequence.  Because the cloning strategy was 
based on the use of these two enzymes, the amplified fragment had to exclude the C-terminal 
coding part of the gene.  
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Gene sequence:  
 
  1 ATG GGT GCT TGT GGG TCG AAG GGC TCG ACG AGC GAC AAG GGG TTG GCG AGC GAT AAG GAC  
 61 GGC AAG AAG GCC AAG GAC CGC AAG GAA GCG TGG GAG CGC ATT CGC CAG GCG ATT CCT CGT  
121 GAG AAG ACC GCC GAG GCA AAA CAG CGC CGC ATC GAG CTC TTC AAG AAG TTC GAC AAG AAC  
181 GAG ACT GGG AAG CTG TGC TAC GAT GAG GTG CAC AGC GGC TGC CTC GAG GTG CTG AAG TTG  
241 GAC GAG TTC ACG CCG CGA GTG CGC GAC ATC ACG AAG CGT GCG TTT GAC AAG GCG AGG GCC  
301 CTG GGC AGC AAG CTG GAG AAC AAG GGC TCC GAG GAC TTT GTT GAA TTT CTG GAG TTC CGT  
361 CTG ATG CTG TGC TAC ATC TAC GAC TTC TTC GAG CTG ACG GTG ATG TTC GAC GAG ATT GAC  
421 GCC TCC GGC AAC ATG CTG GTC GAC GAG GAG GAG CTC AAG CGC GCC GTG CCC AAG CTT GAG  
481 GCG TGG GGC GCC AAG GTC GAG GAT CCC GCG GCG CTG TTC AAG GAG CTC GAT AAG AAC GGC  
541 ACT GGG TCC GTG ACG TTC GAC GAG TTT GCT GCG TGG GCT TCT GCA GTC AAA CTG GAC GCC  
601 GAC GGC GAC CCG GAC AAC GTG CCG GAG AGC GCG TGA 
 
 
Protein sequence: 
 
MGACGSKGSTSDKGLASDKDGKKAKDRKEAWERIRQAIPREKTAEAKQRRIELFKKFDKNETGKLCYDEVHSG
CLEVLKLDEFTPRVRDITKRAFDKARALGSKLENKGSEDFVEFLEFRLMLCYIYDFFELTVMFDEIDASGNML
VDEEELKRAVPKLEAWGAKVEDPAALFKELDKNGTGSVTFDEFAAWASAVKLDADGDPDNVPESA* 
 
 
Figure 3.1-2. Gene and protein sequence of 1F8 antigen.  Codons very rarely used in E. 
coli are highlighted in red, less rarely used in orange. BamHI and HIndIII restriction sites are shown 
in green, and start and stop codons in violet. 
 Secondly, codons “rarely used” by E. coli had to be searched.  These codons and their 
frequencies are shown in the Escherichia coli codon usage (see Figure 3.1-5). There is large 
experimental evidence on the fact that the presence of non-optimal codons (i.e., those 
translated by rare tRNAs) can reduce the translation rate of proteins (Robinson et al., 1984; 
Bonekamp et al., 1985), which is used by the bacteria as strategy for the regulation of protein 
expression (Grantham et al., 1981).  Therefore, in order to avoid these unfavourable codons as 
much as possible, a search in the 1F8 DNA sequence was done.  The results are shown in 
Figure 3.1-2.   
 
 
 
 
 
 
 
 
 
 
 Only two very rare codons were contained in the sequence. Therfore, the N-terminal 
70% of the sequence could be used for cloning.  As overexpressed recombinant proteins are 
insoluble in most of cases and have to be purified with caotropic agents under denaturating 
conditions anyway, omitting of parts of a protein must not be deleterious for its use as antigen. 
Only regions with a stable secondary structure were expected to function as good epitopes, and 
such regions could occur in any part of the protein. 
 To design appropriate PCR primers for amplification, the selected largest possible 
fragment without BamHI and HindIII restriction sites, but still containing some rare codons, was 
entered in the Primer3 program (Rozen et al., 2000, http://frodo.wi.mit.edu/). This software 
allows the designing of optimal primers for PCR and sequencing, but also for hybridization 
probes within an selected sequence.  In order to adapt the results to the own needs, different 
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ATGGGTGCTTGTGGGTCGAAGGGCTCGACGAGCGACAAGGGGTTGGCGAGCGATAAGGACGGCAAGAAGGCCAAGGAC
CGCAAGGAAGCGTGGGAGCGCATTCGCCAGGCGATTCCTCGTGAGAAGACCGCCGAGGCAAAACAGCGCCGCATCGAG
CTCTTCAAGAAGTTCGACAAGAACGAGACTGGGAAGCTGTGCTACGATGAGGTGCACAGCGGCTGCCTCGAGGTGCTG
AAGTTGGACGAGTTCACGCCGCGAGTGCGCGACATCACGAAGCGTGCGTTTGACAAGGCGAGGGCCCTGGGCAGCAAG
CTGGAGAACAAGGGCTCCGAGGACTTTGTTGAATTTCTGGAGTTCCGTCTGATGCTGTGCTACATCTACGACTTCTTC
GAGCTGACGGTGATGTTCGACGAGATTGACGCCTCCGGCAACATGCTGGTCGACGAGGAGGAGCTCAAGCGCGCCGTG 
No mispriming library specified 
Using 1-based sequence positions 
OLIGO            start  len      tm     gc%   any    3' seq  
LEFT PRIMER          5   18   60.25   61.11  4.00  0.00 GTGCTTGTGGGTCGAAGG 
RIGHT PRIMER       460   19   60.24   63.16  6.00  1.00 GCTTGAGCTCCTCCTCGTC 
SEQUENCE SIZE: 468 
INCLUDED REGION SIZE: 468 
 
PRODUCT SIZE: 456, PAIR ANY COMPL: 3.00, PAIR 3' COMPL: 3.00 
Figure 3.1-3 Primer3 results.  The sequence included in the search was 468 bp, without BamHI and 
HindIII restriction sites. The forward and reverse primers returned by the software are highlighted in blue.  
The length of the selected primers, annealing temperature and size of the final product are given by the 
program as well.   
 
parameters such annealing temperature, primer size, fragment size, CG percentage can be 
selected.  The program also predicts the creation of hairpins, by detecting self complementary 
regions.  In the case of the 1F8 antigen, only few of the many possible parameters were 
adjusted.  Product size ranges were selected from 450 to 468 basepairs (length of the 
introduced sequence), primer size in a range of 18 to 20 basepairs, and optimal annealing 
temperature of 60ºC.  Forward and reverse primers with similar size and annealing temperature 
were preferred. By this way, standardisation of PCR conditions was facilitated. According to the 
selected parameters, the programme returned the position of optimal forward and reverse 
primers within the included region and the size of the resulting length of the product of 456 
basepairs.  The results are shown on Figure 3.1-3.   
 
 In order to allow cloning, restriction sites for BamHI (g|gatcc) and HindIII (a|agctt) 
were added manually to the primers designed by the Primer3 software. By PCR amplification 
using the corresponding synthetic primers, these sites were included as a part of the fragment, 
and later used  to create “sticky ends” for cloning of the sequence in the expression vector.  To 
facilitate cleavage of the PCR product by the restriction enzymes, three additional nucleotides 
were included at the ends of the primers each. The restriction sites were introduced in such a 
way that the open reading frame (ORF) of 1F8 could be fused to the ORF of the His-tag in the 
vector pQE-30 at the N-terminal part, and to the ORF of another antigen at the C-terminal part.   
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           m            Fr. 2         Fr. 3         Fr. 4          Fr. 5         Fr. 6        Fr. 7 
   
 
Figure 3.1-4 Protein expression of pET -1F8 clone.  Fractions 3 and 4 contain 
the most part of the protein 1F8.    
 The final design of the 1F8 primers, which resulted after these procedures were two 
primer of 27 base pares each, and their sequences are shown below. 
 
Tcru-1F8-F:   ATA GGA TCC GGT GCT TGT GGG TCG AAG 
Tcru-1F8-R:    CGG AAG CTT CTT GAG CTC CTC CTC GTC 
 
 The amplification of the fragment product of the 1F8-primers was made by PCR at 
standard conditions (see Materials and Methods) using T. cruzi DNA as template. However, due 
to the length of the fragments, the annealing temperature was increased to 70ºC and the 
extension time to 1 minute and 30 seconds.  After checking that the expected band (456 bp) 
was correctly amplified, it was cut out of the gel and diluted by using the NaI/silica DNA 
extraction method (see Materials and Methods).  
 Cloning in pQE vector and protein expression 
For the cloning of 1F8 fragment in pQE-30 expression vector, “sticky ends” with BamHI 
and HindIII restriction enzymes had to be created.  Then, the cleaved 1F8 fragment was ligated 
in pQE vector (also containing sticky ends).  After purification with silica, the DNA of the ligation 
assay was electroporated in competent cells which were therafter grown on selection plates 
containing ampiciline and kanamicine antibiotics. Resulting colonies were analysed by PCR, 
using the 1F8 forward primer and the pQE reverse primer.  Finally, one of the positive clones 
was selected for protein purification, as shown in Figure 3.1-4. 
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TTT F 0.58      TCT S 0.17      TAT Y 0.59      TGT C 0.46 
TTC F 0.42      TCC S 0.15      TAC Y 0.41      TGC C 0.54 
TTA L 0.14      TCA S 0.14      TAA * 0.61      TGA * 0.30 
TTG L 0.13      TCG S 0.14      TAG * 0.09      TGG W 1.00 
 
CTT L 0.12      CCT P 0.18      CAT H 0.57      CGT R 0.36 
CTC L 0.10      CCC P 0.13      CAC H 0.43      CGC R 0.36 
CTA L 0.04      CCA P 0.20      CAA Q 0.34      CGA R 0.07 
CTG L 0.47      CCG P 0.49      CAG Q 0.66      CGG R 0.11 
 
ATT I 0.49      ACT T 0.19      AAT N 0.49      AGT S 0.16 
ATC I 0.39      ACC T 0.40      AAC N 0.51      AGC S 0.25 
ATA I 0.11      ACA T 0.17      AAA K 0.74      AGA R 0.07 
ATG M 1.00      ACG T 0.25      AAG K 0.26      AGG R 0.04 
 
GTT V 0.28      GCT A 0.18      GAT D 0.63      GGT G 0.35 
GTC V 0.20      GCC A 0.26      GAC D 0.37      GGC G 0.37 
GTA V 0.17      GCA A 0.23      GAA E 0.68      GGA G 0.13 
GTG V 0.35      GCG A 0.33      GAG E 0.32      GGG G 0.15 
 
Figure 3.1-5 Genetic standard code of Escherichia coli. Codons are followed by 
the amino acid they code for, and the corresponding usage frequencies. Codons marked in 
red present the lowest frequencies , and another group of condons with low frequencies in 
orange.  Stop codons are indicated with an asterisc. 
 
3.1.3   Synthetic genes 
Tandem repeated sequences 
Production of tandemly repeated recombinant antigens showed some problems while 
trying to clone and express them stably in E. coli.  This was solved by constructing genes with 
different codons in the nucleotide sequences for the repetitive sequences by means of synthetic 
oligonucleotides avoiding codons rarely used by E. coli (see Figure 3.1-5). The two different 
procedures used during the work in this thesis will be next described. 
 
 
 
 
 
 
 
 
 
 
 
 
Example 1: Construction of synthetic B13 antigen 
B13 (CA-2) is localised on the surface of T. cruzi and is one of the immunodominant 
antigens containing many repeats of the 12 amino acid motive PSPFGQAAAGDK (Gruber et 
al., 1993). In the Sanger GeneDB, two different alleles of the gene with together 103 highly 
conserved repeats were observed. Its performance in immunoassays of different groups has 
been found to be very good. The following strategy was used to express a representative 
fragment of the repetitive sequence as a recombinant antigen.  
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It was presumed that three repeats of the conserved sequence PSPFGQAAAGDK may 
represent a good antigen to be recognised by sera from chagasic patients. As three identical 
repeats of the coding region were not stably to be maintained in E. coli, an open reading frame 
for three repeats was designed manually including as many sequence variations between the 
three repeats as possible. This was easily feasible by using the whole spectrum of possible 
base exchanges in codons for specific amino acids with the only restriction not to select codons 
rarely used by E. coli.  The sequence was designed as follows: 
 
        P   S   P   F   G   Q   A   A   A   G   D   K 
       CCA TCA CCA TTT GGA CAG GCC GCA GCA GGT GAC AAA 
      CCG AGC CCG TTC GGT CAA GCA GCC GCA GGA GAT AAG 
       CCT TCT CCC TTT GGC CAG GCA GCT GCA GGC GAT AAA 
 
 
Nucleotides differing from the sequence in the first repeat are underlined in the two other 
repeats. The complete sequence was constructed by means of the following nine 
complementary overlapping synthetic oligonucleotides: 
 
TcruB13-F1:  GATCACCATCACCATTTGGACA 
TcruB13-F2:  GGCCGCAGCAGGTGACAAACCGAGCCCGTT 
TcruB13-F3:  CGGTCAAGCAGCCGCAGGAGATAAGCCTTCT 
TcruB13-F4:  CCCTTTGGCCAGGCAGCTGCAGGCGAT 
TcruB13-F5:  AAACCTGGATCCTTACCGA 
 
TcruB13-R1:  AGCTTCGGTAAGGATCCAGGTTTATCGCCTGCA 
TcruB13-R2:  GCTGCCTGGCCAAAGGGAGAAGGCTTATCTC 
TcruB13-R3:  CTGCGGCTGCTTGACCGAACGGGCTCGGT 
TcruB13-R4:  TTGTCACCTGCTGCGGCCTGTCCAAATGGTGATGGT 
 
To allow ligation of the synthetic DNA fragment into the vector pQE-30 via a BamHI site 
at the 5' end and a HindIII site at the 3' end, sequences matching the corresponding "sticky" 
sites in the vector were added to the terminal oligonucleotides (underlined). The sequence at 
the 5' end was designed in such a way (gatca instead of gatcc) that the BamHI site would not 
exist anymore after ligation. Instead, another BamHI site was added at the end of the repeat in 
front of the HindIII site (in fragments TcruB13-F5 and TcruB13-R1) which would allow to fuse 
B13 trimer later with other genes synthesised according to the same principle. 
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Figure 3.1-6 Preparative expression of B13 trimer. Most of 
the protein is contained in fraction 3. The size of the obtained protein 
corresponded with the expected size of approximately 5 kDa 
Except of TcruB13-F1 and TcruB13-R1, all oligonucleotides were phosphorylated at the 
5' ends by means of polynucleotide kinase and ATP and ligated in stoichiometric amounts to a 
single DNA fragment with T4 ligase. Omitting the phosphorylation of the terminal 
oligonucleotides prevented the polymerisation of the fragment, but did not interfere with later 
ligation into the vector. 
 
   3’ GATCACCATCACCATTTGGACAGGCCGCAGCAGGTGACAAACCGAGCCCGTTCGGTCAAGCAGCCGCAGGAGAT  
   5’     TGGTAGTGGTAAACCTGTCCGGCGTCGTCCACTGTTTGGCTCGGGCAAGCCAGTTCGTCGGCGTCCTCTA 
 
      AAGCCTTCTCCCTTTGGCCAGGCAGCTGCAGGCGATAAACCTGGATCCTTACCGA 5’ 
      TTCGGAAGAGGGAAACCGGTCCGTCGACGTCCGCTATTTGGACCTAGGAATGGCTTCGA 3’ 
 
The ligation product was separated on a 2% agarose gel, a band of correct size (120 bp) 
excised and ligated into pQE-30. By this way, an N-terminal His-tag was added to the B13 
trimer which allowed easy purification of the protein by affinity chromatography on TALON®  
resin. 
 
 
 
 
 
 
 
 
Fusion of B13 and CRA antigens 
 CRA (Cytoplasmic Repetitive Antigen) has been described as another highly 
immunoreactive repetitive antigen (Lafaille et. al., 1989) and three of its tetradecameric repeats 
occurring 130 times in highly conserved form in the genome of T. cruzi had been synthesised 
with oligonucleotides using the same strategy as for the B13 antigen (for the sequence, see 
Table 3.1-1).  CRA was also obtained in minute amounts only upon expression in E. coli and 
affinity purification. The CRA antigen also contains a BamHI restriction site at the 5' end and a 
        m    Fr.1   Fr.2    Fr.3   Fr.4   Fr.5 
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M   R   G   S   H   H   H   H   H   H   G   S   P   S   P   F   G   Q   A    
ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC GGA Tca cca tca cca ttt gga cag gcc  
 
A   A   G   D   K   P   S   P   F   G   Q   A   A   A   G   D   K   P   S    
gca gca ggt gac aaa ccg agc ccg ttc ggt caa gca gcc gca gga gat aag cct tct  
 
                   <---------B13------------ BamHI  --------- CRA --------> 
P   F   G   Q   A   A   A   G   D   K   P   G   S   K   V   A   E   A   E    
ccc ttt ggc cag gca gct gcg ggc gat aaa cct gga tcc aaa gtg gcg gag gcc gaa  
 
K   Q   K   A   A   E   A   T   K   V   A   E   A   E   K   Q   K   A   A    
aag cag aag gca gct gaa gcc acg aag gtt gcc gaa gcg gag aag cag aaa gcg gca  
 
E   A   T   K   V   A   E   A   E   K   Q   K   A   A   E   A   T   K   L    
gaa gct gca gag gta gct gag gca gaa aaa caa aag gct gcg gag gcc act aag ctt  
                                                                    HindIII 
 
Figure 3.1-7 Fusion of B13 and CRA antigens.The nucleotides exchanged in the different repeats are 
underlined. In addition, the N-terminal hexahistidin-tag added by the pQE-30 vector is shown.  The BamHI site 
used for the fusion and the HindIII site at the 3' end are indicated. 
 
Figure 3.1-8 Purification of Tcru-B13-CRA fusion antigen. 5 µl 
of each 500 µl fraction of the B13-CRA fusion antigen eluted from the 
TALON® affinity column was analysed on a 12 % SDS polyacrylamide 
gel and stained with Coomassie Blue. 
HindIII site at the 3' end of the coding sequence. It was combined with the B13 antigen by 
ligation to the BamHI site near the end of B13.  The fusion product has the following sequence: 
 
 The B13-CRA fusion antigen was expressed to a much higher extent in the induced 
E. coli cells than the individual antigens alone. That supports the idea that very small 
recombinant proteins are not stable in E. coli. 
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MGKTVVGASRMFWLMFFVPLLLALCPSEPAHALAPESSRVELFKRQSSKVPFEKDGKVTDRVVHSFRL
PALVNVDGVMVAIADARYETSNDNSLIDTVAKYSVDDGETWETQIAIKNSRVSSVSRVVVPTVIVKGN
KLYVLVGSYNSSKSYWTWQPDGSDWDILLAVGEVTKSTAGGKTTASIKWGSPVSLKKFFPAEMEGMHT
NQFLGGAGVAIVASNGNLVYPVQVTNKRKQVFSKIFYSEDEGKTWKFGKGRSDFGCSEPVALEWEGKL
IINTRVDRARRLVYESSDMGNTWVEAVGTLSRVWGPSPKSDQPGSQSSFTAVTIEGMRVMLFTHPLNF
KGRWLRDRLNLWLTDNQRIYNVGQVSIGDENAAYSSVLYKDDKLYCLHEINTNEVYSLVFARLVGELR
IIKSVLQSWKNWDSHLSSICTPADPAASSSERGCGPAVTTVGLVGFLSGNASQNVWEDAYRCVNASTA
NAERVPNGLKFAGVGGGALWPVSQQGQNQRYRFANHAFTLVASVTIHEVPSVASPLLGASLDSSGGKK
LLGLSYDKKHQWQPIYGSTPVTPTGSWETGKRYHVVLTMANKIGSVYIDGEPLEGSGQTVVPDGRTPD
ISHFYVGGYKRSDMPTISHVTVNNVLLYNRQLNAEEIRTLFLSQDLIGTEAHMDSSS DSSAHGTPST 
PVDSSAHGTPST  PVDSSAHSTPST  PADSSAHGTPST  PVDSSAHGTPST  PVDSSAHSTPST 
PVDSSAHGTPST  PVDSSAHGTPST  PVDSSAHSTPST  PVDSSAHGTPST  PVDSSAHGTPST  
PVDSSAHSTPST  PVDSSAHSTPST  PADSSAHGTPST  PVDSSAHGTPST  PVDSSAHSTPST  
PVDSSAHSTPST  PADSSAHGTPST  PVDSSAHSTHST  PVDSSAHSTPST  PVDSSAHGTPST  
PVDSSAHGTPST  PVDSSAHSTPST  PVDSSAHGTPST  PVDSSAHGTPST  PVDSSAHGTPST  
PVDSSAHSTPST  PVDSSAHGTPST  PVDSSAHGTPST  PVDSSAHSTPST  PVDSSAHGTPST  
PVDSSAHSTPST  PVDSSAHSTPST  PVDSSAHSTPST  PVDSSAHSTPST  PVDSSAHGTPST  
PVDSSAHGTPSA  PVDSSAHSTPST  PVDSSAHSTPST  PVDSSAHGTPST  PVDSSAHSTPST  
PAGNSATRMFLILPDGAAISAFSGGGLLLCACALLLHVFFTAVFF 
 
Figure 3.1-9 Amino acid sequence of T. cruzi SAPA antigen (trans-sialidase). Tandem repeats are 
highlighted in red.  Changes in single amino acid residues in the repeated sequences are shown in black.   
Example 2: SAPA antigen cloning 
SAPA (shed-acute-phase-antigen) has an enzymatic trans-sialidase activity which is 
described only for trypanosomes and is involved in the invasion of host cell. The enzyme is 
made of two domains, the C-terminal region containing immunodominant amino acid repeats 
that define the SAPA antigen. The SAPA antigen induces a strong humoral response detected 
shortly after infection, both in humans and in mice. This response is directed to the 
immunodominant domain but is irrelevant in terms of neutralization of trans-sialidase activity 
(Affranchino et al., 1989). Five different genes containing varying numbers of a repeat of 12 
amino acid residues (PVDSSAHGTPST) were detected in the Sanger GeneDB. The sequence 
of the gene with the highest number of these repeats is shown in Figure 3.1-9. 
  
As can be seen from Figure 3.1-9, the repeat is not completely conserved but contains 
variations in the second position (V-A) and in the eight position (G-S). The longest possible 
DNA sequence (without repetitions longer than eight nucleotides) for a synthetic multimer of the 
amino acid repeat, consisted of five complete repeats.  Variations to the conserved sequence 
are underlined: 
 
PVDSSAHGTPST PVDSSAHGTPST PVDSSAHSTPST PVDSSAHSTPST PADSSAHSTPST 
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 The DNA sequence for the corresponding open reading frame using the genetic code 
preferred by E. coli was designed by means of the DNAWorks computer program described 
above. One of the solutions calculated by this program suggested the following sequence of 
180 nucleotides. 
 
  1 CCTGTGGACTCCTCTGCCCATGGTACCCCTAGCACTCCGGTCGACTCTAGCGCGCACGGC 
 61 ACCCCATCTACCCCAGTTGATTCTTCTGCGCACTCTACTCCATCCACGCCGGTTGACTCT 
121 TCCGCGCACAGCACCCCTTCCACTCCTGCAGACAGCTCTGCTCATAGCACGCCGTCTACG 
 
 The program designs the oligonucleotides to be synthesised. The maximal lengths of 
these oligonucleotides has to be selected at the beginning. As longer the nucleotides, as easier 
is the experimental assembly, but there are technical limitations with most providers of synthetic 
oligonucleotides.  6 oligonucleotides were synthesized: 
 
SAPA2-1 ATAAGATCTCCTGTGGACTCCTCTGCCCATGGTACCCCTAGCACTCCG  (48 bp) 
SAPA2-2 AGATGGGGTGCCGTGCGCGCTAGAGTCGACCGGAGTGCTAGGGGTACC  (48 bp) 
SAPA2-3 GCACGGCACCCCATCTACCCCAGTTGATTCTTCTGCGCACTCTACTCC  (48 bp) 
SAPA2-4 TGTGCGCGGAAGAGTCAACCGGCGTGGATGGAGTAGAGTGCGCAGAAG  (48 bp) 
SAPA2-5 TGACTCTTCCGCGCACAGCACCCCTTCCACTCCTGCAGACAGCTCTGC  (48 bp) 
SAPA2-6 TATAAGCTTCGTAGACGGCGTGCTATGAGCAGAGCTGTCTGCAGGA    (46 bp) 
  
The sequences marked in blue were added manually and provide the restriction sites 
needed for cloning in the vector pQE-30, as previously described for other antigens.  In addition, 
the program provides a scheme of the assembly of these oligonucleotides: 
 
     1 --->                                               3 --->  
   1 CCTGTGGACTCCTCTGCCCATGGTACCCCTAGCACTCCG              gcacggc 
                          CCATGGGGATCGTGAGGCCAGCTGAGATCGCGCGTGCCG 
                                                                  
      P  V  D  S  S  A  H  G  T  P  S  T  P  V  D  S  S  A  H  G  
 
                                                          5 --->  
  61 accccatctaccccagttgattcttctgcgcactctactcc            TGACTCT 
     TGGGGTAGA             gaagacgcgtgagatgaggtaggtgcggccaactgaga 
       <--- 2                                                    
      T  P  S  T  P  V  D  S  S  A  H  S  T  P  S  T  P  V  D  S  
 
                                                                  
 121 TCCGCGCACAGCACCCCTTCCACTCCTGCAGACAGCTCTGC                    
     aggcgcgtgt             AGGACGTCTGTCGAGACGAGTATCGTGCGGCAGATGC 
        <--- 4                                           <--- 6 
      S  A  H  S  T  P  S  T  P  A  D  S  S  A  H  S  T  P  S  T  
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 BamHI* P   V   D   S   S   A   H   G   T   P   S   T        
AGA TCT CCT GTG GAC TCC TCT GCC CAT GGT ACC CCT AGC ACT  
 
 P   V   D   S   S   A   H   G   T   P   S   T 
 CCG GTC GAC TCT AGC GCG CAC GGC ACC CCA TCT ACC 
 
  P   V   D   S   S   A   H   S   T   P   S   T 
 CCA GTT GAT TCT TCT GCG CAC TCT ACT CCA TCC ACG 
 
    P   V   D   S   S   A   H   S   T   P   S   T 
 CCG GTT GAC TCT TCC GCG CAC AGC ACC CCT TCC ACT 
 
   P   A   D   S   S   A   H   S   T   P   S   T   HindIII 
 CCT GCA GAC AGC TCT GCT CAT AGC ACG CCG TCT ACG AAG CTT 
 
Figure 3.1-10 Synthetic SAPA antigen pentamer.  The sequence codons are shown in 
black under the corresponding amino acid residues (in red).  In blue, the restriction sites of BamHI 
and HindIII added later.  Note that different codons are coding for the same amino acid, and the 
amino acid sequence remains unaltered, even though nucleotide sequence changes in each 
repeat.  
 Furthermore, the program calculates the annealing temperature for the overlaps of the 
oligonucleotides, which in this case was 62°C: 
 
                  Tm Range    # of Overlaps  
                    61            1 
                    62            4 
 
 The DNAWorks program uses the same principles for selection of codons as 
described in example 2, to avoid repetitions of more than eight nucleotides in the DNA. This is 
shown in Figure 3.1-10, where the sequences of the open reading frames for the five repeats 
were written one upon the other.  
 
 
 
 
 
 
 
 
 
To synthesise the gene, the 6 oligonucleotides were mixed in standard PCR buffer in the 
presence of desosoxyribonucleotide triphosphates in different concentrations, 0.15 µM for the 
inner oliconucleotides SAPA-2, SAPA-3, SAPA-4 and SAPA-5, and 1 µM for the flanking 
oligonucleotides SAPA-1 and SAPA-6.  After 2 minutes incubation at 62°C, Taq DNA 
polymerase was added and the temperature kept at 62°C for another 2 minutes.  Then followed 
3 cycles of denaturation at 94°C for 20 seconds and DNA synthesis at 60°C for 1 minute, 
thereafter 30 cycles of heating to 94°C for 20 seconds and DNA synthesis at 72°C for 30 
seconds, and finally 5 minutes at 72°C to fill in the ends of the fragment completely. 
The product of this amplification reaction was separated on a 2% agarose gel and 
stained with ethidium bromide. As can be seen from Figure 3.1-11, the expected fragment of 
190 base pairs was the major product. 
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Figure 3.1-2 Purified recombinant SAPA 
antigen. On the left side, the size marker (m), and 
from left to right, metal affinity column eluted fractions 
1 to 4 are shown.  Protein is contained basically in 
fraction 2.  
                          
 
 
Figure 3.1-11 Synthetic SAPA antigen. It was 
analysed by electrophoresis on a 2 % agarose gel. 
The expected size (190 bp) was obtained. 
 
 
 
 
 
 
 
 
 
The fragment was cut out of the gel, the DNA extracted with NaI and silica, digested with 
Bam HI and HindIII, and finally ligated in the vector pQE-30.  Upon transformation of E. coli cells 
by electroporation and selection of several resulting colonies by PCR, one appropriate clone 
was selected and induced to express the recombinant protein.  The protein was extracted, 
purified by metal affinity chromatography and analysed by SDS polyacrylamide gel 
electrophoresis.  After staining with Coomassie Blue, a protein band with the expected size of 
approximately 7 kDa was observed (Figure 3.1-12). 
 
 
 
 
 
 
 
 
The repetitive motives of the antigens MAP, TcD, TcE and TcMyo were synthesised 
according to the same principle. MAP (micrutubule-associated antigen) is a trimer of the 
sequence PRHVDPDHFRSTTQDAYRPVDPSAYKRALPQEEEEDVG, TcD is a nonameric 
m  Fr.1  Fr.2  Fr. 3 Fr. 4 
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Figure 3.1-13 Line blot test of different SAP A concentrations and 
quantification. Different SAPA proteins were tested on a line blot in 
different concentrations and with chagasic patient sera and negative 
control sera, and a line of positive antigen control (B13-CRA fusion). The 
upper line is human serum diluted 1:70 as a control for the staining 
reaction, the next line is the B13-CRA antigen as a positive marker, and the 
three lower lines correspond to three different dilutions of the SAPA 
antigen. The middle dilution (1:40) is appropriate for further tests. 
repeat of the five amino acid residues PKPAE, TcE is a hexameric repetition of PPAKAAA and 
TcMyo corresponds to 4 repeats of the tetradecameric sequence LAQREADNEKLAED whereby 
the last the residues are slightly variable. The complete sequences of these antigens are shown 
in Table 3.1-1 above.  
 
3.1.4   Sensitivity and specificity of antigens   
Efficiency of the purified recombinant diagnostic antigens was tested using an 
immunoblot technique called line blot (described in the Materials and Methods section).  This 
technique allowed reaching basically two objectives: to determine the optimal concentration of 
the antigens in immunoassays, and to detect possible cross-reactions.  The line blot allows the 
comparison of the reactivity of different antigens and of different concentrations of these 
antigens in a single assay.  To determine the optimal concentration, the antigen is applied in 
serial dilutions on the membrane, and then this later is either incubated with chagasic patient 
serum or with control serum.  At the optimal concentration, the antigen leads to a clear reaction 
with specific sera, but not with the control sera which were obtained from healthy German 
persons.  A too high concentration of the antigen leads to false positive reactions with control 
sera, and a too low concentration reduces sensitivity of the test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             Chagas disease              Negative controls 
h. serum  
B13-CRA  
SAPA 1:20 
SAPA 1:40 
SAPA 1:80 
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Figure 3.1-14 Cross-reaction tests for the different obtained antigens.  The first line is a 
colorimetric reaction positive control (human serum), and the second lane a positive control for Chagas 
disease antigens (fusion B13-CRA).  All obtained antigens were tested on lanes with Chagas disease 
and visceral leishmaniasis patients, and healthy German donors.  A strong FRA reaction with visceral 
leishmaniasis patients is to be seen, as well as further cross-reactions of JL8 and 1F8. 
 Intensity of reaction with patient sera is a property of the antigen and depends on the 
concentration of specific antibodies.  Some antigens have to be used at concentrations as high 
as 200 µg per ml, others lead to strong positive reactions at concentrations less than 1 µg per 
ml.  The most reactive antigens were a dimer of the FRA repeat which reacted strongly with 
more than 95 % of all infection sera, and the fusion B13-CRA.  The antigens 1F8, MAP, SAPA, 
TcD, TcE and JL8 revealed a lower or moderate immunoreactivity. 
 Some antigens show a strong background reaction with control sera from healthy 
persons. This holds mainly for antigens with low specific reactivity which have to be used at 
high concentrations. As the affinity purification procedure does not remove bacterial 
components such as lipopolysaccharid completely, the high background reaction with the 
control sera may be due to antibodies directed against these components.  E. coli-specific 
antibodies are present in all human sera and prevail even more in sera from people in 
developing countries. Bacterial contaminations in the antigen preparations cannot be removed 
completely without great effort. However, as more diluted an antigen can be used in 
immunoassays, as lower the cross-reaction with bacterial contaminations will be.  
 Line blot was also used to determine the specificity of the immunoreaction of the 
recombinant antigens. The test stripes were incubated with sera from patients suffering from 
cutaneous and visceral leishmaniasis, syphilis, or brucellosis. The latter sera were obtained 
from patients from Mongolia, and the leishmaniasis sera were from the Republic of Yemen. 
These countries are all free of Chagas disease. Thus, accidental infection with T. cruzi could be 
excluded. None of the antigens led to reactions with the syphilis and brucellosis sera, but with 
the antigens JL8, 1F8 and FRA cross-reactivity with sera from visceral leishmaniasis patients 
was clearly to be recognised (Figure 3.1-14). 
Human serum 
B13-CRA 
MAP 
TcD 
TcE 
SAPA 
JL8 
1F8 
FRA 
             Chagas disease                 visceral leishmaniasis            neg. controls 
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L. infantum: LDPKPEGVPLRCVPLDEDAEFVALEDEWRGLLQ-DPQRNSMPLKDLERRMNDRAHDVACGKKWADRDRV  
identity:    LD KPEGVPLR +PLD+D++FVA+E E R LL+ DP+RN+  +  LE  MN RA ++A +KK ADR   
T. cruzi:    LDQKPEGVPLRELPLDDDSDFVAMEQERRQLLEKDPRRNAREIAALEESMNARAQELAREKKLADRAF  
  (FRA2)                            MEQERRQLLEKDPRRNAREIAALEESMNARAQELAREKKLADRAF 
 
Fig 3.-15 Similarity of FRA antigen between T. cruzi, L. infantum and L. major.  80 % homology 
between the T. cruzi FRA antigen and a repeat in a calpain-like cystein protease of L. infantum  (LinJ27.0400) and, 
in identical form, of L. major (LmjF27.0490) was found. The repeat is  present 43 times in L. infantum  and 23 times in 
L. major. The synthetic FRA2 antigen (lower line) corresponds to the least conserved part of the repeat. 
To search for the reason for the observed cross-reactivity with leishmaniasis patient 
sera, the genomes of L. infantum and L. major in the Sanger GeneDB were analysed with the 
BLAST software (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) for potential homologies.  For all 
cross-reactive antigens significant homologies were detected with Leishmania genes containing 
similarly arranged tandem repeats (accidental homologies with single sequences were 
disregarded). 
The original version of the recombinant FRA antigen, consisting of two copies of the 68 
amino acid residue repeat, led to a strong cross-reactivity with sera from leishmaniasis patients. 
It turned out that a related tandem repeat occurs also in Leishmania, thus the cross-reactivity 
became understandable.  A much weaker cross-reactivity was observed with sera from patients 
with cutaneous leishmaniasis, even though the repeat is also present in L. major in almost 
identical form as in L. infantum.  However, there are fewer copies of the repeat in L. major which 
may lead to a weaker immune response as compared to L. infantum where the repeat is three 
times more frequent than in T. cruzi (Fig. 3.1-15).  
Recombinant FRA antigen is used in several commercial diagnostic kits for Chagas 
disease, most probably because of its high reactivity. As it was not clear whether the FRA 
antigen in such kits corresponds to the complete length of the repeat or to a subregion only, a 
trimer of the least conserved part of the repeat was produced (Fig. 3.1-15). In order to allow the 
molecule to fold in a structure similar to the complete repeat, short spacer peptides containing 
two proline residues each were included. However, the resulting antigen FRA2 was still cross-
reactive with leishmaniasis patient sera, even though at a lower degree. Therefore, this antigen 
was not included in further tests.  
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Similarly, the BLAST program detected up to 50 % homology of 1F8 antigen to a 
sequence corresponding to a putative flagellar calcium-binding protein in the genome of 
Leishmania infantum (LinJ16.0960). For the JL8 antigen only a weak sequence homology to L. 
infantum and L. major was found. Nevertheless, a clear cross-reactivity was observed in the line 
blot. Due to their obvious unspecificity, the three antigens FRA, 1F8 and JL8 were excluded 
from further use in immunodiagnosis, even though they have been described as good 
recombinant antigens in the literature by others (Umezawa et al., 1999; Gomes et al., 2001). 
Also for the MAP repeat of T. cruzi, homology with a microtuble-associated protein of L. 
infantum (LinJ05.0380) was detected. The protein of L. infantum contains 27 repeats of a 
sequence with 40 % homologous amino acid residues. However, no cross-reactions were 
observed in the immunoblots, and the MAP antigen was further used in the following assays.   
No related sequences were detected for the tandem repeats of the antigens B13, CRA, 
TcD, TcE and SAPA, and there was also no doubt on their specificity for T. cruzi from the 
experimental results. 
 
3.1.5   Fusion of the selected antigens  
After the individual recombinant antigens had been analysed thoroughly in line blot 
assays, they were tested in ELISA assays.  Even though ELISA assays depend on special 
equipment such as optical readers and washers, they are more appropriate for tests in large 
scale because they can be automated. It turned out that some of the recombinant antigens 
showed low immunoreactivity in ELISAs, in spite of the fact they performed well in the 
immunoblots.  A possible explanation for this phenomenon was that the small peptides did not 
bind properly to the plastic surface of the microplate and were lost during the washing steps.  
Another aspect was that the production of these small proteins in E. coli and/or their purification 
was not very efficient. To overcome these problems, it was attempted to combine the small 
peptides to larger fusion proteins.   
In contrast to the simple mixture of individual recombinant antigens in immunoassays 
(Umezawa et al., 2003), their fusion in a unique polypeptide has some advantages.  The 
production is simplified, because only one protein, instead of several, has to be purified.  
Furthermore, by the fusion of the selected recombinant antigens, it turned out that their 
efficiency was not only summed up, but enhanced.  This could be explained by an altered 
conformation of the final polypeptide, leading to better recognition by specific antibodies. 
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In order to allow the synthetic proteins to adopt the natural conformation needed to 
function as antigenic determinants, the selected synthetic genes were fused with the help of 
“adapter” oligonucleotides.  These adapters had several functions.  First, they had to join the 3’ 
terminal HindIII site of the anterior antigen in the correct reading frame with the BamHI site of 
the following antigen.  The nucleotide sequence was designed in such way that both restriction 
sites were destroyed by the fusion.  Second, the adapters served as spacers between the 
different antigens. In order to allow maximal flexibility between the fused antigens, one or two 
proline residues were introduced in the spacer elements.  Proline residues are frequently 
present in flexible areas of proteins (e.g. in the "hinge" regions of immunoglobulins).  It was 
assumed that such flexible elements would prevent – or reduce at least – the interference of 
secondary structures of the individual antigenic regions between each other, and thus to 
facilitate the individual antigenic motives to fold in the correct structure.  To avoid repetitions of 
homologous sequences in the fused genes, three different adaptor fragments were constructed 
(Figure 3.1-16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hind-Bam-AD1 
 
          HindIII                           BamHI 
 
5' NNN A       AG CTG CCG AGC CTG AGC A       GA TCC NNN 3' 
3' NNN TTC GA       C GGC TCG GAC TCG TCT AG       G NNN 5' 
 
    X   K          L   P   S   L   S   R          S   X 
 
Hind-Bam-AD3 
 
5' NNN A       AG CTC TCT CCG CTG CCG A       GA TCC NNN 3' 
3' NNN TTC GA       G AGA GGC GAC GGC TCT AG       G NNN 5'    
 
    X   K          L   S   P   L   P   R          S   X 
 
Hind-Bam AD4  
 
5' NNN A       AG CTT CCA GAT CCG TTA A       GA TCC NNN 3' 
3' NNN TTC GA       A GGT CTA GGC AAT TCT AG       G NNN 5' 
 
    X   K          L   P   D   P   L   R          S   X 
 
Figure 3.1-16 Adapter sequences used to fuse antigen coding regions.  
Nucleotide sequences of the adapter oligonucleotides are depicted in complementary form. 
Residues providing "sticky ends" for the res triction site HindIII and BamHI are in blue, and 
amino acid sequences encoded by the different adaptors are shown below the nucleotide 
sequences  in red.  All three adapters bind between BamHI and HindIII restriction sites, but 
have different sequences. 
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At first, the coding regions of TcD and TcE antigens were fused with the adapter Hind-
Bam-AD1. With this objective, the plasmid pQE-TcD was cleaved with HindIII and then ligated 
with the two non-phosphorylated oligonucleotides of adapter Hind-Bam-AD1.  By this way, the 
negative strand of the adapter was covalently linked to the 3' ends of the HindIII site, whereas 
the positive strand was bound by hydrogen bonds only.  Then, the vector was cleaved with PvuI 
in a region some 700 basepairs outside of the cloning site.  In parallel, the plasmid pQE-TcE 
was cleaved in a double-digest with BamHI and PvuI.  The digestion products of both plasmids 
were separated by agarose gel electrophoresis and the 1.1 kb PvuI-HindIII fragment from pQE-
TcD and the 3 kb BamHI-PvuI fragment from pQE-TcE were isolated.  
 
 
 
 
 
 
 
 
 
The two fragments were ligated whereby the positive strand of the adapter was added 
again since it was not covalently linked and probably lost during the isolation of the DNA 
fragments. The resulting construct was a pQE vector containing the desired fusion protein. 
According to the same principle also the antigens MAP and SAPA were combined to a MAP-
SAPA fusion protein. To prevent sequence repetitions, the different adapter Hind-Bam-AD-3 
was used. The antigens B13 and CRA had been fused before by means of an artificial BamHI 
site at the end of the open reading frame of B13 (see above). The immunoreactivity of the fused 
dimeric antigens was tested in ELISA and was found to be markedly higher than the reactivity of 
the monomeric antigens alone (data not shown).  
For the ease of purification and in the hope to increase the immunoreactivity even more, 
the TcD-TcE dimer was fused to the B13-CRA dimer in the same way, this time using the Hind-
Bam-AD1 adapter. The final construct included 3 repeats of B13, 3 repeats of CRA, 9 repeats of 
 
 
 
 
Figure 3.1-17 Gel electrophoresis of the digested pQE-TcD 
and pQE-TcE plasmids. The positions of the eluted fragments are 
indicated. 
      pQE-TcE                 pQE-TcD 
x PvuI + HindIII       x PvuI + BamHI 
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T. cruzi 
antigens 
amino acid sequence  sensitivity 
Fusion 
B13-CRA 
MRGSHHHHHHGSPSPFGQAAAGDKPSPFGQAAAGDKPSPFGQAAAGDKP GSKVAEAE
KQKAAEATKVAEAEKQKAAEATKVAEAEKQKAAEATKL high 
Fusion 
TcD-TcE 
MRGSHHHHHHGSPKPAEPKPAEPKPAEPKPAEPKPAEPKPAEPKPAEPKPAEPKPAEK
LPSLSRSPAKAAAPPAKAAAPPAKAAAPPAKAAAPPAKAAAPPAKAAAPPAKAAAPKL  high 
Fusion 
B13-CRA-
TcD-TcE 
(TcBCDE) 
MRGSHHHHHHGSPSPFGQAAAGDKPSPFGQAAAGDKPSPFGQAAAGDKP GSKVAEAE
KQKAAEATKVAEAEKQKAAEATKVAEAEKQKAAEATKLPSLSRSPKPAEPKPAEPKPA
EPKPAEPKPAEPKPAEPKPAEPKPAEPKPAEKLPSLSRSPAKAAAPPAKAAAPPAKAA
APPAKAAAPPAKAAAPPAKAAAPPAKAAAP KL  
extremely 
high 
Fusion 
MAP-
SAPA 
MRGSHHHHHHLPRHVDPDHFRSTTQDAYRPVDPSAYKRALPLEEEEDVGPRHVDPDHF
RSTTQDAYRPVDPSAYKRALPLEEEEDVGPRHVDPDHFRSTTQDAYRPVDPSAYKRALP
QEEEEDVGKLSPLPRSPVDSSAHGTPSTPVDSSAHGTPSTPVDSSAHSTPSTPVDSSAH
STPSTPADSSAHSTPSTKL 
very 
high 
Fusion 
B13-CRA-
TcD-TcE-
MAP-
SAPA 
MRGSHHHHHHGSPSPFGQAAAGDKPSPFGQAAAGDKPSPFGQAAAGDKP GSKVAEAE
KQKAAEATKVAEAEKQKAAEATKVAEAEKQKAAEATKLPSLSRSPKPAEPKPAEPKPA
EPKPAEPKPAEPKPAEPKPAEPKPAEPKPAEKLPSLSRSPAKAAAPPAKAAAPPAKAA
APPAKAATcEPAPPAKAAAPPAKAAAPPAKAAAP KLPDPLRSPRHVDPDHFRSTTQDAY
RPVDPSAYKRALPLEEEEDVGPRHVDPDHFRSTTQDAYRPVDPSAYKRALPLEEEEDVG
PRHVDPDHFRSTTQDAYRPVDPSAYKRALPQEEEEDVGKLSPLPRSPVDSSAHGTPSTP
VDSSAHGTPSTPVDSSAHSTPSTPVDSSAHSTPSTPADSSAHSTPSTKL  
extremely 
high 
 
Table 3.1-18 Antigen fusions table. On the left column, fusions of the individual antigens , a tetrameric and an 
hexameric fusions  are indicated.  In the middle, the corresponding sequences.  Metionine codons, histidine-tag and amino 
acids coded by adapters and intermediate sequences (in black and underlined).  Antigen sequences that form the fusions are 
depicted in different colours.    
TcD and 6 repeats of TcE antigens, designated TcBCDE with a molecular weight of 20 kDa.  
The fusion was expressed with good yield in E. coli cells (approximately 2 mg antigen per litre of 
culture) and was easily purified by metal affinity chromatography. 
An unexpected extremely high increase of the immunoreactivity was observed with the 
tetrameric fusion product. It was needed to dilute the antigen 1:100.000 for coating the 
microtiter plates, otherwise the staining reaction exceeded the range of the photometer within 
few minutes.  The calculated optimal protein concentration was as little as one nanogram per 
assay only, a result never seen in any immunoassay before.  This result could not be explained 
solely by a better adhesion of the antigen to the microtiter plate.  Rather the protein 
conformation must have been changed so that the epitopes were exposed to the specific 
antibodies in an optimal way.  It is not clear whether this effect was due to the absence of the 
histidine-tag in front of the second fusion partner, or the introduction of a flexible spacer region, 
or a combination of both.   
Finally, a very large polypeptide was constructed by fusing the the B13-CRA-TcD-TcE 
tetramer antigen and the MAP-SAPA dimer.  However, the reactivity of the long hexameric 
fusion was not higher than that of the tetrameric fusion. For this reason, and to avoid instability 
of the construct, it was decided to use the tetrameric antigen for further assays. The different 
antigen fusions are depicted in Table 3.1-18.  
 
Results                                                                                                                                                        70 
_____________________________________________________________________________ 
3.2 Test of the antigens with patient sera  
3.2.1   ELISA 
A large number of sera had been tested in line blots during this work to characterise the 
quality of the recombinant antigens. However, line blot is not a very practical method for the 
routine in a diagnostic laboratory.  In most laboratories, ELISA is the method of choice due to its 
capacity to be automated, and the possibility to test large amounts of samples.  Furthermore, 
the results are more objective, since they can be exactly quantified by photometry.   
At the beginning, alkaline phosphatase-conjugated second antibodies were used for the 
immunostaining.  Alkaline phosphatase assays are highly sensitive and the conjugates have the 
advantage to be very stable during storage.  However, the tests can be too sensitive and 
sometimes false positive values were obtained, most probably due to accidental 
contaminations.  Phosphatases are ubiquitous and very resistant enzymes which are also 
contained in body fluids such as sweat, saliva etc.  They can be easily spread by handling 
reaction tubes and microtiterplates even wearing gloves.  For this reason, the ELISA tests were 
adapted later to be used with horse radish peroxidase conjugated second antibodies, and the 
corresponding colour assays.  Peroxidase assays are widely used and have the same 
sensitivity as alkaline phosphatase assays.  They have the disadvantage that the enzymatic 
activity is not as stable as the activity of phosphatase, i.e. the conjugates have a limited 
halftime.  However, this is compensated by the lower risk of contamination, since peroxidases 
occur less frequent in nature than phosphatases. 
To obtain more exact values in the ELISA tests, double determinations were done for 
each sample, and then the average value was calculated.  By this way test-to-test variations 
were reduced.  To discriminate positive from negative results, usually a cut off value is 
established by using the following formula: 
Cut off = average of negative controls + 2-5 x standard deviation (SD) of negative controls. 
 To determine how many SD had to be used in the formula, a test was performed with a 
large number of T. cruzi positive sera and negative sera from healthy persons calculating the 
cut off value differently with 2, 3, 4, or 5 x SD.  Taking 2 x SD, several false positives were 
obtained and taking 5 x SD, several false negative were observed.  In contrast, neither false 
positive nor false negative results were obtained using 3 and 4 x SD.  For this reason, it was 
decided to multiply factor 4, increasing thereby slightly the stringency of the results.  Using 
negative patient sera from Bolivia as negative controls, a slightly increase in the cut off value 
was observed, as compared with the value obtained with German negative sera.   
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When the ELISA tests were carried out with 1:10.000 diluted TcBCDE as antigen, a 
slight background was obtained with visceral leishmaniasis sera from the Republic of Yemen 
Therefore, the concentration of the TcBCDE was reduced to 1:100.000 corresponding to one 
nanogram of antigen per well in the microtiter plates. Under these conditions, clear negative 
results with these sera, whereas chagasic sera reacted still to strongly positive.  
 
3.2.3   Comparison of TcBCDE ELISA with commercial kits.  Cross-reactions 
The ELISA assay developed so far was compared with to types of commercial diagnostic 
kits for Chagas disease. The one kit (BiosChileIII, Ingeniería Genética S.A., Chile) uses T. cruzi 
crude extracts as antigen, and the other kit (bioelisa CHAGAS, Biokit S.A., Spain) uses a 
mixture of several T. cruzi recombinant proteins (B13 (PEP-2), TcD, TcE and TcLo1.2 (trans-
sialidase protein) in a different form as the antigens developed during this work. For the test, 
approximately 400 sera provided from a laboratory in Cochabamba, Bolivia (SEDES, Servicio 
Departamental de Salud) were used. These sera had been tested in Bolivia before with the 
BiosChileIII diagnostic kit containing whole extracts of Trypanosoma cruzi of the two strains 
Tulahuen and Mn as antigen.  Approximately 45% of the sera were positive, another 45% were 
negative, and 10% were determined as "inconclusive" due to ambiguous results with this 
diagnostic test kit. The ambiguous samples had been tested with an agglutination immunoassay 
and many of them were positive in this second test.  However, since the agglutination assay 
was also based on crude extract antigens from T. cruzi, similar results were to be expected.  
65 positive and 65 negative Bolivian sera, tested previously with the BiosChileIII 
commercial kit, were analysed by the TcBCDE ELISA with 5 µl of serum. The cut off of TcBCDE 
assay was calculated as explained above, and the cut off of the BiosChileIII kit was determined 
according to the instruction of the supplier, which is: 
 
(mean absorbance reading of positive controls + mean absorbance reading of negative controls) x 0.35 
 
None of the samples defined as ambiguous in the previous analysis in Bolivia were used 
in this experiment, however, weakly positive and borderline negative samples were included. 
The ambiguous samples were analysed later in another set of tests (see below). The same 
positive and negative sera were also tested Bioelisa CHAGAS kit from Biokit S.A., Spain, which 
uses recombinant proteins as antigens. The results of all these comparative ELISAs are shown 
in Figure 3.2-1. 
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Figure 3.2-1 Comparison of TcBCDE ELISA with commercial kits. On the left (blue) results 
obtained with TcBCDE ELISA.  Observe the high values of most positive samples.  Only 5 samples 
showed weaker values , but still clearly positive.  The group of negative samples show clear negative 
results, but with higher values than the negative group of bioelisa Chagas Biokit (commercial kit using 
recombinant antigens).  Therefore, the cut off value is higher too.  In the middle, Biokit results (red) with 
the positive samples group, that resulted in lower values. However, most values are clearly positive, and 
only a small group show weaker values.  Finally, on the right side, results of BiosChileIII performed in 
Bolivia (green), have lower values than the previous assays, and the discrimination between positive and 
negative is not well defined. Observe, in the group of negative serum samples, several values similar to 
the positives, which could be diagnosed as false pos itives.  The possible explanations will be further 
discussed.  
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The results obtained with the two ELISAs using recombinant antigens appeared to be 
very similar, even though the OD values obtained with TcBCDE ELISA were clearly higher than 
the ones obtained with Biokit Chagas ELISA.  In contrast, with the BiosChile crude extract 
ELISA several samples led to ambiguous results.  In this test, there is also a more or less 
continuous transition from negative to positive results and there is no clear decision feasible in 
many cases. 
It is generally accepted that diagnostic methods using recombinant antigens show a 
higher specificity than tests using crude extracts of the parasite.  This has been corroborated by 
the results obtained in this work.  In the graphic, a clear separation between OD values 
corresponding positive and negative samples obtained with the TcBCDE ELISA contrasts to the 
results of BiosChileIII ELISA. This lack of specificity with crude extract immunoassays 
represents a problem for the definitive diagnostic of a patient.  Therefore, and according to 
WHO recommendations, at least two tests must be performed to conclude whether the patient 
is positive for T. cruzi or not.  In the laboratory in Cochabamba an indirect hemagglutination 
(HAI) assay is used as a confirmatory technique.  However, also this test is based on crude 
extract antigens and can lead to uncertain results.  Some of the samples test negative by 
hemagglutination and positive by BiosChileIII ELISA, being then urged to be analysed by a third 
technique.   
Some of the samples clearly negative with both ELISAs using recombinant antigens 
were positive with the BiosChile crude extract ELISA. A possible explanation for the high OD 
values observed by the latter immunoassay could theoretically be a technical error, or mistaken 
serum number labels.  However, the more probable explanation is a cross-reaction with visceral 
leishmaniasis.  This is easily possible due to the fact that the region where the Bolivian 
laboratory is located (Cochabamba) is endemic for leishmaniasis too. In the same laboratory, 
cutaneous leishmaniasis is diagnosed by optical observation (typical skin ulcer).  However, no 
tests for visceral leishmaniasis are available, being most probably undiagnosed therefore.  Due 
to the well known cross-reactivity of antisera between both organisms, it is possible that the 
patients were wrongly diagnosed as Chagas disease patients instead of leishmaniasis patients. 
Since cutaneous leishmaniasis is self-healing after few months, but the specific antibodies may 
persist for many years, cross-reactions with both, cutaneous as well as visceral leishmaniasis 
may occur. Furthermore, there is some anecdotic evidence that T. cruzi antigens may cross-
react with sera from syphilis patients. 
Therefore, 30 serum samples classified as "inconclusive" by previous assays were 
analysed in another approach with four different diagnostic tests: the TcBCDE ELISA, the 
BiosChile ELISA, a self-made ELISA with crude extract from Leishmania major (kindly provided 
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by Michael Heimann) and a line blot assay with recombinant antigens from Treponema pallidum 
(E. Beck, unpublished).  
Whereas none of the sera led to a positive result in the Treponema pallidum-specific line 
blot (data not shown), the majority of samples ambiguous or even positive in the BiosChile 
ELISA, but negative in the TcBCDE ELISA, were clearly positive with the Leishmania-specific 
crude extract ELISA as shown in Figure 3.2-2. 
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Fig 3.2-2 TcBCDE ELISA assay compared with commercial T. cruzi 
crude extracts and self-made Leishmania crude extracts test. On the 
left (blue), TcBCDE ELISA results, which are all under the calculated cut off. On 
the middle (green), results obtained with the commercial BiosChile which uses T. 
cruzi crude extracts.  Observe the high values obtained with some samples.  On 
the right (orange) the same samples were tested with a self-made Leishmania 
crude extracts test.  Note the similar distribution of both T. cruzi and Leishmania 
crude extracts tests, in contrast to the clearly negative results by TcBCDE 
recombinant antigens.  The corresponding cut off values are shown as a lane by 
each test. 
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Thus, it can be concluded that the reason why some samples clearly negative in 
immunoassays with recombinant antigens test positive in assays using crude extracts, is the 
cross-reaction between Trypanosoma cruzi and different Leishmania species. In the laboratory 
in Cochabamba, several people are diagnosed regularly for cutaneous leishmaniasis, thus at 
least the cutaneous form of the disease exists in the area. Once infected, the Leishmania 
antibodies may persist for long time, even if the disease appears to be clinically cured. It is 
these antibodies which show a high reactivity against the antigens from T. cruzi crude extracts.  
For this reason, not only samples from people suffering from undetected visceral leishmaniasis 
are prone to show cross-reactivity, but also samples from people who suffered from cutaneous 
leishmaniasis in the past.   
 
In summary it can be stated that the TcBCDE ELISA has an excellent performance. It 
reveals a high specificity and has probably a much higher sensitivity than other immunoassays 
available at present.  However, the test has to be validated with larger amounts of samples (in 
order of thousands) under local conditions.  This was not feasible in the frame of this work, 
since the access to such an amount of sera is not (yet) possible in Europe.  However, this will 
be done in the next future during a long stay in Bolivia, a country most heavily affected by 
Chagas disease.   
 
 TcBCDE ELISA 
(our test) 
BiosChileIII ELISA 
(crude extract) 
Chagas Bioelisa Biokit 
(recombinant antigens) 
Sample set positive negative unclear positive negative unclear positive negative unclear 
Chagasic 
patients  
(n=65) 
65 0 0 58 0 7 65 0 0 
Leishmaniasis  
patients  
 (n=30) 
0 30 0 ---- ---- ---- ---- ---- ---- 
Syphilis 
patients  
(n=40) 
0 40 0 ---- ---- ---- ---- ---- ---- 
Healthy 
individuals 
(n=65) 
0 65 0 0 2 63 0 65 0 
Table 3.2-3 Summary of the results with three different T. cruzi-specific ELISA tests.  This panel of results 
shows the clear positive results obtained by recombinant antigens test (TcBCDE and Biokit) in front of the some unclear values 
obtained with the crude extract antigens (BiosChile).  Tests with leishmaniasis patients were only perform ed with TcBCDE 
ELISA, which lead to clearly negative results, indicating no cross-reactions.   Additional syphilis samples were tested with the 
same TcBCDE assay, again with negative reactivity.  Finally, the negative samples group clearly negative values were obtained 
with recombinant antigens assays, contrasting with the large amount of unclear results by using crude extracts.  
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3.3 Molecular methods: PCR 
 PCR has been shown to be useful in different areas of Chagas disease control.  In this 
work, the focus is on the diagnosis of T. cruzi in blood of patients, but this assay has also been 
used to detect the parasite in Triatomine bug feces, being more sensitive than traditional 
microscopy (Pizarro et al., 2007).  Congenital T. cruzi infection is also diagnosed by means of 
this technique (Virreira et al., 2003), because it represents an advantage as compared with 
serologic tests, which have problems to distinguish antibodies from the mother and from the 
child.  PCR represents an important contribution also for paleobiology. As previously mentioned, 
the detection of T. cruzi DNA in tissues from 9000 years old Chilean mummies has been 
reported (Aufderheide et al., 2004).  
In cases of low parasitemia such as in the chronic form of the disease, a highly sensitive 
technique is needed.  Common used methods in this phase include xenodiagnosis, blood 
culture and serology.  The two first methods show a high specificity but a low sensitivity, and in 
serological tests cross-reactions are commonly observed with samples of patients infected with 
other trypanosomatides.  PCR has a higher sensitivity and specificity, and therefore it is a good 
alternative to these techniques (Salomone et al., 2003). 
Monitoring of the success of treatment with drugs has been a problem since long time 
and still represents a challenge due to the lack of appropriate methods (de Castro, 1993).  Tools 
commonly used for the assessment of the therapy are mainly serological, following the patient 
until the negative “seroconversion”.  This can take years, since the antibodies against T. cruzi  
persist in blood for long time.  The PCR technique has the advantage that it detects the DNA of 
the parasite in the patient sample which directly demonstrates  the presence of the agent, not 
indirectly as specific antibodies.  Thus, it is able to distinguish an “active” infection from a “past” 
infection, allowing discriminating if a person is already cured or not (Galvão et al., 2003).  
Therefore, PCR diagnosis complements the immunodiagnostic tools developed during this work 
and covers the gap of serologic methods.  
 
3.3.1 18S ribosomal RNA-specific nested PCR 
To increase the sensitivity of the PCR it is recommended to use sequences occuring 
several times in the genome of a pathogenic agents as  target.  For this reason, the 
amplification of the 18S ribosomal RNA sequence was thought to be a good option, since it is a 
repeatedly existent fragment.  The genome of T. cruzi contains an estimated number of 218 
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L. tarentolae     AGAAATAGAGTTGTCAGTCCATTTGGATTGTCATTT-CAATGGGGGATATTTAAACCCAT  
L. donovani       AGAAATAGAGTTGTCAGTCCATTTGGATTGTCATTT-CAATGGGGGATATTTAAACCCAT  
L. amazonensis    AGAAATAGAGTTGTCAGTCCATTTGGATTGTCATTT-CAATGGGGGATATTTAAACCCAT  
L. major          AGAAATAGAGTTGTCAGTCCATTTGGATTGTCATTT-CAATGGGGGATATTTAAACCCAT  
T. cruzi-VINCH    AGAAATAGAGCCGACAGTGCTTTTGCATTGTCGTTTTCAATGGGGGATATTTAAACCCAT  
T. cruzi-SLU31    AGAAATAGAGCCGACAGTGCTTTTGCATTGTCGTTTTCAATGGGGGATATTTAAACCCAT  
T. rangeli        AGAAATAGAGCCGACAGTGCTTT-GCATTGTCGTTTTCAATGGGGGATATTTAAACCCAT  
                  **********  * **** * ** * ****** *** *********************** 
                               I--Tcru18S-out-F --> 
 
// 100 nucleotides // 
 
L. tarentolae     TAGTTGAACTGTGGGCTGTGCAGGTTTGTCCCTGGTCGTCCCGTCCATGTCGGATTTGGT  
L. donovani       TAGTTGAACTGTGGGCTGTGCAGGTTTGTTCCTGGTCGTCCCGTCCATGTCGGATTTGGT  
L. amazonensis    TAGTTGAACTGTGGGCTGTGCAGGTTTGTTCCTGGTCGTCCCGTCCATGTCGGATTTGGT  
L. major          TAGTTGAACTGTGGGCTGTGCAGGTTTGTTCCTGGTCGTCCCGTCCATGTCGGATTTGGT  
T. cruzi-VINCH    TAGTTGAATTGAGGGCCTCTAAGGCGCAATGGTT-TAGTCCCATCCACTTCGGATT-GGT  
T. cruzi-SLU31    TAGTTGAATTGAGGGCCTCTAAGGCGCAATGGTT-TAGTCCCATCCACTTCGGATT-GGT  
T. rangeli        TAGTTGAATTGTGGGCCTTCGAGGCGCAATGGTT-TAGTCCCGTCCACTTCGGATT-GGT  
                  ******** ** ****     ***        *  * ***** ****  ******* ***  
                                 I--Tcru18S-inn-F--> 
 
// 380 nucleotides // 
 
L. tarentolae     TCGTCCGGCCGTA----------------ACGCCTTT--TCAACTCACGGCCTCTAGGAA  
L. donovani       TCGTCCGGCCGTA----------------ACGCCTTT--TCAACTCACGGCCTCTAGGAA  
L. amazonensis    TCGTCCGGCCGTA----------------ACGCCTTT--TCAACTCACGGCCTCTAGGAA  
L. major          TCGTCCGGCCGTA----------------ACGCCTTT--TCAACTCACGGCCTCTAGGAA  
T. cruzi-VINCH    CTTGCC-TCCGCATATTTTCACATGTGTCATGCCTTCCCTCAACTCACGGCATCCAGGAA  
T. cruzi-SLU31    CTTACCCTTCGCAT---CTCACATGTGTCATGCCTTCCCTCAACTCACGGCATCCAGGAA  
T. rangeli        CGTACGG--CGCAT-TACACACACTGCCTTCGCCTTCCCTCAACTCACGGCATCCAGGAA  
                           ** *                  *****   ************ ** ***** 
                                          <---Tcru18S-inn-R--I 
                                                        <--Tcru18S-out-R--I 
 
Figure 3.3-1 Alignment of parts of the genes for 18S rRNA of different species of 
trypanosomatides.  The location of the PCR primers described in the text are indicated. Differences 
between T. cruz i and T. rangeli are indicated in green letters. 
genes for ribosomal RNA (El-Sayed et al, 2005).  The 18S rRNA sequence of T. cruzi differs 
significantly from the corresponding genes in humans or other organisms. However, there is a 
high sequence homology within the Trypanosomatide family, and different pathogenic and 
apathogenic forms of this family co-exist in Latin America (T. cruzi, T. rangeli and several 
Leishmania species) making the design of specific primers demanding. Comparison of the 18S 
rRNA sequences of these forms reveals that several parts in the central part of the genes differ 
sufficiently to derive species-specific primers. These sequences are shown for several 
representative Trypanosomatides in the following Figure 3.3-1. 
 
 
PCR primers sequences were selected from regions differing most between the 
Trypanosomatides. Since it was not possible to select completely different sequences for the  
oligonucleotides, the 3' ends of the oligonucleotides were chosen in a way that no hybridisation 
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to the DNA of the other species was possible.  By this way the oligonucleotides could not be 
extended by the Taq DNA polymerase, even if the would bind to the template. Such a selection 
was feasible easily for one set of primers (Tcru18S-inn-F and Tcru18S-inn-R).  In this case, 
Primer3 software could not be used to select optimal sequences as in case of cDNA synthesis 
described above, but the program was used to predict the physical properties of the chosen 
oligonucleotides such as annealing temperature and self-complementarity.  
In order to increase sensitivity of the PCR assay, a set of outer primers was selected 
additionally.  No highly specific sequences were found for these outer primers (Tcru18S-out-F 
and Tcru18S-out-R), so that PCR with these primers would not lead with certainty to a specific 
discrimination of the species.  However, the function of the outer primers was solely to amplify 
the target region in a first step, and the specificity would then be provided by a nested PCR with 
the inner primers. 
 
 
Primers for T. cruzi-specific 18S rRNA PCR 
Name Sequence Fragment length 
Tcru18S-out-F ACAGTGCTTTTGCATTGTCG 
Tcru18S-out-R CTGGATGCCGTGAGTTGAG 
642 bp 
Tcru18S-inn-F CCTCTAAGGCGCAATGGTT 
Tcru18S-inn-R GTTGAGGGAAGGCATGACAC 
467 bp 
 
 
The specificity of the primers was shown in an experiment including purified DNAs from 
Trypanosoma  cruzi, Leishmania major and Leishmania infantum.  
 
 
 
 
 
 
 
 
 m    1    2     3     4    5    6    7     8    9 
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Figure 3.3-2 Test of Tcru18S outer PCR primers (upper part) and inner 
primers (lower part) with DNA from T. cruzi, L. infantum  and L. major with 
different concentrations of DNA at 60°C annealing temperature. Lane 1 to 3 
and 10 to 12 T. cruzi DNA; lanes 4 and 5 L. infantum  DNA; lanes 6 to 8 and 
15-17 L. major DNA; lanes 1,6, 10 and 15 10 ng DNA each, lanes 2, 4, 7, 11, 
13, and 16 1 ng each; lanes 3, 5, 8, 12, 14, and 17 0.1 ng DNA each; lanes 9 
and 18 no DNA. 
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Figure 3.3-3 Specificity of 18S rRNA-specific nested PCR at higher temperatures. To determine the 
optimal hybridisation conditions, PCRs were performed with different annealing temperatures for 18S rRNA outer 
and inner primers using 0.1 ng of the individual parasitic DNAs per assay. Four annealing temperatures were 
selected: 64°C (lanes 1, 5, 9, 13, 19 and 23); 66°C (lanes 2, 6, 10, 14, 20, 24); 68°C (lanes 3, 7, 11, 15, 21, 25); 
70°C (lanes 4, 8, 12, 16, 22, 26); T. cruzi DNA: lanes 1 to 4 and 13 to16; L. infantum  DNA lanes 5 to 8 and 19 to 22; 
L. major DNA lanes 9 to 12 and 23 to 26; lanes 17 and 18: no DNA. 
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Figure 3.3-4 Tcru-18S rRNA-specific nested PCR with blood 
samples.  PCR was performed with DNA extracted from 20 blood samples of 
chagasic patients at 68°C annealing temperature in both, primary and 
secondary cycles. The numbers refer to patient samples, C1 is a positive 
control with purified T. cruzi DNA, and C2 is a negative control with water. 
 
The PCR with the outer primers performed at 60°C annealing temperature was specific 
for T. cruzi leading to a single 640 bp band, but the inner primers led in addition to the specific 
band with 470 base pairs to an artificial product of approximately 900 bp with the DNA of L. 
infantum.  Therefore, the stringency of the reaction conditions was increased and the PCR was 
repeated at different higher annealing temperatures between 64°C and 70°C.  
The result shows that at an elevated annealing temperature of 68°C, the PCR assay is 
equally sensitive as before, but there are no more cross-reactions with L. infantum. 
The efficiency of this 18S rRNA-specific PCR was tested with 20 blood samples of 
chagasic patients.  After isolation, the blood of these patients had been mixed with one volume 
of 5 M guanidinium hydrochloride and was stored for several weeks at 4°C.  DNA was extracted 
from 400 µl of these samples with the guanidinium-silica method and dissolved in 20 µl each.  
Two µl of these DNA samples were used in each PCR assay 
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Only some of the patient samples led to a positive result in this assay. This may have 
been due to the fact that the samples had been stored before DNA extraction for several 
months in the refrigerator. It is well known that DNA is degraded in guanidinium-blood upon 
extended storage. As described in the Materials section, an alternative method of DNA 
extraction starting from buffy coat was developed. In future experiments, this new procedure will 
be used. During work on this thesis, no alternative blood samples were available. 
However, the same blood samples tested positive several months before with another 
PCR assay in a laboratory in Barcelona.  Therefore, it was not to be excluded that the sensitivity 
of the 18S rRNA-specific PCR was not sufficiently sensitive.  
 
3.3.2 Kinetoplast minicircle DNA-specific PCR 
In order to test whether the sensitivity of the molecular biological approach could be 
increased, another PCR assay was designed based on minicircle DNA of the parasite. 
Minicircle DNA occurs in more than 10.000 copies in each tryptomastigote and is very 
heterogeneous in size, but it contains a conserved sequence of approximately 380 base pairs in 
each circle. Alignment of three representative examples of many different minicircle DNA 
sequences contained in gene data bases are shown in Figure 3.3-5. 
Several primers amplifying different regions of the kinetoplast minicircle DNA have been 
largely used.  First described, the primers 121, 122 (Wincker et al. 1994) amplify a 330 bp 
fragment of the minicircle kDNA. This original protocol has been improved by using additional 
primers to create a nested PCR assay, leading to an increase of sensitivity and specificity 
(Ribeiro-Dos-Santos et al., 1999). Analysis of the primers used in these former assays by 
Primer3 software revealed that the annealing temperatures differed between forward and 
reverse primers by more than 20°C. This can negatively interfere with the PCR assay, since the 
low annealing temperature needed for one primer easily leads to unspecific hybridisation of the 
other primer with the template which may result in artefact bands. In order to optimise the 
described nested PCR protocol, additional new primers with similar predicted annealing 
temperatures were designed by means of Primer3 software. These primers are shorter than the 
formerly used oligonucleotides and are termed “new” in the following Figure 3.3-6. 
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                         I--------TcMC-122--------> 
                            I--TcMC-122 short--> 
                I------TcMC-89/90--------> 
                I-TcMC-89/90short-> 
X04680-2        GGAGGTGGGGGTTCGATTGGGGTTGGTGTAATATAAGTTAGGTATGGTGGTTAGGATTTT 
X04680-3        GGGAGGTGGGGTTCGATTGGGGTTGGTGTAATATAG-AGGGTTTTGAGGGTTAACGTATT 
X04680-1        GGGAGGTGGGGTTCGATTGGGGTTGGTGTAATATACTACTGAATAGAAGGTGTGGTTAAT 
                **..*  ****************************  :  * :::*. *** :.  *::* 
 
X04680-2        ATATGGTGTTATTAGGATGGTAGATTGTATATGTACATTGTGATAGTTATGATATCGTGT 
X04680-3        ATG---------AATGATTATGGTATTGTTATGTGAGTAGTTTATGATTGTATATTATAG 
X04680-1        TTG-----------AATGTCTTGATTTGATAGATTATGTGACTACGTGTTATTGACTTGT 
                 *                  * *  *   **  *     *     *      *    *   
 
X04680-2        ATAATTTGTGTATTCAGTATGTTGATAAAGCCTGATGTGTGTTGTTATAGTTGTGTTATT 
X04680-3        TTTTATAGTGTAGTGATGATGAT--AGAAGTCTGACGTGAGATAGAGGATGAGTAATGGT 
X04680-1        TGTATTTCTTGAGTGGTTGTAGTGCTAGAGATAATACAGTGTATAATAATGTTTGTTGAA 
                     *  *  * *     *  *     **        * *       *    *  *    
 
X04680-2        CATTCTGGTTATAAACGTATTTATGGTTATGGGTATGGTGTGGTTGTGTTGAAGCTATAG 
X04680-3        GATGAGAACTTTGATATGTTGTGTAGTAATAATATTAATAAGATT-TGATAAACTTTATA 
X04680-1        TATTCTGAAAGTATAAATGTTTATTTGTTGGAGTGGTGTATAGTATTGGTTGTGAAATAT 
                 **        *       * * *              *    *  ** *           
 
                                                              <--TcMC-91-short 
                                                               <----TcMC-91- 
X04680-2        TTGGAGTTTGAATGTTATTTGGGATTAGGAAATTCCTGAAATCTGTGTTTTGGGAGGGGC 
X04680-3        TTGGTG-----GTGTAATAAGGGGTTGAGAATTTGGTTAAGTCG-TGTTTTGGGAGGGGC 
X04680-1        TTGATA---------AAAGTGGTACCCTGAAATTCGGTAAATTATAGTTTTGGGAGGGGC 
                ***             *   **      *** **    ** *    ************** 
 
             91-short----I 
                --TcMC 91------I      <--------TcMC-121--------I 
X04680-2        GTTCAACTTTTGGGGCCGAAATTCATGCATCTCCCCCGTACATTATTTGTGCCAAAATCC 
X04680-3        GTTCAACTTTTGGGGCCGAAATTCATGCATCTCCCCCGTACATTATTTCCGCCAAAATGC 
X04680-1        GTTCAAATTTGGGCCGGAAAAATCATGCATCTCCCCCGTACATTATTTTGGGATTTTAGG 
                ****** *** **     *** **************************  *          
                                                                             
X04680-2        CGAATTTTCA-- 
X04680-3        TAAATTTTCA-- 
X04680-1        GGGTTGTTCAAT 
                    * ****   
 
Figure 3.3-5 Alignment of representative examples of T. cruzi minicircle DNAs 
 
   name  sequence     Tm  comments 
TcMC-121        AAATAATGTACGGGKGAGATGCATGA          66°C (old outer-reverse)1 
TcMC-122        GGTTCGATTGGGGTTGGTGTAATATA          65°C   (old inner–forward)1 
TcMC-122-short     TCGATTGGGGTTGGTGTAAT           60°C (new inner-forward) 
TcMC-89         GGGAGGTGGGGTTCGATTGGGGTTGG          78°C   (old outer—forward)2 
TcMC-89-short   GGGAGGTGGGGTTCGATTG   65°C (new outer-forward) 
TcMC-90         GGGAGGTGGGGGTTCGATTGGGGTTGG  89°C (old outer—forward)2 
TcMC-90-short   GGGAGGTGGGGGTTCGATTG   66°C (new outer-forward) 
TcMC-91         GSCCCMAAAKTTGAACGCCCCTCCC           72°C   (old inner-reverse)2 
TcMC-91-short         AAAKTTGAACGCCCCTCCCA          67°C   (new inner reverse) 
 
Figure 3.3-6 Nested PCR primers for T. cruzi minicircle DNA 
1 Wincker et al., 1994; 2 Ribeiro-Dos -Santos  et al., 1999; M = A+C; K = G+T 
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These primers were tested in PCR assays with different annealing temperatures and 
different concentrations of purified T. cruzi DNA.  It has to be noted that, while performing PCR 
amplifying kDNA, the kinetoplast network (present in the cell in highly concatemeric form) has to 
be cleaved in order to allow the homogeneous distribution of minicircle molecules in blood 
samples.  This can be reached by chemical methods, but also by physical means, as heating, 
whose results are the same, and are less expensive.  This latter method was used in this work, 
that is, the purified DNA was boiled for 10 minutes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results from this experiment clearly revealed that the published longer versions of 
primers for minicircle-specific PCR performed better than the computer-predicted new shorter 
versions.  As only exception, the new primer TcMC-91-short led to equivalent results as the 
longer (old) version (data not shown).  However, in contrast to the published protocol, it is 
needed to use an annealing temperature of 66°C for both, outer as well as inner primers.  
A nested PCR under the determined conditions was performed with 10 DNA samples 
extracted from the above mentioned chagasic patients guanidinium-blood.  For the primary 
PCR, the outer primers TcMC-89/90 and TcMC 121 were used.  In the second PCR, one 
microlitre of the primary product was amplified with two combinations of inner primers each, 
  
 
 
 
Figure 3.3-7 Annealing conditions for the outer and inner primers for T. cruzi minicircle 
DNA.  Four different combinations of forward and reverse primers have been tested under standard PCR 
conditions except of varying annealing temperatures with T. cruzi DNA as template.: Combination I: primers 
121 + 122 (lanes 1 to 10); combination II: primers 89/90 + 121 (lanes 11 to 20); combination III: primers 122 
short + 121 (lanes 21 to 25); combination IV: primers 89 short/90 short + 122 (lanes 26 to 30). DNA 
concentration was 1 ng/assay in lanes 1 to 5, 11 to 15 and 21 to 30; and 0.1 ng/assay in lanes 6 to 10 and 16 
to 20. Annealing temperatures: 58°C (lanes 1, 6, 11, 16, 21, 26); 60°C (lanes 2, 7, 12, 17, 22, 27); 62°C 
(lanes 3,8, 13, 18, 23, 28); 64°C (lanes  4, 9, 14, 19, 24, 29); 66°C (lanes 5, 10, 15, 20, 25, 30). 
 m   1     2    3    4     5    6    7     8    9    10 
 
  m    11   12  13  14   15  16  17  18  19  20 
 
   m   21  22    23  24    25    26  27   28   29   30 
 
Results                                                                                                                                                        84 
_____________________________________________________________________________ 
 
 
 
Figure 3.3-8 Minicircle-specific nested PCR with DNA from 10 
patient sera. In the primary PCR the primers TcMC-89/90 + TcMC-121 
were used. In the secondary PCR, the inner primers TcMC-122 + TcMC-91 
(lanes 1 to 10) or TcMC-121 + TcMC-91-short (lanes 11 to 20) were used. C1 
and C2 are positive controls with 0.1 ng purified T. cruzi DNA. 
TcMC-122 + TcMC-91 in one set of samples, and TcMC-122 + TcMC-91-short in another set of 
samples.  As can be seen from Figure 3.3-8,  only the longer inner primers led to a positive 
result. In this case, 5 out of 10 blood samples tested clearly positive in the assay.  Faint bands 
are also to be observed in lanes 1 and 2.  Thus, the minicircle-based nested PCR appears to be 
more sensitive as the 18S rRNA-based nested PCR described before. 
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4.   DISCUSSION 
 Chagas disease is the most important parasitic disease of the Americas accounting for 
670,000 disability-adjusted life years per annum. In principle, the disease can be cured 
efficiently, but most infected people do not know that they have become infected, as the 
symptoms are usually unspecific or mild in the early stages. Infections remain largely 
asymptomatic often for years or even decades, until up to 30% of patients develop chronic 
disease, i.e., cardiac or gastrointestinal complications, which are severely debilitating and in 
many cases fatal.  In contrast to the possibility of successfully treatment early after infection, 
cure becomes ineffective in the late chronic stage with the drugs available at present.  With a 
timely diagnosis – which has to be affordable for the affected and mostly impoverished 
population – the magnitude of this disease could be largely reduced. Diagnostic procedures for 
the diagnosis of Chagas disease are available, however, they either lack specificity and 
sensitivity, or they are too expensive and not appropriate for laboratories in developing 
countries, due to the sophisticated equipment they require.  
The purpose of this work was to develop new diagnostic procedures which are not only 
highly sensitive and specific, but could also be produced in an inexpensive and independent 
way in countries endemic for Chagas disease, so that, in future, patients can be detected in 
time to start treatment as soon as possible.  
The necessary basic bioinformatic tools for developing new diagnostics such as the 
genomic sequence of the parasite, or computer programs to manipulate these sequences are 
all freely available in the internet and were used in this project to design recombinant diagnostic 
antigens. In contrast to diagnostic tests that use crude extracts as antigens, assays using 
recombinant proteins show high specificity. It turned out that the predominant structures of the 
parasite that elicit a strong immune response were tandemly repeated amino acid sequences. 
Therefore such repetitive amino acid sequences were produced during this work as 
recombinant antigens.  
Fusion of the recombinant antigens into a single polypeptide led to an extraordinary and 
unexpected high reactivity with sera from patients infected with T. cruzi. Furthermore, and in 
contrast to the results obtained with commercial diagnostic kits, it was observed that the 
specificity was very high, being helpful to discriminate the so called “weak positives”, which are 
the main problem in the diagnosis of patients with the available methods at present. Application 
of the assay developed during this work for a large number of patient samples revealed that 
some of the samples diagnosed as Chagas disease “positive” by other tests, were actually 
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samples from patients infected with Leishmania species, organisms closely related to 
Trypanosoma cruzi, and therefore prone to show cross-reactions. 
In conclusion, this work led to three important results.  At first it was demonstrated that 
favourable protein folding can strongly increases the sensitivity of immunoassays.  The second 
main result is the finding that some commercial diagnostic kits lack specificity, being not able to 
distinguish between T. cruzi and Leishmania infections. This is especially problematic in areas 
where leishmaniasis and Chagas disease coexists since wrong diagnosis may have fatal 
consequences. The third important result is that the new diagnostic assay combining the 
properties of high sensitivity and high specificity can be produced by simple means and at low 
costs, which makes it affordable also for the poor population in the affected countries. 
 
4.1   Production of recombinant antigens 
Establishing the almost complete DNA sequence of the genome of Trypanosoma cruzi 
(El-Sayed et al., 2005) was crucial for this work.  The complete genetic information is online 
available in the Wellcome Trust Sanger Data Bank.  Also all other bioinformatic tools necessary 
for this work such as the designing of synthetic oligonucleotides, designing of PCR primers, 
aligning of sequences, or searching for restriction sites are freely accessible in the internet. 
Recombinant antigens produced during this work consist almost exclusively on tandemly 
repeated amino acid sequences. This kind of sequence repetitions occurs also in other protozoa 
such as Leishmania species and Plasmodium species, and in all these organisms they 
represent efficient antigens for inducing specific antibodies. As these parasites replicate inside 
of cells, the strong humoral immune response may not affect them very much, but rather 
deviates the immune system from a protective cellular response.  
Cloning and expression of the genes for repetitive sequences in Escherichia coli 
presented some difficulties, probably due to the fact that they were not tolerated by the repair 
system of the cells. First it was tried to clone the antigens in E. coli strains defective in 
homologous recombination (recA- strains), but without success. The problem could only be 
solved by the construction of synthetic genes avoiding direct repeats of more than 8 
nucleotides. By combining four different tandemly repeated amino acid sequence motives by 
means of flexible spacer regions, an extremely immunoreactive antigen was obtained. A 
standard protein preparation containing approximately one milligram protein per millilitre has to 
be diluted 100.000 fold for use in immunoassays. By this way, there is as good as no 
contaminating bacterial contamination present and correspondingly no immunological cross-
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reaction with E. coli antibodies which usually causes background problems in other 
immunoassays involving recombinant proteins.  Production of the polyvalent antigen is easily 
reproducible.  Several batches of the protein have been prepared in the laboratory and all 
performed exactly equally.  
 
4.2   Specificity of the diagnosis 
Cross-reactions between T. cruzi antibodies and antigens from other organisms are 
widely known.  Strongest cross-reactivity is observed with related pathogenic and apathogenic 
members of the Trypanosomatide family. While this can be tolerated in screenings of samples 
in blood banks since suspicious samples have to be eliminated anyway, wrong diagnosis of 
patients may lead to fatal consequences.  Traditional diagnostic protocols using crude parasite 
extracts as antigens cross-react especially with sera from persons infected with different 
species of Leishmania, or with the apathogenic parasite Trypanosoma rangeli (Saldaña et al., 
1996).  T. cruzi and T. rangeli are closely related and occur within the same geographic regions, 
and both species use the same Triatomine bugs as vectors.  Humans are infected by T. rangeli 
directly by the bite of the vector, whereas T. cruzi occurs in the feces of the insect and can enter 
the body via mucosa or little wounds only. Co-infections with both species are also possible. 
However, no homologies of the T. cruzi-specific recombinant proteins used in the TcBCDE 
antigen have been detected so far in T. rangeli sequences by BLAST homology searches, thus 
a reactivity of sera from persons infected with T. rangeli with the recombinant antigen appears 
to be highly improbable. Even though no T. rangeli infected samples were available in the 
laboratory, the antigens synthesised had already been tested against this organism by other 
groups without finding any cross-reaction (Ferreira et al., 2001). In addition, this view is 
supported by the fact that commercial diagnostic kits including recombinant antigens of T. cruzi 
related to the amino acid structures of TcBCDE have been shown to be highly specific and did 
not react with sera from T. rangeli-infected persons.  
The high specificity for T. cruzi does not hold for all produced recombinant antigens. By 
line blot assays, it turned out that one of the highly reactive recombinant antigens, FRA, cross-
reacted with leishmaniasis sera samples.  FRA is included in several commercial diagnostic kits, 
most probably due to its high sensitivity.  However, FRA was discarded in this project because 
of its lack of specificity.  The antigen might be included in diagnostic kits in areas free of 
leishmaniasis but, according to our results, should not be used elsewhere in order to avoid false 
positive results.  Other diagnostic antigens described previously, JL8 and 1F8 were found to 
cross-react with leishmaniasis sera as well.   
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Clear discrimination between Chagas disease and leishmaniasis is a major problem in 
many parts of Latin America. As shown above, immunoassays with crude extracts of 
Leishmania major as antigens led to a strong cross-reaction with sera of T. cruzi patients, and it 
became clear that the difference between patient sera positive with T. cruzi crude extract 
antigen, but negative with recombinant antigens was due to this fact. In order to prove that the 
TcBCDE antigen does not cross-react with leishmaniasis sera, it was of great importance that 
the origin of leishmaniasis samples was from the Republic of Yemen which is an area free of 
T. cruzi. On that way, co-infections were excluded, and positive results obtained with the 
Bolivian sera could be evaluated as cross-reaction.   
Using recombinant antigens, clear discrimination between Chagas disease and 
leishmaniasis is feasible only for T. cruzi at present.  The clear identification and differentiation 
of infections with different species of Leishmania remains problematic. While the relatively 
harmless cutaneous form of leishmaniasis can easily be diagnosed by observation of skin 
ulcers, there is no good diagnosis for the mucocutaneous and visceral forms of the disease. 
Leishmaniasis is most probably highly underdiagnosed in Latin America, and even co-infections 
with T. cruzi and Leishmania species are possible.  Chagas disease has an overlapping 
geographic distribution with leishmaniasis, and mixed infections have been demonstrated 
(Bastrenta et al., 2003).  The visceral form of leishmaniasis represents a major problem, 
because, as Chagas disease, it does not present clear clinical symptoms. Some of the drugs 
indicated for leishmaniasis (antimonial derivatives) are strongly disrecommended for patients 
with severe chagasic cardiopathy, and there are some registered cases of sudden death and 
electrocardiograph changes derived from this situation (Sampaio et al., 1988; Antezana et al., 
1992).  With respect to the observed high cross-reactivity of chagasic sera with crude extract 
antigen from L. major, the use of such crude extracts for diagnosis of leishmaniasis is 
problematic in areas with high prevalence of Chagas disease.  Some recombinant antigens for 
the specific diagnosis of visceral leishmaniasis have been produced and tested. However, they 
still have limited sensitivity and specificity with respect to the discrimination of the different forms 
of the disease. Due to these limitations and the high costs of corresponding diagnostic test kits, 
most cases of visceral leishmaniasis remain undiagnosed in Latin America. 
It has been reported that T. cruzi antigens may also cross-react with sera from patients 
with other diseases such as leprosy, malaria and multiple myeloma (Guevara and Ouaissi, 
http://www.cdfound.to.it/html/trip1.htm#tc15). However, this may hold for crude extract antigens, 
but not for carefully selected recombinant antigens.  To analyse possible cross-reactions with 
other widespread infectious diseases, the TcBCDE antigen was tested with sera from syphilis 
patients and brucellosis patients. These sera were from Mongolian patients who cannot be 
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accidentally infected with T. cruzi or any Leishmania species. No cross-reactions were 
observed. Complementary tests, incubating chagasic sera with recombinant antigens from 
Treponema pallidum were also negative (data not shown). 
  
4.3   ELISA 
For most infectious diseases, diagnosis is usually performed only when patients suffer 
from any evident clinical symptoms, because only then patients search for medical care. At 
present, this holds also for the diagnosis of Chagas disease. However, when clinical symptoms 
such as cardiac or digestive dysfunctions become apparent, cure with the available drugs is not 
possible anymore in most cases. At the other hand, cure with these drugs is highly effective, if 
the infection is recognised early, this means long before the onset of clinical symptoms. 
Therefore, the only way for timely recognition of the disease would be screening of large 
populations in endangered regions in regular periods of time. This demands diagnosis in large 
scale, including millions of persons rather than hundreds or thousands per year. For this reason, 
diagnostic procedures appropriate for use in large scale have to be selected. 
The ELISA technique is one of the most widespread methods for the diagnosis of large 
amounts of samples, essentially due to its capacity to be automated. In addition, by this 
technique, results are quantifiable. Thus, the recombinant antigens purified in this work were 
adapted to be used in this kind of assay. The first synthesised antigens did not bind sufficiently 
to the plastic surface of the microtiter plates, probably due to their small size. Therefore, it was 
decided to fuse the single antigens to larger fusion proteins. The longer fusions bound better to 
the plastic, indeed, but unexpectedly the immune reaction was more increased than the added 
reaction of the individual antigens. Probably, the antigens were better accessible to the 
antibodies when presented as a larger protein. This effect was even more pronounced when a 
fusion of four different diagnostic antigens was constructed. By this way, the strength of the 
immunoreaction increased by a factor of one hundred, or more.   
Fusing different antigens to a single protein compared with the simple mixing of the 
same antigens has additional advantages. It facilitates the production of the recombinant 
proteins, because purification of just one polypeptide, instead of several ones, is necessary. By 
this way, there is less content of bacterial contaminations leading to low background reactions. 
In addition, large-scale purification is simplified and the production costs are reduced.  
 The TcBCDE ELISA assay developed during this work was compared with two different 
commercial diagnostic kits for Chagas disease, one (BiosChileIII, Chile) using a crude extract of 
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T. cruzi epimastigotes as antigen, and a second one (Bioelisa Chagas from Biokit, Spain) using 
the recombinant fusion protein TcF (Houghton et al., 1999; Ferreira et al., 2001) which contains 
in part the same antigens as used in TcBCDE, but in a different structure. The TcF antigen 
contains two repeats of the antigens B13, TcD, TcE and TcLo1.2 (related, but not identical to 
SAPA) as direct fusions, i.e. not separated by proline containing linker sequences like in 
TcBCDE.  Using equal amounts of patient sera in the tests, the TcBCDE ELISA led to much 
higher OD values than the two commercial diagnostic kits, and led to better discrimination 
between negative and positive sera.  From 65 chagasic sera tested with the TcBCDE ELISA, 
most reacted strongly positive and only very few showed a weak positive reaction (which was 
still well to be discriminated from negative sera), whereas 20% of the same serum samples led 
to weak positive signals with the Biokit ELISA.  With the BiosChile crude extract ELISA, the 
same sera led also all to positive results, even though many of them were weakly positive only. 
The problem with the crude extract ELISA was rather the negative control sera which led in part 
to results which were in the range of weakly positive sera. This phenomenon is well known and 
some authors describe the OD range where negative and positive sera result in similar values 
as "gray zone" (Ferreira et al., 2001). As shown in the Results section, most of the weakly 
positive signals obtained with the control sera were caused by immune reactions against 
leishmaniasis infections which are frequent in many areas of Latin America.  At present, such 
ambiguous immunological results have to be tested with another diagnostic technique, which in 
many cases leads unfortunately to similarly inconclusive results. TcBCDE ELISA is expected to 
avoid these problems in the future. However, the results have to be validated with larger 
amounts of sera in endemic areas in Latin America.  
 
4.4  Polymerase Chain Reaction  
The polymerase chain reaction is not only the most sensitive and specific procedure for 
diagnosis of many infectious diseases, it is, in principle, also one of the most inexpensive 
diagnostic tests. Furthermore, a positive PCR result is a direct indication of the presence of the 
pathogen, i.e. an active infection, whereas a positive result in an immunoassay does not 
discriminate between acute and overcome infections. Unfortunately, this technique is not very 
popular in developing countries, due to the need of a thermocycler, the need of purchasing 
thermostable DNA polymerases and the risk of false positive results due to smallest 
contaminations occurring easily under suboptimal conditions in poorly equipped laboratories.   
However, PCR is the only objective way to measure the success of treatment of 
chagasic patients with drugs.  Upon elimination of the parasites with drugs, the titre of specific 
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antibodies drops very slowly during a period of many months or even years and can therefore 
not be used as a measure to determine when the drug therapy can be stopped. As many 
patients suffer much from the side effects produced by the only available drugs benznidazole 
and nifurtimox, treatment should last only as long as absolutely needed. Thus, in addition to a 
sensitive immunological method for the general detection of T. cruzi infections, another 
sensitive procedure to measure the presence of parasites in the circulation is needed. As the 
titre of circulating parasites can be very low, depending on the time of infection, microscopy is 
ineffective in most cases. Xenodiagnosis takes at least a month to obtain results and is 
therefore also inappropriate.  The detection of the DNA of the parasites with PCR remains for 
these reason as the only suitable alternative diagnostic procedure. 
The sensitivity of a PCR assay depends on the number of DNA molecules available at 
the beginning of the test. Theoretically, a single DNA molecule would be sufficient, however, 
some hundred molecules as targets for a selected pair of primers are needed under the 
suboptimal conditions prevailing normally in reality. With titres as low as ten parasites per 
millilitre of blood, the lower limit for a reliable PCR result is quickly reached. It is therefore 
reasonable to select amplified target sites in the genome such as the genes for ribosomal RNAs 
(in T. cruzi approximately 220 per haploid genome) or conserved telomeric sequences 
(approximately 60 per haploid genome) as targets for PCR amplification.  The kinetoplast of 
trypanosomatides contains up to 10.000 copies of the so called minicircle DNA and has 
therefore been the preferred target for developing specific PCR assays.  
In this work, a new PCR assay for the detection of the 18S rRNA genes has been 
established, and a minicircle-specific test described in the literature (Wincker et al., 1994; 
Ribeiro-Dos-Santos et al., 1999) has been modified. Respecting the expected low titres of 
circulating parasites in blood, both assays have been designed as nested PCRs to increase 
sensitivity.  Both assays turned out to function well with the blood samples available for the 
tests, however they have to be tested  more accurately with more samples in the future. During 
work on this thesis it was not possible to obtain larger amounts of such blood samples. 
A major concern in PCR assays is the quality of the DNA used in the tests. At the one 
hand, the DNA is frequently fragmented in short pieces in clinical samples due to inappropriate 
isolation and storage. PCR assays comprising long amplification products are more affected 
than those amplifying short sequences only. DNA fragments shorter than 200 base pairs are 
difficult to separate clearly by simple electrophoresis on agarose gels, which is the preferred 
procedure in developing countries. Fragments shorter than 100 base pairs are perfect targets 
for light cyclers, but this technology is not affordable. At the other hand, contaminations in the 
DNA can severely interfere with the activity of the Taq DNA polymerase. It is well known that 
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hemin is a strong inhibitor of the polymerase, and other contaminations such as 
polysaccharides, glycolipids and other cellular components are inhibitory as well. Therefore, it is 
essential to use an appropriate procedure to purify DNA carefully for use in PCR assays. 
Many kits for the purification of DNA are available from different commercial sources, but 
the purification costs using these kits are in the range of one to two dollars per sample which is 
unacceptable for poor countries. Therefore, new and inexpensive procedures for the purification 
of DNA from blood samples have been developed in this work. They are based on the principle 
that DNA binds selectively to crystalline silica (SiO 2) under anhydrous conditions. Dehydration 
of DNA can be reached in the presence of high concentrations of salt, or chaotropic substances 
such as guanidinium hydrochloride, or in the presence of alcohols such as ethanol or 
isopropanol. The procedures used in this work include lysis of the tissue in guanidinium 
hydrochloride, addition of a small amount of silica to bind the solubilised DNA and washing 
cellular contaminations away with 60% ethanol. At the end, the DNA is dissolved in water and 
separated from silica by centrifugation. This procedure is simple, fast and inexpensive and 
yields a highly pure DNA. The only costs are the plastic material used (two reaction tubes and 
several pipette tips). This method has not only been used in the DNA preparations for the PCR 
assays, but also for all plasmid constructions described above. The procedure is highly 
reproducible and robust and therefore perfectly applicable in developing countries.  
For simplicity reasons, blood samples for PCR analysis are usually mixed with 
guanidinium hydrochloride which conserves DNA for some time also at ambient temperature 
and inactivates potential pathogens at the same time. However, the disadvantage of this 
method is that the DNA is fragmented to small pieces after some weeks, and the extraction of 
DNA is messy due to the large amount of protein derived from the lysed erythrocytes. A more 
comfortable procedure was developed during this work which includes collecting of blood in the 
presence of citrate or EDTA and separating plasma and blood cells by short centrifugation, or, 
in absense of a centrifuge, keeping the syringe in vertical position over night. The blood 
components are separated by this way in three parts, the upper part is plasma and can be used 
for immunoassays, the lower part is the sedimented red blood cells, and on top of these cells is 
a yellow layer of leucocytes and platelets, called buffy coat, which can be harvested by a pipette 
upon removal of the plasma. Even if a fraction of the erythrocytes is co-collected with the buffy 
coat, DNA can be extracted much easier and cleaner and with better yields than from whole 
blood. Since during the chronic phase of the disease most parasites are inside of cells, they are 
present in highly enriched form in the buffy coat. DNA extraction is by far faster and efficient by 
this way, and the method has to be applied when large numbers of blood samples are to be 
analysed by PCR.  
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The DNA sequence of the genes for the 18S ribosomal RNA vary sufficiently from the 
corresponding sequences in other eukaryotes and bacteria, but are quite conserved between 
the different members of trypanosomatides. It was not feasible to design sequences for the 
outer primers for a nested PCR which would warrant absolute specificity for T. cruzi. However, 
the experimental data revealed that the discrimination between T. cruzi and Leishmania species 
was satisfactory at higher annealing temperatures. Amplification with the outer primers worked 
perfectly with 1 nanogram of purified T. cruzi DNA, but was borderline with 0.1 nanogram. One 
nanogram of DNA corresponds to 50 molecules of the haploid genome, or 25 parasites. A 
detection limit of 10-50 parasites per millilitre of blood is not sufficient since this is the maximal 
number of parasites circulating during chronic infection. Therefore, PCR with the outer primers 
alone is not sufficient, but it serves to amplify enough target DNA for the nested PCR with an 
inner set of primers.  The calculation indicates also that use of less than one millilitre of blood 
would be limiting for the efficiency of the assay. This amount of blood has to be extracted to 
make sure that enough parasites are contained, even though the DNA is fragmented in 
chromosomes, and there are more than 200 target sites for the PCR primers in each parasite. 
As the major content of DNA extracted from blood is derived from leukocytes (several 
micrograms DNA per millilitre of blood), only part of the purified DNA can be added to single 
PCR assay anyway (maximal one to two microgram total DNA per assay).   
The use of minicircle DNA for PCR can increase the sensitivity of the test because of the 
high number of target sites for the primers. However, even if there are 10.000 minicircle 
sequences in a single parasite, the minimal amount of blood to warrant a sufficient number of 
parasites is subjected to the same limitations as discussed above. Other constraints of the 
minicircle DNA concern the sequence heterogeneity of the individual DNA sequences found in 
the cell which lead to a slightly diffuse appearance of the PCR product and the fact that the 
circles exist as a highly concatenated network which is hardly to be dissolved homogeneously in 
buffer. The isolated DNA has to be fragmented by 10 minutes of boiling before it is sufficiently 
accessible for PCR amplification.  Because only a short part of the minicircle DNA is conserved, 
there is limited choice for the selection of primers. Different sequences can be found for the 
reverse primers, but overlapping sequences have to be used for outer and inner forward 
primers. Most of the possible primer combinations have been tested by others already (Wincker 
et al., 1994; Ribeiro-Dos-Santos et al., 1999), however, the calculated annealing temperatures 
differed as much as 20°C between forward and reverse primers. This may lead to 
mishybridisations of the primers with the higher temperature resulting in amplification of DNA 
fragments with heterogeneous size.  Therefore it was tried to use shorter primers with more 
similar annealing temperatures. However, testing of different combinations of forward and 
reverse primers revealed that except of one of the new short primers, the oligonucleotides 
Discussion                                                                                                                                                                                    94  
_____________________________________________________________________________ 
designed before by others were superior to the new primers, even though annealing 
temperatures markedly higher than described had to be used for optimal results.  
Minicircle PCR turned out to be more sensitive than 18S rRNA-specific PCR. However, 
this may be due rather to the bad quality of the DNA extracted from the blood samples than to 
the selected target sites. The minicircle PCR yielded fragments of approximately 380 base 
pairs, whereas the 18S rRNA-specific PCR led to 640 and 460 base pair fragments with outer 
and inner primers, respectively. The latter procedure led to much clearer results and may reveal 
100% sensitivity when used with freshly prepared DNA. The blood samples available for the 
tests had been stored for almost half a year as a suspension in guanidinium hydrochloride 
before DNA extraction.  
The inner primers of the nested 18S rRNA PCR were selected in a way that no cross-
reaction with T. rangeli should occur. This problem had not been solved by earlier approaches 
using the 18S rRNA target. Instead, another group has developed a PCR specific for the 
telomeric region of the chromosomes (Chiurillo et al., 2003) which differs between these 
species.   
 
4.5   Conclusion  
 The present work is an example how available knowledge of informatic tools and 
molecular biology can be used to adapt medical problems such as the diagnosis of infectious 
diseases to the real needs of developing countries.  The World Health Organisation assured in 
1996, that Chagas disease would be eliminated by the year 2010, however, this is by large not 
going to happen. In contrast, a clear picture of the real extent of this highly neglected disease is 
just emerging. Strong effort has to be made to restrict the huge magnitude of this disease using 
the available drugs and diagnostics efficiently. Diagnosis as well as therapy have to be 
improved in the future.  At present, only two drugs for the treatment of Chagas disease are 
available, and they are effective only in the primary stages.  For this reason, early diagnosis of 
Chagas disease becomes a priority.   
 Some objectives were reached during this work. First, a highly sensitive and specific 
diagnostic assay has been developed.  And second, this diagnostic tool has been created in a 
way which is adapted to the limited economic and suboptimal technical conditions that occur 
unfortunately very often in developing countries. New and inexpensive PCR assays 
complementary to the immunoassays were also designed during this work.  Due to the lack of 
blood samples of infected patients it was not possible to test and improve them sufficiently. It 
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has to be kept in mind that PCR is the only technique which allows monitoring the success of 
the treatment with the available drugs. In the case of Chagas disease, treatment has to be 
reduced as much as possible in order to avoid severe side effects.  Some adjustments will be 
necessary to adapt the PCR assays to the use under poor laboratory conditions. To avoid 
contamination, separated areas for DNA extraction and performing the PCR assays have to be 
established, the laboratory personnel has to be trained to use different pipetters in the different 
places and, so far affordable filter tips. To reduce further sources of contaminations, all 
components of the PCR assays except of the DNA sample can be pre-mixed, divided in test 
tubes and lyophylised. Finally, the Taq DNA polymerase can be self-made with a recombinant 
clone reducing markedly the final cost of the assays (E. Beck, unpublished).   
The necessary diagnostic screening of large populations can only be managed using 
immunodiagnostic assays since they can be automated. Use of the existing commercial ELISA 
assays for this purpose is not feasible due to the enormous costs. However, the TcBCDE 
antigen described in this work can be produced inexpensive and in a very simple way. A single 
batch of the antigen is sufficient for one million assays, and the efficiency of different batches of 
the antigen was highly reproducible. This will help to reduce the costs of the diagnosis greatly. 
Because most of the population suffering from Chagas disease lives in rural areas, 
where medical facilities are insufficient, there will be an urgent need of additional diagnostic 
tools such as rapid lateral flow assays in the future (Villa et al., 2007).  These diagnostic assays 
can be performed without any special equipment. Such a lateral flow test is already on the 
market (StatPak®), however, this test is not yet specific and sensitive enough and cannot be 
used in areas where co-infections with Leishmania and T. rangeli occur. This test stick is based 
on recombinant antigens used also in other immunoassays. It should not be too difficult to 
develop such a lateral flow device on the basis of TcBCDE.  Efforts will be done in the future in 
this direction.   
As a next future goal, the methods developed during this work have to be validated with 
larger amounts of patient samples in a country endemic for Chagas disease. This will show 
whether the developed assays function under real conditions and is planed to be done within 
the next months in Bolivia. In addition, the technology has to be transferred to the local 
scientists to enable them to solve the urgent health problems of their population by own means.  
Finally, it has to be emphasized that the rich countries with their enormous developing capacity 
should try to contribute more to the real needs of poor countries, and not only to their own ones.   
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